Sorafenib | Bay 43-9006 | FLT3 | VEGFR | PDGFR | Raf | c-Kit

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

产品名称	c-Kit ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ c-Kit (Swiss 3T3), IC50: 1.8 μM	PDGFR	99%+
Masitinib	+ Kit, IC50: 200 nM		99%+
Motesanib Diphosphate	+++ Kit, IC50: 8 nM		97%
Ki8751	++ c-Kit, IC50: 40 nM		99%
Tivozanib	++ c-Kit, IC50: 78 nM		99%+
Pazopanib	+ c-Kit, IC50: 140 nM		99%
Sitravatinib	+++ Kit, IC50: 6 nM		99%+
Pexidartinib	+++ Kit, IC50: 10 nM		99%+
Lactate	++++ c-Kit, IC50: 2 nM	FLT3	85%
Amuvatinib	+++ c-Kit (D816H), IC50: 10 nM		99%+
Imatinib Mesylate	+ c-Kit, IC50: 100 nM	PDGFR	99%
AZD2932	+++ c-Kit, IC50: 9 nM		99%
Axitinib	++++ Kit, IC50: 1.7 nM		98%
Dovitinib	++++ c-Kit, IC50: 2 nM	FLT3	99%+
Sunitinib	✔	FLT3	98%
OSI-930	+ Kit, IC50: 80 nM		99%+
Telatinib	++++ c-Kit, IC50: 1 nM		99%+
Dasatinib monohydrate	++ c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM	Src	98%
Dasatinib	++ c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM	Src	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	PDGFR ↓ ↑	PDGFRα ↓ ↑	PDGFRβ ↓ ↑	其他靶点	纯度
Tyrphostin A9	+ PDGFR, IC50: 0.5 μM			EGFR	98%
Tyrphostin AG1296					99%+
Motesanib Diphosphate	++ PDGFR, IC50: 84 nM				97%
Pazopanib	++ PDGFR, IC50: 84 nM				99%
Imatinib	+ PDGFR, IC50: 100 nM			c-Kit	98%
Imatinib Mesylate	+ PDGFR, IC50: 100 nM			c-Kit	99%
Sennoside B	✔				99%+
PP121	++++ PDGFR, IC50: 2 nM			VEGFR,mTOR	99%+
Crenolanib		++++ PDGFRα, Kd: 2.1 nM	++++ PDGFRβ, Kd: 3.2 nM		99%+
Masitinib		+ PDGFRα, IC50: 540 nM	+ PDGFRβ, IC50: 800 nM		99%+
Ki8751		++ PDGFRα, IC50: 67 nM		c-Kit	99%
Tivozanib		++ PDGFRα, IC50: 40 nM	++ PDGFRβ, IC50: 49 nM		99%+
Ponatinib		++++ PDGFRα, IC50: 1.1 nM			98%
Amuvatinib		++ PDGFRα (V561D), IC50: 40 nM			99%+
Axitinib		+++ PDGFRα, IC50: 5.0 nM	++++ PDGFRβ, IC50: 1.6 nM		98%
CP-673451		+++ PDGFRα, IC50: 10 nM	++++ PDGFRβ, IC50: 1 nM		99%+
Telatinib		+++ PDGFRα, IC50: 15 nM		c-Kit	99%+
Nintedanib		++ PDGFRα, IC50: 59 nM	++ PDGFRβ, IC50: 65 nM		99+%
Avapritinib		++++ PDGFRα (D842V), IC50: 0.5 nM			99%+
MK-2461			+++ PDGFRβ, IC50: 22 nM		98%+
Lactate			+++ PDGFRβ, IC50: 27 nM	FLT3,c-Kit	85%
Linifanib			++ PDGFRβ, IC50: 66 nM		99%+
AZD2932			+++ PDGFRβ, IC50: 4 nM	c-Kit	99%
Dovitinib			+++ PDGFRβ, IC50: 27 nM	FLT3,c-Kit	99%+
Sorafenib			++ mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM		99%
Sunitinib			++++ PDGFRβ , IC50: 2 nM	FLT3	98%
Orantinib			+++ PDGFRβ, Ki: 8 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	FLT3 ↓ ↑	其他靶点	纯度
R406	✔	Syk	98%
Go6976	✔		99%+
Quizartinib	+++ FLT3 (WT), IC50: 4.2 nM FLT3 (ITD), IC50: 1.1 nM		98%
Gilteritinib	++++ FLT3, IC50: 0.29 nM		99%+
Amuvatinib	+ FLT3 (D835Y), IC50: 81 nM		99%+
Pacritinib	++ FLT3, IC50: 22 nM FLT3 (D835Y), IC50: 6 nM		97%
Dovitinib	++++ FLT3, IC50: 1 nM	c-Kit	99%+
Denfivontinib	++++ FLT3, IC50: 0.4 nM FLT3 (D835Y), IC50: 0.4 nM	RET	99%+
TAK-659 HCl	++ FLT3, IC50: 4.6 nM	Syk	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	A-raf ↓ ↑	B-Raf ↓ ↑	C-Raf/Raf-1 ↓ ↑	Raf ↓ ↑	其他靶点	纯度
Encorafenib		✔				99%+
GDC-0879		++++ B-Raf, IC50: 0.13 nM				99%+
SB-590885		++++ B-Raf, Ki: 0.16 nM				99%+
RAF265						99%+
Dabrafenib		++++ B-Raf, IC50: 5.2 nM B-Raf (V600E), IC50: 0.7 nM	+++ C-Raf, IC50: 6.3 nM			98%
Lifirafenib	++++ WT A-RAF, IC50: 1 nM	++ BRAF WT, IC50: 32 nM BRAF(V600E), IC50: 23 nM	+++ C-RAF (Y340/341D), IC50: 7 nM		EGFR	98%
ZM 336372			+ C-Raf, IC50: 70 nM			99%+
NVP-BHG 712			+ C-Raf, IC50: 0.395 μM			99%+
CCT196969		+ BRAF, IC50: 0.1 μM	++ CRAF, IC50: 0.01 μM		Src	98%
Vemurafenib		++ B-Raf, IC50: 100 nM B-Raf (V600E), IC50: 31 nM	+ C-Raf, IC50: 48 nM			98+%
PLX4720		++ B-Raf, IC50: 160 nM B-Raf (V600E), IC50: 13 nM	+++ C-Raf-1 (Y340D/Y341D), IC50: 6.7 nM		BRK	99+%
GW 5074			+++ C-Raf, IC50: 9 nM			99%+
Avutometinib		+++ BRAF, IC50: 19 nM BRAF V600E, IC50: 8.2 nM	+ CRAF, IC50: 56 nM			98%
LY3009120		++++ BRAF WT, IC50: 15 nM BRAF(V600E), IC50: 5.8 nM	++++ C-Raf, IC50: 4.3 nM			99%+
Agerafenib		++ B-Raf, Kd: 36 nM B-Raf (V600E), Kd: 14 nM	+ C-Raf, Kd: 39 nM		RET	99%+
TAK-632		+++ B-Raf, IC50: 8.3 nM	++++ C-Raf, IC50: 1.4 nM			99%+
AZ 628		+ B-Raf, IC50: 105 nM B-Raf (V600E), IC50: 34 nM	++ C-Raf-1, IC50: 29 nM			98%
PLX7904				✔		98+%
Sorafenib		++ B-Raf (V599E), IC50: 38 nM B-Raf, IC50: 22 nM	++++ Raf-1, IC50: 6 nM	++++ Raf-1, IC50: 6 nM		99%
Tovorafenib				✔		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	97%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,PDGFR,c-Kit	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Fms/CSF1R,c-Kit	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	FLT3,c-Kit	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ hVEGFR2, IC50: 9 nM mVEGF2, IC50: 165 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Apatinib mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cell Line AML12 and BNLCL.2 cells Hep3B cells L02 hepatocytes Huh7 SK-Hep1 MHCC97L MHCC97H MOLM-13 cells MV4-11 cells Ba/F3-ITD cells HSC-T6 cells HSC-LX2 cells HSC-T6 HSC-LX2 HT-29 colorectal cancer cells	Concentration	Treated Time	Description	References
AML12 and BNLCL.2 cells	2 μM	5 days	Evaluation of toxicity in untransformed liver cells, showing that compound 40 combined with sorafenib had low toxicity in normal liver cells	J Med Chem. 2025 Apr 10;68(7):7180-7196
Hep3B cells	1.7 μM	5 days	Assessment of cell viability, showing that compound 40 combined with sorafenib significantly reduced Hep3B cell viability	J Med Chem. 2025 Apr 10;68(7):7180-7196
L02 hepatocytes	10 μM	18 h	To investigate the effects of Sorafenib on lipid accumulation and inflammation, the results showed that Sorafenib significantly reduced lipid accumulation in L02 hepatocytes and suppressed the expression of inflammatory factors.	Cell Metab. 2020 May 5;31(5):892-908.e11.
Huh7	10 μM	24 h	To investigate Sorafenib-induced macropinocytosis and its effect on ferroptosis. Results showed that Sorafenib induced macropinocytosis through activation of PI3K-RAC1-PAK1 signaling, replenishing intracellular cysteine and conferring resistance to Sorafenib.	J Exp Clin Cancer Res. 2022 Mar 14;41(1):98.
SK-Hep1	10 μM	24 h	To investigate Sorafenib-induced macropinocytosis and its effect on ferroptosis. Results showed that Sorafenib induced macropinocytosis through activation of PI3K-RAC1-PAK1 signaling, replenishing intracellular cysteine and conferring resistance to Sorafenib.	J Exp Clin Cancer Res. 2022 Mar 14;41(1):98.
MHCC97L	10 µM	24 h	To assess the effect of Sorafenib on cell viability, the results showed that Sorafenib significantly reduced cell viability.	J Exp Clin Cancer Res. 2024 May 14;43(1):143.
MHCC97H	10 µM	24 h	To assess the effect of Sorafenib on cell viability, the results showed that Sorafenib significantly reduced cell viability.	J Exp Clin Cancer Res. 2024 May 14;43(1):143.
MOLM-13 cells	0.1 μM	24 h	Sorafenib increased IL-15 production by inhibiting ATF4 expression, thereby activating the IRF7/IL-15 axis.	Nat Med. 2018 Mar;24(3):282-291.
MV4-11 cells	0.1 μM	24 h	Sorafenib increased IL-15 production by inhibiting ATF4 expression, thereby activating the IRF7/IL-15 axis.	Nat Med. 2018 Mar;24(3):282-291.
Ba/F3-ITD cells	10 nM	24 h	Sorafenib increased IL-15 production by inhibiting ATF4 expression, thereby activating the IRF7/IL-15 axis.	Nat Med. 2018 Mar;24(3):282-291.
HSC-T6 cells	10 μM	24 h	To investigate the effect of Sorafenib on ferroptosis in HSC-T6 cells, results showed that Sorafenib significantly inhibited cell growth and induced ferroptosis.	Autophagy. 2020 Aug;16(8):1482-1505.
HSC-LX2 cells	10 μM	24 h	To investigate the effect of Sorafenib on ferroptosis in HSC-LX2 cells, results showed that Sorafenib significantly inhibited cell growth and induced ferroptosis.	Autophagy. 2020 Aug;16(8):1482-1505.
HSC-T6	5 μM	24 h	To evaluate the effect of Sorafenib on HSC-T6 cells, the results showed that Sorafenib induced ferroptosis, which was validated by the inhibition of the ferroptosis inhibitor ferrostatin-1.	Autophagy. 2018;14(12):2083-2103.
HSC-LX2	5 μM	24 h	To evaluate the effect of Sorafenib on HSC-LX2 cells, the results showed that Sorafenib induced ferroptosis, which was validated by the inhibition of the ferroptosis inhibitor ferrostatin-1.	Autophagy. 2018;14(12):2083-2103.
HT-29 colorectal cancer cells	6 μM	24 h	To study the effect of sorafenib on ERK1/2 and CSE1L phosphorylation in HT-29 cells. Results showed that sorafenib treatment inhibited ERK1/2 and CSE1L phosphorylation.	J Transl Med. 2015 Jun 13;13:191.

Species Mice Mice Mice BALB/c nude mice Mice Mice C57BL/6 mice Nude Balb/c mice	Animal Model Akt1Myr;MycOE HCC organoids NASH-HCC model SK-Hep1 and Huh7 xenograft models Subcutaneous tumor model and orthotopic tumor model Bile duct ligation-induced liver fibrosis model Bile duct ligation (BDL)-induced liver fibrosis model Subcutaneous Hepa1-6 liver cancer model HepG2/SOR tumor model	Administration	Dosage	Frequency	Description	References
Mice	Akt1Myr;MycOE HCC organoids	In vitro culture	4 μM	5 days	Assessment of therapeutic efficacy, showing that compound 40 combined with sorafenib exhibited significant therapeutic effects in HCC organoids	J Med Chem. 2025 Apr 10;68(7):7180-7196
Mice	NASH-HCC model	Oral	15 mg/kg/2 days	Every 2 days for 8 weeks	To evaluate the therapeutic effects of low-dose Sorafenib on the NASH-HCC model, the results showed that Sorafenib significantly reduced tumor incidence and size, and improved major pathological features of NASH, including steatosis, inflammation, and fibrosis.	Cell Metab. 2020 May 5;31(5):892-908.e11.
Mice	SK-Hep1 and Huh7 xenograft models	Intraperitoneal injection	5 mg/kg	Daily for 3 days	To investigate the effect of combined Sorafenib and Amiloride treatment on tumor growth. Results showed that Amiloride enhanced the antitumor effect of Sorafenib by inhibiting macropinocytosis, significantly suppressing tumor growth.	J Exp Clin Cancer Res. 2022 Mar 14;41(1):98.
BALB/c nude mice	Subcutaneous tumor model and orthotopic tumor model	Oral	10 mg/kg	Once daily for two weeks	To evaluate the efficacy of Sorafenib in inhibiting tumor growth, the results showed that Sorafenib significantly inhibited tumor growth.	J Exp Clin Cancer Res. 2024 May 14;43(1):143.
Mice	Bile duct ligation-induced liver fibrosis model	Intraperitoneal injection	10 mg/kg	Once every other day for 2 weeks	To investigate the effect of Sorafenib on liver fibrosis in mice, results showed that Sorafenib significantly alleviated liver fibrosis and induced HSC ferroptosis.	Autophagy. 2020 Aug;16(8):1482-1505.
Mice	Bile duct ligation (BDL)-induced liver fibrosis model	Intraperitoneal injection	10 mg/kg	Once every other day for 2 weeks	To evaluate the effect of Sorafenib on murine liver fibrosis, the results showed that Sorafenib alleviated liver fibrosis by inducing HSC ferroptosis.	Autophagy. 2018;14(12):2083-2103.
C57BL/6 mice	Subcutaneous Hepa1-6 liver cancer model	Oral gavage	10 mg/kg	Daily for 12 days	To evaluate the antitumor effects of low-dose Sorafenib alone or in combination with R848 in a liver cancer model. The results showed that the combination of low-dose Sorafenib with R848 significantly enhanced antitumor activity with no obvious toxic side effects.	Adv Sci (Weinh). 2023 Jun;10(18):e2207650
Nude Balb/c mice	HepG2/SOR tumor model	Intravenous injection	5 mg/kg	Every two days for a total of four injections, lasting 14 days	To evaluate the anti-tumor effect of CTNP-PMS/SOR in the HepG2/SOR tumor model. Results showed that CTNP-PMS/SOR significantly inhibited tumor growth and prolonged the survival time of mice.	Drug Deliv. 2019 Dec;26(1):1080-1091

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03565536	Thyroid Cancer, Anaplastic	Phase 2	Recruiting	October 30, 2019	China, Fujian ... 展开 >> Fujian Medical University Union Hospital Recruiting FuZhou, Fujian, China, 350001 Contact: bo wang, md 13705947900 wangbo@fjmu.edu.cn 收起 <<
NCT00984425	Solid Tumors	Phase 1	Completed	-	Italy ... 展开 >> Istituto Clinco Humanitas Rozzano, Milano, Italy, 20089 收起 <<
NCT01259193	Hepatocellular Carcinoma	Phase 2	Unknown	July 2012	China, Shanghai ... 展开 >> Liver Cancer Institute Recruiting Shanghai, Shanghai, China, 200032 Contact: Zheng-Gang Ren, Ph.D 0086-021-64041990 ext 2137 ren.zhenggang@zs-hospital.sh.cn Contact: Lan Zhang, Master 0086-021-64041990 ext 2171 zhang.lan@zs-hospital.sh.cn Principal Investigator: Zheng-Gang Ren, Ph.D Sub-Investigator: Jubo Zhang, PhD 收起 <<
NCT01640665	Metastatic Breast Cancer ... 展开 >> Gastrointestinal Tumors 收起 <<	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Yale Cancer Center New Haven, Connecticut, United States, 06519 收起 <<
NCT01901692	Hepatocellular Carcinoma	Phase 2 Phase 3	Completed	-	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Korea, Republic of, 05505 收起 <<
NCT02716766	Carcinoma, Hepatocellular ... 展开 >> Secondary 收起 <<	Phase 2	Active, not recruiting	December 2020	Hong Kong ... 展开 >> Queen Mary Hospital Hong Kong, Hong Kong 收起 <<
NCT02227914	Advanced Hepatocellular Carcin... 展开 >>oma 收起 <<	Phase 1 Phase 2	Withdrawn(Study stopped due to... 展开 >> administrative reasons) 收起 <<	-	United States, California ... 展开 >> Lahey Hospital & Medical Center Burlington, California, United States United States, Colorado Rocky Mountain Cancer Centers Denver, Colorado, United States United States, Florida University of Miami Hospital & Clinics Miami, Florida, United States United States, Illinois The University of Chicago Medical Center Chicago, Illinois, United States United States, Ohio The Ohio State University, Martha Morehouse Medical Plaza Columbus, Ohio, United States United States, Wisconsin University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States 收起 <<
NCT00572078	SOLID TUMORS	Phase 1	Completed	-	United States, Indiana ... 展开 >> Indiana University Cancer Center Indianapolis, Indiana, United States, 46202 收起 <<
NCT01075113	Liver Cancer	Phase 1	Active, not recruiting	January 31, 2023	United States, Virginia ... 展开 >> Hunter Holmes McGuire VA Medical Center Richmond, Virginia, United States, 23249 Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT01851408	Melanoma Recu... 展开 >>rrent Melanoma Stage III Melanoma Stage IV Melanoma 收起 <<	Phase 2	Withdrawn(No progression of Ph... 展开 >>ase 1 trial to Phase 2.) 收起 <<	-	-
NCT00893373	Acute Myeloid Leukemia (AML)	Phase 2	Completed	-	Germany ... 展开 >> Sozialstiftung Bamberg Klinikum am Bruderwald Bamberg, Germany, 96049 Klinikum Bayreuth Bayreuth, Germany, 95445 Charite Campus Benjamin Franklin Berlin, Germany Ev. Diakonie-Krankenhaus gGmbH Bremen Bremen, Germany, 28239 University Hospital Dresden Dresden, Germany, 01307 Klinikum Frankfurt (Oder) GmbH Frankfurt (Oder), Germany, 15236 Westpfalz-Klinikum GmbH Kaiserslautern, Germany, 67655 Agaplesion Diakoniekrankenhaus Rotenburg Rotenburg, Germany, 27356 Robert-Bosch-Krankenhaus Stuttgart, Germany, 70376 收起 <<
NCT00884416	Glioblastoma ... 展开 >>Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligoastrocytoma Anaplastic Oligodendroglioma 收起 <<	Phase 1	Completed	-	Switzerland ... 展开 >> Geneva University Hospital (Hopitaux Universitaires de Geneve), Department of Oncology Geneva, GE, Switzerland, 1211 收起 <<
NCT00964743	Neoplastic Meningitis	Not Applicable	Terminated(Low Accrual)	-	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT00862082	-		Terminated(PR104 plus sorafeni... 展开 >>b was poorly tolerated in patients with advanced HCC) 收起 <<	-	-
NCT00813293	Hepatocellular Cancer	Phase 2	Active, not recruiting	December 2017	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 收起 <<
NCT01613846	Renal Cell Carcinoma	Phase 3	Completed	-	-
NCT00565370	Advanced Gastric Cancer	Phase 1 Phase 2	Completed	-	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Korea, Republic of, 138-736 收起 <<
NCT00964743	-		Terminated(Low Accrual)	-	-
NCT01005875	Hepatocellular Carcinoma ... 展开 >> Liver Cancer 收起 <<	Not Applicable	Terminated(Sponsor(Bayer)did n... 展开 >>ot wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes.) 收起 <<	-	United States, Alabama ... 展开 >> UAB Birmingham, Alabama, United States, 35294 收起 <<
NCT00565370	-		Completed	-	-
NCT02072486	Advanced Adult Hepatocellular ... 展开 >>Carcinoma Localized Non-Resectable Adult Hepatocellular Carcinoma Stage III Childhood Hepatocellular Carcinoma Stage IIIA Hepatocellular Carcinoma Stage IIIB Hepatocellular Carcinoma Stage IIIC Hepatocellular Carcinoma Stage IV Childhood Hepatocellular Carcinoma Stage IVA Hepatocellular Carcinoma Stage IVB Hepatocellular Carcinoma 收起 <<	Not Applicable	Active, not recruiting	December 3, 2018	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT00862082	Hepatocellular Carcinoma	Phase 1 Phase 2	Terminated(PR104 plus sorafeni... 展开 >>b was poorly tolerated in patients with advanced HCC) 收起 <<	-	United States, Arizona ... 展开 >> University of Arizona Tucson, Arizona, United States, 85724 United States, California Moores UCSD Cancer Center La Jolla, California, United States, 92093 University of California, Irvine Orange, California, United States, 92868 Sharp Clinical Oncology Research San Diego, California, United States, 92123 Pacific Oncology/Hematology San Francisco, California, United States, 94115 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Indiana Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Maryland Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins Baltimore, Maryland, United States, 21231 United States, New York Columbia University Medical Center New York, New York, United States, 10032 Hong Kong Prince of Wales Hospital Shatin, New Territories, Hong Kong Singapore Singapore General Hospital Singapore, Singapore Taiwan Chang Gung Memorial Hospital Kaohsiung, Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung, Taiwan Chi Mei Medical Center, Liouying T'ai-nan, Taiwan China Medical University Hospital Taichung City, Taiwan Cathay General Hospital Taipei City, Taiwan, 10630 National Taiwan University Hospital Taipei, Taiwan 收起 <<
NCT01005875	-		Terminated(Sponsor(Bayer)did n... 展开 >>ot wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes.) 收起 <<	-	-
NCT02323906	Carcinoma, Hepatocellular	Phase 1	Terminated(Slow enrollment and... 展开 >> business decision. No safety concerns were identified for the study drugs.) 收起 <<	-	United States, California ... 展开 >> University of California San Francisco San Francisco, California, United States, 94115 United States, Florida University of Florida College of Med Gainesville, Florida, United States, 32610-0277 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Indiana Indiana University Cancer Center Indianapolis, Indiana, United States, 46202-528 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, South Carolina Greenville Hospital System Greenville, South Carolina, United States, 29605 United States, Utah University of Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 收起 <<
NCT01804374	Metastatic Osteosarcoma ... 展开 >> Relapsed Osteosarcoma 收起 <<	Phase 2	Completed	-	Italy ... 展开 >> Fondazione del Piemonte per l'Oncologia IRCC Candiolo Candiolo, Torino, Italy, 10060 收起 <<
NCT01041482	Renal Cell Carcinoma	Phase 2	Unknown	November 2013	China, Beijing ... 展开 >> Jianhui Ma Recruiting Beijing, Beijing, China, 100730 Contact: Jianhui Ma Jianhui Ma Jianhui Ma, Doctor 01086108878 收起 <<
NCT02971696	HCC	Phase 3	Completed	-	Egypt ... 展开 >> El Kahraba Hosital Cairo, N/A = Not Applicable, Egypt, 1234 Ain Shams University Hospital Cairo, Egypt Nasser Institute Cairo, Egypt 收起 <<
NCT00887107	Thyroid Cancer	Phase 2	Completed	-	Netherlands ... 展开 >> Leiden University Medical Center Leiden, Netherlands, 2300 RC 收起 <<
NCT00892658	Hepatocellular Carcinoma	Phase 1	Active, not recruiting	December 2019	Canada, Ontario ... 展开 >> University Health Network Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00942682	Neuroendocrine Tumor ... 展开 >> Carcinoid Tumor Pancreatic Neuroendocrine Tumor 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00917462	Esophageal Cancer ... 展开 >> Gastroesophageal Junction Cancer 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00880542	-		Terminated(The study lost fund... 展开 >>ing.) 收起 <<	-	-
NCT00880542	Sarcoma	Phase 2	Terminated(The study lost fund... 展开 >>ing.) 收起 <<	-	United States, California ... 展开 >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 收起 <<
NCT00703365	Carcinoma, Hepatocellular	Phase 2	Completed	-	Thailand ... 展开 >> Department of Medicine, Siriraj Hospital Bangkoknoi, Bangkok, Thailand, 10700 Medical Oncology Unit, Chulalongkorn Hospital Patumwan, Bangkok, Thailand, 10330 Horizon Regional Cancer Center, Bamrungrad Hospital Sukhumvit 3, Bangkok, Thailand, 10110 收起 <<
NCT01539018	Advanced Hepatocellular Carcin... 展开 >>oma 收起 <<	Phase 2	Terminated(After interim resul... 展开 >>ts data showed no evidence of a difference between both groups) 收起 <<	-	Egypt ... 展开 >> Ain shams university Cairo, Egypt Cairo University Hospitals Cairo, Egypt National cancer institute Cairo, Egypt NHTMRI Cairo, Egypt National Liver Institute Monofeiya, Egypt 收起 <<
NCT02672488	Hepatocellular Carcinoma	Phase 2	Unknown	December 2018	China ... 展开 >> Tianjin Medical University Cancer Institute and Hospital Recruiting Tianjin, China, 300060 Contact: TI ZHANG, MD +862223340123 ext 3092 zhangti@tjmuch.com Contact: Huikai Li, MD +862223340123 ext 3091 lihuikai@tjmuch.com 收起 <<
NCT00854620	Carcinoma, Renal Cell ... 展开 >> Kidney Disease Kidney Cancer 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT00854620	-		Completed	-	-
NCT01025453	Thyroid Cancer	Phase 2	Completed	-	United States, New Jersey ... 展开 >> Memorial Sloan-Kettering at Basking Ridge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan-Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan-Kettering at Mercy Medical Center Rockville Centre, New York, United States Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center Sleepy Hollow, New York, United States, 10591 收起 <<
NCT02185560	-		Recruiting	June 30, 2021	Japan ... 展开 >> Recruiting Multiple Locations, Japan 收起 <<
NCT01025453	-		Completed	-	-
NCT00480389	Renal Cell Carcinoma ... 展开 >> Metastatic Disease 收起 <<	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Hospital, University Health Network Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00956436	Hepatocellular Carcinoma	Phase 1	Completed	-	United States, Colorado ... 展开 >> Resesarch Site Denver, Colorado, United States United States, Florida Resesarch Site Ocoee, Florida, United States United States, Indiana Resesarch Site Indianapolis, Indiana, United States United States, Massachusetts Resesarch Site Boston, Massachusetts, United States United States, New York Resesarch Site New York, New York, United States United States, Virginia Resesarch Site Norfolk, Virginia, United States Singapore Resesarch Site Singapore, Singapore Taiwan Resesarch Site Tainan, Taiwan Resesarch Site Taipei, Taiwan Resesarch Site Tao-Yuan, Taiwan United Kingdom Resesarch Site Edgbaston, Birmingham, United Kingdom 收起 <<
NCT00810394	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> University of California Davis Cancer Center Sacramento, California, United States, 95817 收起 <<
NCT00810394	-		Completed	-	-
NCT01319942	-		Unknown	June 2013	Taiwan ... 展开 >> Chi-Mei Hospital Recruiting Tainan, Taiwan, 600 Contact: Li-Ching Lin, MD 886-6-2812811 ext 53501 liching51@yahoo.com.tw Principal Investigator: Li-Ching Lin, MD Taipei Medical University Hospital Recruiting Taipei, Taiwan, 100 Contact: Jeng-Fong Chiou, MD;PhD 886-2-27372181 ext 2130 sjfchiou@xuite.net Principal Investigator: Jen-Fong Chiou, MD;PhD 收起 <<
NCT01230697	-		Unknown	September 2011	Italy ... 展开 >> Alfredo Berruti Recruiting Orbassano (To), Turin, Italy, 10043 Contact: Elisa Bellini, MD (+39) 011 9026 ext 526 elisa.bellini3@tin.it Principal Investigator: Alfredo Berruti, PHD Sub-Investigator: Isabella Chiappino, MD Sub-Investigator: Cinzia Ortega, MD Sub-Investigator: Mario Pirisi, PHD Sub-Investigator: Antonino Picciotto, PHD Sub-Investigator: Camillo Porta, MD Sub-Investigator: Anna Pia, MD Sub-Investigator: Elena Bianco, MD 收起 <<
NCT03037437	Hepatocellular Cancer	Phase 2	Recruiting	December 2018	United States, Texas ... 展开 >> University of Texas Health Cancer Center Recruiting San Antonio, Texas, United States, 78229 Contact: Epp Goodwin 210-450-5798 goodwine@uthscsa.edu 收起 <<
NCT03170895	AML FLT3-ITD ... 展开 >>Mutation 收起 <<	Phase 2	Recruiting	October 1, 2021	Hong Kong ... 展开 >> The University of Hong Kong Recruiting Hong Kong, Hong Kong Contact: Chunxiao Zhang, SC 852-22554361 chunxiao@hku.hk 收起 <<
NCT00924807	-		Terminated(Sponsor closed the ... 展开 >>trial) 收起 <<	-	-
NCT01306058	Hepatoma Live... 展开 >>r Neoplasms Adenoma, Liver Cell Carcinoma, Hepatocellular Liver Neoplasms, Experimental 收起 <<	Phase 1 Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02562755	Hepatocellular Carcinoma (HCC)	Phase 3	Recruiting	October 2019	-
NCT00808145	Hepatocellular Carcinoma	Phase 2	Withdrawn(Lack of enrollment, ... 展开 >>many screen failures and non eligible study participants) 收起 <<	-	United States, Massachusetts ... 展开 >> Lahey Clinic Burlington, Massachusetts, United States, 01805 收起 <<
NCT01306058	-		Completed	-	-
NCT00801801	Non Squamous Cell Lung Cancer ... 展开 >> Non Small Cell Lung Cancer 收起 <<	Phase 2	Terminated(Sponsors withdrew f... 展开 >>unding; preliminary efficacy data was not encouraging.) 收起 <<	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 - 0104 收起 <<
NCT00544609	Bladder Cancer	Phase 1	Completed	-	Spain ... 展开 >> Hospital Clínic i Provincial de Barcelona Barcelona, Spain Hospital de la Santa Creu i Sant Pau Barcelona, Spain Institut Català d' Oncología Barcelona, Spain 收起 <<
NCT00924807	Prostate Cancer	Phase 1 Phase 2	Terminated(Sponsor closed the ... 展开 >>trial) 收起 <<	-	United States, New York ... 展开 >> St.Luke's-Roosevelt Hospital Center New York, New York, United States, 10019 收起 <<
NCT00801801	-		Terminated(Sponsors withdrew f... 展开 >>unding; preliminary efficacy data was not encouraging.) 收起 <<	-	-
NCT02961998	Hepatocellular Carcinoma	Phase 4	Completed	-	-
NCT02538393	Biological Availability	Phase 1	Completed	-	Germany ... 展开 >> Berlin, Germany, 13353 收起 <<
NCT01141309	Thyroid Cancer	Phase 2	Active, not recruiting	June 2019	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00954278	Carcinoma, Non Small Cell Lung	Phase 1	Active, not recruiting	December 2018	United States, Wisconsin ... 展开 >> University of Wisconsin - Madison Madison, Wisconsin, United States, 53792 收起 <<
NCT02529761	Hepatocellular Carcinoma	Not Applicable	Unknown	October 2018	China, Shaanxi ... 展开 >> Xijing Hospital of digestive disease, Fourth Military Medical University Recruiting Xi'an, Shaanxi, China, 710032 Contact: Han hangh@fmmu.edu.cn Principal Investigator: Guohong Han, MD,Ph.D 收起 <<
NCT01328223	-		Unknown	December 2012	Taiwan ... 展开 >> Shang-Wen Chen Recruiting Taichung, Taiwan, 404 Contact: Shang-Wen Chen, MD 886-4-22052121 ext 7450 vincent1680616@yahoo.com.tw Sub-Investigator: Yu-Cheng Kuo Sub-Investigator: Ji-An Liang, MD Li-Ching Lin Recruiting Tainan, Taiwan, 700 Contact: Li-Ching Lin, MD liching51@yahoo.com.tw Jeng-Fong Chiou Recruiting Taipei, Taiwan, 100 Contact: Jeng-Fong Chiou, MD;PhD sjfchiou@xuite.net 收起 <<
NCT01029418	Hepatocellular Carcinoma	Phase 1 Phase 2	Terminated(The phase II portio... 展开 >>n was not conducted due to funding issue.) 收起 <<	-	Singapore ... 展开 >> National University Hospital Singapore Singapore, Singapore, 119074 National Cancer Centre Singapore Singapore, Singapore, 169610 收起 <<
NCT01736878	Medullary Thyroid Carcinoma	Phase 2	Withdrawn(Study was withdrawn ... 展开 >>due to unanticipated hassle in patient recruitment.) 收起 <<	-	Germany ... 展开 >> University Hospital Ulm, Clinic for Nuclear Medicine Ulm, Baden-Wuerttemberg, Germany, D-89081 收起 <<
NCT02150317	Advanced Hepatocellular Carcin... 展开 >>oma 收起 <<	Not Applicable	Unknown	December 2016	China, Shanghai ... 展开 >> Eastern Hepatobiliary Surgery Hospital Recruiting Shanghai, Shanghai, China, 200438 Contact: Ai-jun Li, M.D. 0086-021-81875531 yinlei409@hotmail.com Contact: Lei Yin, M.D. 0086-021-81875532 dermatology2008@126.com 收起 <<
NCT01334710	-		Terminated(safety issue observ... 展开 >>ed on another hepatocellular study using OSI906) 收起 <<	-	-
NCT00933777	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific Non-Small Cell Lung Cancer 收起 <<	Phase 1	Completed	-	Germany ... 展开 >> Center for Integrated Oncology, Dep.I of Internal Medicine, University Hospital Cologne Cologne, Germany 收起 <<
NCT01398501	Acute Myeloid Leukemia	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02214 收起 <<
NCT03606590	Hepatocellular Carcinoma	Phase 2	Recruiting	December 2020	Spain ... 展开 >> Vall d'Hebron Institute of Oncology (VHIO) Recruiting Barcelona, Spain Contact: Teresa Macarulla, Dr. +34-932748855 tmacarulla@vhio.net Contact: Raquel García Pelaez +34-934893000 rgarcia@vhio.net Principal Investigator: Teresa Macarulla Mercade, Dr. HM Hospitales - Centro Integral Oncológico Clara Campal Recruiting Madrid, Spain, 28050 Contact: Antonio Cubillo, Dr. acubillo@hmhospitales.com Principal Investigator: acubillo@hmhospitales.com acubillo@hmhospitales.com, Dr. 收起 <<
NCT00478114	Renal Cell Carcinoma	Phase 3	Completed	-	Thailand ... 展开 >> Siriraj Hospital, Department of Medicine Bangkoknoi, Bangkok, Thailand, 10700 收起 <<
NCT01334710	Liver Cancer	Phase 2	Terminated(safety issue observ... 展开 >>ed on another hepatocellular study using OSI906) 收起 <<	-	United States, Georgia ... 展开 >> Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 收起 <<
NCT02691780	Refractory Solid Tumors	Not Applicable	Active, not recruiting	December 2018	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, seoul, korea, Republic of, Korea, Republic of, 135-710 收起 <<
NCT01833299	Hepatocellular Carcinoma ... 展开 >> Face Cancer 收起 <<	Phase 4	Unknown	December 2014	China ... 展开 >> Cancer Centre of Sun Yat-Sen University Recruiting Guangzhou, China, 510060 Contact: min-shan chen, M.D.,Ph.D. 87343117 Chminsh@mail.sysu.edu.cn Principal Investigator: min-shan chen, M.D.,Ph.D. 收起 <<
NCT01342627	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Terminated(low enrollment rate... 展开 >>) 收起 <<	-	Italy ... 展开 >> Centro di Riferimento Oncologico Aviano, Pordenone, Italy, 33081 收起 <<
NCT00997022	Hepatocellular Cancer	Phase 1	Completed	-	United States, California ... 展开 >> University of Southern California Los Angeles, California, United States, 90089 University of California, Los Angeles Los Angeles, California, United States, 90095 United States, New York Columbia University Medical Center New York, New York, United States, 10032 收起 <<
NCT00846131	Hepatocellular Carcinoma	Phase 1	Completed	-	United States, Illinois ... 展开 >> Northwestern Memorial Hospital Chicago, Illinois, United States, 60611 收起 <<
NCT02834546	-		Recruiting	October 2019	France ... 展开 >> Institut Bergonié Not yet recruiting Bordeaux, France Principal Investigator: Dominique BECHADE, MD CHU de Limoges Not yet recruiting Limoges, France Principal Investigator: Véronique LOUSTAUD-RATTI, MD CHU de Montpellier Not yet recruiting Montpellier, France Principal Investigator: Eric ASSENAT, MD CHU de Bordeaux Recruiting Pessac, France Contact: Clémence FRON, MD 05 57 65 64 39 ext +33 clemence.fron@chu-bordeaux.fr Contact: Nathalie TERRAS 05 57 62 34 60 ext +33 nathalie.terras@chu-bordeaux.fr Principal Investigator: Clémence FRON, MD Sub-Investigator: Jean-Frédéric BLANC, MD-PhD CHU de Toulouse Not yet recruiting Toulouse, France Principal Investigator: Jean-Marie PERON, MD 收起 <<
NCT00780169	Metastatic Colorectal Cancer	Phase 1	Completed	-	Canada, Ontario ... 展开 >> The Ottawa Hospital Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 收起 <<
NCT01338857	-		Terminated(Sorafenib ineffecti... 展开 >>ve for tx of recurrent or progressive PLGA) 收起 <<	-	-
NCT00875745	Leukemia, Myeloid, Acute ... 展开 >> Leukemia, Promyelocytic, Acute Myelodysplastic Syndromes 收起 <<	Phase 1	Completed	-	United States, Indiana ... 展开 >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 收起 <<
NCT01444807	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Recruiting	September 2019	Italy ... 展开 >> Istituto Tumori Milano Recruiting Milan, Mi, Italy, 20156 Contact: Giuseppe Procopio, MD +390223902557 Giuseppe.Procopio@istitutotumori.mi.it Contact: Elena Verzoni, MD +390223902557 elena.verzoni@istitutotumori.mi.it Principal Investigator: Giuseppe Procopio, MD Cinzia Ortega Recruiting Alba, Italy Alessandra Bearz Recruiting Aviano, Italy Alfredo Berruti Recruiting Brescia, Italy Saverio Cinieri Recruiting Brindisi, Italy Francesco Atzori Recruiting Cagliari, Italy Rodolfo Passalaqua Recruiting Cremona, Italy Francesco Di Costanzo Recruiting Firenze, Italy Vincenzo Emanuele Chiuri Recruiting Lecce, Italy Alessandra Mosca Recruiting Novara, Italy Vittorio Gebbia Recruiting Palermo, Italy Enrico Cortesi Recruiting Roma, Italy Francesco Cognetti Recruiting Roma, Italy Contact: Michele Milella Franco Morelli Recruiting San Giovanni Rotondo, Italy 收起 <<
NCT02332031	Drug Interactions	Phase 1	Completed	-	Germany ... 展开 >> Berlin, Germany, 13353 收起 <<
NCT01254890	Leukemia	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02311205	Hepatocellular Carcinoma ... 展开 >> Metastasis 收起 <<	Phase 2	Active, not recruiting	June 2018	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Korea, Republic of 收起 <<
NCT01338857	neurofibromatosis1 (NF1) ... 展开 >> Recurrent or Progressive Optic Pathway Gliomas (OPG) Recurrent or Progressive Low-grade Glioma 收起 <<	Phase 2	Terminated(Sorafenib ineffecti... 展开 >>ve for tx of recurrent or progressive PLGA) 收起 <<	-	United States, New York ... 展开 >> New York University Stephen D. Hassenfeld Children's Center for Cancer & Blood Disorders New York, New York, United States, 10016 收起 <<
NCT02530476	Leukemia Acut... 展开 >>e Myeloid Leukemia 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01507064	Hepatocellular Carcinoma	Phase 2	Completed	-	Italy ... 展开 >> UOSC Epatologia - Cardarelli Hospital Napoli, Italy, 80131 收起 <<
NCT01254890	-		Completed	-	-
NCT01510756	-		Terminated(slow enrollment)	-	-
NCT01510756	Chronic Lymphocytic Leukemia	Phase 2	Terminated(slow enrollment)	-	United States, California ... 展开 >> UCSD Medical Center La Jolla, California, United States, 92093 收起 <<
NCT02474290	Acute Myeloid Leukemia ... 展开 >> Hematopoietic Stem Cell Transplantation 收起 <<	Phase 2 Phase 3	Unknown	August 2018	China, Guangdong ... 展开 >> Department of Hematology,Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Li Xuan +86-020-61641613 356135708@qq.com Principal Investigator: Qifa Liu 收起 <<
NCT01561833	T Cell Lymphoma	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Yale Cancer Center New Haven, Connecticut, United States, 06510 收起 <<
NCT01203787	Hepatocellular Carcinoma	Phase 4	Completed	-	United States, Florida ... 展开 >> University of Florida Hepatology Gainesville, Florida, United States, 32610-0277 Mayo Clinic Jacksonville, Florida, United States, 32224 Florida Hospital Transplant Center Orlando, Florida, United States, 32804 Tampa General Hospital Tampa, Florida, United States, 33606 United States, Illinois Loyola University Medical Center Maywood, Illinois, United States, 60153 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 United States, Pennsylvania Drexel University College of Medicine Philadelphia, Pennsylvania, United States, 19107 United States, Texas University of Texas Health Science Center Houston Houston, Texas, United States, 77030 Brooke Army Medical Center San Antonio, Texas, United States, 78234 收起 <<
NCT01471353	Colorectal Cancer Metastatic	Phase 2	Completed	-	United States, Florida ... 展开 >> UF Health Cancer Center Gainesville, Florida, United States, 32610 收起 <<
NCT01203787	-		Completed	-	-
NCT01556815	PHENYTOIN/SORAFENIB [VA Drug I... 展开 >>nteraction] Liver Neoplasms Carcinoma, Hepatocellular Digestive System Neoplasms Neoplasms by Site Liver Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type DOXORUBICIN/TRASTUZUMAB [VA Drug Interaction] HBV 收起 <<	Phase 2	Unknown	May 2015	China, Shandong ... 展开 >> Shandong Cancer Hospital and Institute Not yet recruiting Jinan, Shandong, China, 250117 Contact: Wenbo Shao, MD, Ph D +8653167626412 shaowenbomd@gmail.com Principal Investigator: Jinlong Song, MD Sub-Investigator: Wenbo Shao, MD, Ph D 收起 <<
NCT02069145	Hepatocellular Cancer ... 展开 >> Liver Cancer 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> USC/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Colorado University of Colorado Cancer Center Aurora, Colorado, United States, 80045 United States, Indiana Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Massachusetts Massachussetts General Hospital Boston, Massachusetts, United States, 02114 United States, New York Mount Sinai Medical Center New York, New York, United States, 10029 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 收起 <<
NCT01906216	Hepatocellular Carcinoma	Phase 2 Phase 3	Recruiting	December 2018	China, Shaanxi ... 展开 >> Xijing Hospital of Digestive Disease Recruiting Xi`an, Shaanxi, China, 710032 Contact: Wei Bai, MD +8615991771343 Contact: Yan Zhao, MD +8613571884093 收起 <<
NCT01471353	-		Completed	-	-
NCT02196857	Leukemia	Phase 2	Active, not recruiting	February 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02298348	Neuroblastoma	Phase 1	Active, not recruiting	May 2019	United States, California ... 展开 >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027-0700 UCSF Comprehensive Cancer Center San Francisco, California, United States, 94143 United States, Colorado Children Hospital of Colorado Aurora, Colorado, United States, 80045 United States, Georgia Children's Healthcare of Atlanta Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago, Comer Children's Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Childrens Hospital Boston, Dana-Farber Cancer Institute. Boston, Massachusetts, United States, 02115 United States, Michigan C.S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Texas Cook Children's Healthcare System Fort Worth, Texas, United States, 76104 United States, Washington Children's Hospital and Regional Medical Center - Seattle Seattle, Washington, United States, 98105 Canada, Ontario Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 收起 <<
NCT01900002	Liver Cancer	Phase 2	Active, not recruiting	September 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02599337	Fasting	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Inventiv Health Clinique Inc. Québec, Quebec, Canada, G1P 0A2 收起 <<
NCT02021929	Hepatopulmonary Syndrome	Phase 2	Terminated	-	United States, Arizona ... 展开 >> Mayo Clinic Arizona Phoenix, Arizona, United States, 85054 United States, Illinois Northwestern University Feinberg School of Medicine Chicago, Illinois, United States, 60611 United States, Minnesota Mayo Clinic - Rochester Rochester, Minnesota, United States, 55905 United States, New York Columbia University-NewYork-Presbyterian Hospital New York, New York, United States, 10032 United States, Pennsylvania University of Pennsylvania - Perelman Center Philadelphia, Pennsylvania, United States, 19104 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29424 United States, Texas University of Texas Health Science Center at Houston Medical School Houston, Texas, United States, 77030 收起 <<
NCT02560779	Hepatocellular Carcinoma	Phase 1 Phase 2	Recruiting	November 2020	United States, Alabama ... 展开 >> University of Alabama Recruiting Birmingham, Alabama, United States, 35294-3300 United States, California City of Hope Withdrawn Duarte, California, United States, 91010 United States, Maryland National Cancer Institute Withdrawn Bethesda, Maryland, United States, 20892 United States, Ohio University Hospitals Recruiting Cleveland, Ohio, United States, 44106 United States, Texas MD Anderson Recruiting Houston, Texas, United States, 77030-4009 收起 <<
NCT03582618	Hepatocellular Carcinoma ... 展开 >> Advanced Cancer 收起 <<	Phase 2	Recruiting	June 2021	United States, California ... 展开 >> Innovative Clinical Research Institute Recruiting Whittier, California, United States, 90603 United States, South Carolina Charleston Hematology Oncology Associates Recruiting Charleston, South Carolina, United States, 29403 Taiwan National Cheng Kung University Hospital Not yet recruiting Tainan, Taiwan, 704 收起 <<
NCT02867280	Hepatocellular Carcinoma ... 展开 >> Recurrence 收起 <<	Phase 3	Recruiting	June 2023	China, Guangdong ... 展开 >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Minshan Cchen, M.D. 8620-87343117 chenmsh@sysucc.org.cn Contact: Li Xu, M.D. xuli@sysucc.org.cn Principal Investigator: Minshan Chen, M.D. 收起 <<
NCT02084732	Thyroid Cancer	Phase 2	Unknown	June 2018	Colombia ... 展开 >> Instituto Nacional de Cancerología Recruiting Bogotá, Cundinamarca, Colombia, 00000 Contact: Yeinnyer C. Muleth, BSc 3340106 ymuleth@cancer.gov.co Principal Investigator: Luis F Fierro, Md Sub-Investigator: Gloria Garavito, Md Sub-Investigator: Andres A Cuellar, Md Sub-Investigator: Jose A. Carreño, Md Sub-Investigator: Juan S Castillo, Md 收起 <<
NCT03535259	Hepatocellular Carcinoma, Radi... 展开 >>otherapy, Sorafenib 收起 <<	Phase 2	Recruiting	April 1, 2021	China, Beijing ... 展开 >> Bo Chen Recruiting Beijing, Beijing, China, 100021 Contact: Bo Chen, MD 008613240000876 chenboo@outlook.com Contact: Yexiong Li, MD 00861087788860 yexiong12@163.com Principal Investigator: Yexiong Li, MD Principal Investigator: Bo Chen, MD Sub-Investigator: Huiying Zeng, MD Sub-Investigator: Liming Wang, MD 收起 <<
NCT03722498	Hepatocellular Carcinoma	Phase 2	Recruiting	November 1, 2018	China, Guangdong ... 展开 >> Ming Shi Recruiting Guangzhou, Guangdong, China Contact: Ming Shi, MD (8620)-87343938 shiming@sysu.edu.cn Principal Investigator: Ming Shi, MD 收起 <<
NCT02733809	Hepatocellular Carcinoma	Phase 4	Recruiting	December 2024	Saudi Arabia ... 展开 >> King Saud University Medical City Recruiting Riyadh, Saudi Arabia, 7805 Contact: Weam S Husseim +966541480459 wshussain@ksu.edu.sa Principal Investigator: Dr. Mazen M Hassanain, MBBS FRCSC FACS PhD Sub-Investigator: Prof. Ayman A Abdo, MD, FRCPC, FACP Sub-Investigator: Dr. Khalid A Alswat, MD, ABIM, MRCP,FACP Sub-Investigator: Prof. Waleed K Alhamoudi Principal Investigator: Dr. Shouki M Bazarbashi 收起 <<
NCT02288507	Hepatocellular Cancer	Phase 1	Withdrawn(Closed due to no acc... 展开 >>rual) 收起 <<	-	United States, Hawaii ... 展开 >> University of Hawaii Honolulu, Hawaii, United States, 96813 收起 <<
NCT02122003	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Terminated(availability of new... 展开 >> and more promising therapeutic agents than expected in the experimentation in question) 收起 <<	-	Italy ... 展开 >> Istituto Tumori Milan, Mi, Italy, 20156 收起 <<
NCT01425216	Keloids	Phase 2	Terminated(IND application was... 展开 >> not approved by the US FDA - Project was never started) 收起 <<	-	United States, New York ... 展开 >> Michael H. Tirgan, MD New York, New York, United States, 10023 收起 <<
NCT02636426	Neoplasms	Phase 1	Completed	-	Netherlands ... 展开 >> VU University Medical Center Amsterdam, Noord-Holland, Netherlands, 1081 HV 收起 <<
NCT01223027	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 3	Completed	-	-
NCT03622541	FLT3-ITD Mutation ... 展开 >> AML 收起 <<	Phase 2	Recruiting	November 2019	Hong Kong ... 展开 >> The University of Hong Kong Recruiting Hong Kong, Hong Kong Contact: Chunxiao Zhang, SC 852-22554361 chunxiao@hku.hk 收起 <<
NCT01223027	-		Completed	-	-
NCT00971126	Hepatocellular Carcinoma	Phase 1 Phase 2	Terminated(Two patients in the... 展开 >> first dose level be counted as reaching DLT. DSMB recommend terminated early this trial.) 收起 <<	-	Taiwan ... 展开 >> Ghang-Gung Memorial Hospital at Chia-Yi Chia-Yi, Taiwan, 613 收起 <<
NCT00634634	Metastatic Breast Cancer	Phase 1 Phase 2	Active, not recruiting	May 2019	United States, District of Col... 展开 >>umbia Georgetown University Hospital Washington, District of Columbia, United States, 20007 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08901 Cooper Hospital/University Medical Center Voorhees, New Jersey, United States, 08690 收起 <<
NCT00779311	-		Terminated(Dose limiting toxic... 展开 >>ity at the lowest planned dose level.) 收起 <<	-	-
NCT01482442	Liver Carcinoma	Phase 3	Completed	-	France ... 展开 >> CHU Amiens #2 Amiens, France, 80054 CHU Angers #3 Angers, France, 49933 CHRU Besançon Hôpital Jean Minjoz #21 Besançon, France, 25030 Hôpital Jean Verdier #25 Bondy, France, 93140 Hôpital Côte de Nacre #4 Caen, France, 14033 Hôpital Antoine Béclère #29 Clamart, France, 92140 Hopital beaujon #1 Clichy, France, 92110 Henri Mondor #24 Créteil, France, 94000 CHU Dijon Hôpital Bocage #22 Dijon, France, 21000 CHU Grenoble #5 Grenoble, France, 38043 Hôpital Edouard Herriot #6 Lyon, France, 69003 Lyon La croix Rousse #27 Lyon, France, 69004 Institut Paoli Calmettes #7 Marseille, France, 13009 CHU Marseille Hôpital La Timone #23 Marseille, France, 13385 Hôpital Saint Eloi #8 Montpellier, France, 34295 Hôpital de Brabois #9 Nancy, France, 54511 Hotel Dieu #10 Nantes, France, 44093 Hôpital de L'Archet #11 Nice, France, 06002 Hôpital Européen Georges Pompidou #13 Paris, France, 75908 Hôpital Haut Leveque #14 Pessac, France, 33604 CHU Poitiers La Milétrie Poitiers, France, 86021 CHU Robert Debré #28 Reims, France, 51100 CHU Saint Etienne Hôpital Nord #17 Saint-Priest en Jarez, France, 42270 Hôpital de Hautepierre #18 Strasbourg, France, 67098 Paul Brousse #19 Villejuif, France, 94275 Institut Gustave Roussy #20 Villejuif, France, 94805 收起 <<
NCT00779311	Metastatic Colorectal Cancer	Phase 1	Terminated(Dose limiting toxic... 展开 >>ity at the lowest planned dose level.) 收起 <<	-	United States, Georgia ... 展开 >> Central Georgia Cancer Care Macon, Georgia, United States, 31201 United States, Montana Hematology Oncology Centers of the Northern Rockies Billings, Montana, United States, 59101 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 收起 <<
NCT01903694	Child-Pugh A Hepatocellular Ca... 展开 >>rcinoma 收起 <<	Phase 3	Completed	-	France ... 展开 >> CHU de Dijon Dijon, France, 21079 收起 <<
NCT01258608	Carcinoma, Hepatocellular	Phase 2	Completed	-	-
NCT00131937	-		Completed	-	-
NCT03247088	Acute Myeloid Leukemia	Phase 1 Phase 2	Recruiting	July 2022	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations CR_Study_Registration@mdanderson.org 收起 <<
NCT00466232	Small Cell Carcinoma ... 展开 >> Lung Cancer 收起 <<	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Park Nicollet Institute St. Louis Park, Minnesota, United States, 55416 收起 <<
NCT00844168	Adult Primary Hepatocellular C... 展开 >>arcinoma Advanced Adult Primary Liver Cancer Localized Resectable Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer Recurrent Adult Primary Liver Cancer 收起 <<	Phase 1	Completed	-	United States, Washington ... 展开 >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT01093222	Extrahepatic Bile Duct Adenoca... 展开 >>rcinoma Gallbladder Adenocarcinoma Gallbladder Adenocarcinoma With Squamous Metaplasia Hilar Cholangiocarcinoma Recurrent Extrahepatic Bile Duct Carcinoma Recurrent Gallbladder Carcinoma Undifferentiated Gallbladder Carcinoma Unresectable Extrahepatic Bile Duct Carcinoma Unresectable Gallbladder Carcinoma 收起 <<	Phase 2	Completed	-	-
NCT00131937	Anaplastic Large Cell Lymphoma... 展开 >> Angioimmunoblastic T-cell Lymphoma Hepatosplenic T-cell Lymphoma Peripheral T-cell Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Eastern Cooperative Oncology Group Boston, Massachusetts, United States, 02215 收起 <<
NCT01093222	-		Completed	-	-
NCT00734526	Glioblastoma ... 展开 >>Gliosarcoma 收起 <<	Phase 1	Terminated	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01335074	Hepatocellular Carcinoma	Phase 1 Phase 2	Withdrawn	-	Germany ... 展开 >> University Hospital Giessen and Marburg Marburg, Germany, 35043 收起 <<
NCT00678288	-		Terminated	-	-
NCT00300885	-		Terminated(Based on the result... 展开 >>s of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early.) 收起 <<	-	-
NCT00300885	Carcinoma, Non-Small Cell Lung	Phase 3	Terminated(Based on the result... 展开 >>s of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early.) 收起 <<	-	-
NCT00678288	Carcinoma, Renal Cell	Phase 2	Terminated	-	Austria ... 展开 >> Salzburg, Austria, 5020 Wien, Austria, 1090 France Avignon, France, 84000 Bayonne, France, 64100 Bordeaux, France, 33000 Marseille, France, 13015 Marseille, France, 13385 Nantes, France, 44020 Paris, France, 75014 Paris, France, 75651 Reims, France, 51100 Strasbourg, France, 67000 Toulouse, France, 31052 Vandoeuvre Les Nancy, France, 54000 Ireland Cork, Ireland Dublin, Ireland, 24 Italy Aviano, Pordenone, Italy, 33081 Legnago, Verona, Italy, 37045 Napoli, Italy, 80131 Pavia, Italy, 27100 Perugia, Italy, 06156 Reggio Emilia, Italy, 42100 Poland Gdansk, Poland, 80-219 Lublin, Poland, 20-090 Warszawa, Poland, 04-141 Wroclaw, Poland, 50 - 556 Spain Barcelona, Spain, 08035 Madrid, Spain, 28041 Madrid, Spain, 28046 Oviedo, Spain, 33006 Pamplona, Spain, 31008 Valencia, Spain, 46009 United Kingdom Northwood, Middlesex, United Kingdom, HA6 2RN Newcastle Upon Tyne, Tyne and Wear, United Kingdom, NE4 6BE London, United Kingdom, SW3 6JJ 收起 <<
NCT01126645	Hepatocellular Carcinoma	Phase 2	Unknown	March 2018	Germany ... 展开 >> University of Magdeburg Magdeburg, Germany, 39120 收起 <<
NCT00619242	Esophageal Cancer	Not Applicable	Terminated(Low accrual)	-	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT00542971	-		Completed	-	-
NCT00510250	Cancer of the Cervix	Phase 1 Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00619242	-		Terminated(Low accrual)	-	-
NCT01557127	-		Completed	-	Poland ... 展开 >> Many Locations, Poland 收起 <<
NCT01578109	Acute Myeloid Leukemia in Remi... 展开 >>ssion Acute Myeloid Leukemia With FLT3/ITD Mutation 收起 <<	Not Applicable	Active, not recruiting	-	United States, Maryland ... 展开 >> University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 收起 <<
NCT00542971	AML Acute Mye... 展开 >>loid Leukemia Myelodysplastic Disorders 收起 <<	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01033240	Advanced Hepatocellular Carcin... 展开 >>oma Liver Cancer Hepatic Cancer Liver Neoplasms 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Kenmar Research Group Los Angeles, California, United States, 90057 United States, District of Columbia Georgetown-Lombardi Cancer Center Washington DC, District of Columbia, United States, 20007 United States, New York The Mount Sinai Medical Center New York, New York, United States, 10029 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 Japan Kurume University Hospital Kurume-shi, Fukuoka, Japan, 830-0011 Hiroshima University Hiroshima-city, Hiroshima, Japan Kanazawa University Kanazawa, Ishikawa, Japan Kinki University Hospital Osaka, Osaka-sayama, Japan, 589-8511 Osaka Med Center Cancer and Cardiovascular Disease Higashinari-ku, Osaka, Japan, 537-8511 Yamaguchi University Hospital Ube, Yamaguchi, Japan Chiba University Hospital Chiba, Japan, 260-8677 Okayama University Hospital Okayama, Japan, 700-8558 Musashino Red-Cross Hospital Tokyo, Japan, 180-8610 Korea, Republic of Samsung Medical Center Gangnam-gu, Seoul, Korea, Republic of, 135-710 Keimyung University Dongsan Hospital Daegu, Korea, Republic of, 700-712 Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Severance Hospital Seoul, Korea, Republic of, 120-752 Korea University Anam Hospital Seoul, Korea, Republic of, 136-705 Catholic Univ. of Korea, Seoul St. Mary's Hospital Seoul, Korea, Republic of, 137-701 Asan Medical Center Seoul, Korea, Republic of, 138-736 Taiwan Chang Gung Memorial Hospital Putz, Chiayi, Taiwan Kaohiung Chang Gung Hospital Kaohsiung, Niaosung Hsiang, Taiwan Chi-Mei Medical Center Liouying, Tainan County, Taiwan, 736 Changhua Christian Hospital Changhua, Taiwan, 500 Kaohslung Medical University Hospital Kaohsiung, Taiwan, 807 National Cheng-Kung University Hospital Tainan city, Taiwan, 704 National Taiwan University Hospital Taipei, Taiwan Chang Gung Medical Foundation-Linkuo Taoyuan, Taiwan, 33305 收起 <<
NCT01194869	Breast Cancer	Phase 2	Terminated(Slow accrual, avail... 展开 >>ability of other clinical options) 收起 <<	-	United States, Georgia ... 展开 >> Grady Memorial Hospital Atlanta, Georgia, United States, 30303 Emory University Hospital Midtown Atlanta, Georgia, United States, 30308 Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30322 收起 <<
NCT01194869	-		Terminated(Slow accrual, avail... 展开 >>ability of other clinical options) 收起 <<	-	-
NCT01450384	Unspecified Adult Solid Tumor	Phase 1	Completed	-	United States, Virginia ... 展开 >> Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT01715441	Metastatic Colorectal Cancer P... 展开 >>atients With KRAS Mutated Tumors 收起 <<	Phase 2	Unknown	September 2015	France ... 展开 >> Hôpital AVICENNE Recruiting Bobigny, France, 93009 Contact: Thomas APARICIO, MD Thomas.aparicio@avc.aphp.fr Principal Investigator: Thomas APARICIO, MD Centre François Baclesse Recruiting Caen, France, 14076 Contact: Marie-Pierre GALAIS, MD Principal Investigator: Marie-Pierre GALAIS, MD Centre Oscar Lambret Recruiting Lille, France, 59020 Contact: Antoine ADENIS, MD a-adenis@o-lambret.fr Principal Investigator: Antoine ADENIS, MD Centre Léon Bérard Recruiting Lyon, France, 69373 Contact: Françoise DESSEIGNE, MD Principal Investigator: Françoise DESSEIGNE, MD Hôpital LA TIMONE Recruiting Marseille, France, 13365 Contact: Jean-François SEITZ, MD Jean-françois.seitz@ap-hm.fr Principal Investigator: Jean-François SEITZ, MD CRLC Val d'Aurelle-Paul Lamarque Recruiting Montpellier, France, 34298 Contact: Emmanuelle SAMALIN, MD Principal Investigator: Emmanuelle SAMALIN, MD C.H.U. de REIMS Recruiting Reims, France, 51092 Contact: Olivier BOUCHE, MD Obouche@chu-reims.fr Principal Investigator: Olivier BOUCHE, MD CHU Charles Nicolle Recruiting Rouen, France, 76038 Contact: Frédéric Di FIORE, MD 33 2.32.88.81.01 Frederic.Di-Fiore@chu-rouen.fr Principal Investigator: Frédéric Di FIORE, MD Institut de Cancérologie de l'Ouest - René Gauducheau Recruiting St. Herblain, France, 44805 Contact: Jaafa BENNOUNA, MD Jaafa.bennouna@ico.unicancer.fr Principal Investigator: Jaafa BENNOUNA, MD 收起 <<
NCT00064350	Lung Cancer	Phase 2	Completed	-	-
NCT00722072	Breast Cancer	Phase 2	Terminated(Sponsor pulled fund... 展开 >>ing and low accrual) 收起 <<	-	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Portland, Oregon, United States, 97239-3098 收起 <<
NCT00064350	-		Completed	-	-
NCT00722072	-		Terminated(Sponsor pulled fund... 展开 >>ing and low accrual) 收起 <<	-	-
NCT00418496	Renal Cancer ... 展开 >>Melanoma 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> Ohio State University Columbus, Ohio, United States, 43210 收起 <<
NCT01411436	-		Completed	-	Japan ... 展开 >> Many locations, Japan 收起 <<
NCT01585870	Neoplasms	Phase 1	Completed	-	France ... 展开 >> Toulouse, France, 31052 Germany Freiburg, Baden-Württemberg, Germany, 79106 Heidelberg, Baden-Württemberg, Germany, 69120 Berlin, Germany, 10117 收起 <<
NCT01933945	-		Completed	-	-
NCT00373373	Acute Myeloid Leukemia	Phase 2	Completed	-	Germany ... 展开 >> Charité Campus Benjamin Franklin, Med. Klinik III Berlin, Germany, 12203 Klinikum Chemnitz GmbH, Klinik für Innere Medizin III Chemnitz, Germany, 09113 Universitätsklinikum Carl Gustav Carus der TU Dresden, Medizinische Klinik I Dresden, Germany, 01307 St. Johannes Hospital, Medizinische Klinik II Duisburg, Germany, 47166 Universitätsklinikum Essen, Zentrum für Innere Medizin, Medizinische Klinik und Poliklinik für Hämatologie Essen, Germany, 45147 Klinikum der J. W. Goethe-Universität Frankfurt am Main, Medizinische Klinik II Frankfurt / Main, Germany, 60590 Allgemeines Krankenhaus St. Georg, Hämatologische Abteilung Hamburg, Germany, 20099 Universitätsklinikum Heidelberg, Med. Klinik V Heidelberg, Germany, D-69120 Klinikum der Universität zu Köln, Klinik I für Innere Medizin Köln, Germany, 50937 Klinikum der Johannes Gutenberg Universität, 3. Medizinische Klinik und Poliklinik Mainz, Germany, 55101 Philipps Universität, Abteilung für Hämatologie, Onkologie und Immunologie Marburg, Germany, 35043 Klinik für Hämatologie und Onkologie Klinikum Minden Minden, Germany, 32423 TU München, Medizinische Klinik III München, Germany, 81675 Universitätsklinikum Münster, Medizinische Klinik A Münster, Germany, 48149 Klinikum Nürnberg, 5. Medizinische Klinik Einheit für Knochenmarktransplantation Nürnberg, Germany, 90419 Universität Regensburg, Abteilung für Hämatologie und Internistische Onkologie Regensburg, Germany, 93042 Robert-Bosch Krankenhaus Stuttgart Stuttgart, Germany, 70376 Julius-Maximilians-Universität Würzburg, Medizinische Klinik und Poliklinik II Würzburg, Germany, 97979 收起 <<
NCT00889057	Osteosarcoma	Phase 2	Completed	-	Italy ... 展开 >> I.R.C.C. - Unit of Medical Oncology Candiolo, Torino, Italy, 10060 Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors Bologna, Italy, 40136 Istituto Nazionale Tumori - Unit of Medical Oncology Milano, Italy, 20133 Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology Torino, Italy, 10126 收起 <<
NCT00722969	Non-Small Cell Lung Cancer	Phase 2	Unknown	April 2009	Netherlands ... 展开 >> VU university medical center Amsterdam, Netherlands, 1007 MB Netherlands Cancer Institute Amsterdam, Netherlands University Medical Center Groningen Groningen, Netherlands University Hospital Maastricht Maastricht, Netherlands 收起 <<
NCT02024087	Advanced Adult Hepatocellular ... 展开 >>Carcinoma 收起 <<	Phase 1 Phase 2	Completed	-	United States, Illinois ... 展开 >> The University of Chicago Medical Center Chicago, Illinois, United States United States, Kansas University of Kansas Medical Center (KUMC) Westwood, Kansas, United States United States, Massachusetts Beth Israel Deaconess Medical Center (BIDMC) Boston, Massachusetts, United States United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States University of Rochester Rochester, New York, United States United States, Ohio University of Cincinnati Cancer Institute Cincinnati, Ohio, United States 收起 <<
NCT00610246	Cancer	Phase 1	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00405366	Kidney Cancer	Early Phase 1	Completed	-	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 收起 <<
NCT00602862	Clear Cell Renal Cell Carcinom... 展开 >>a 收起 <<	Not Applicable	Completed	-	Netherlands ... 展开 >> Radboud University Nijmegen Medical Center Nijmegen, Gelderland, Netherlands, 6500 HB 收起 <<
NCT01272557	Liver Carcinoma	Phase 2	Unknown	December 2014	Germany ... 展开 >> Medizinische Klinik und Poliklinik, Heinrich-Heine-Universität Düsseldorf, Germany, 40225 Martin-Luther-University Halle-Wittenberg Halle (Saale), Germany, D-06099 Universitätsklinikum des Saarlande Homburg/Saar, Germany, 66421 Ortenau Klinikum Lahr-Ettenheim Lahr, Germany, 77933 Universitätsklinikum Leipzig Leipzig, Germany, 04013 Klinikum Ludwigsburg Ludwigsburg, Germany, 71640 收起 <<
NCT01047891	Ovarian Cancer	Phase 2	Completed	-	Germany ... 展开 >> Charité Campus Virchow-Klinikum Berlin, Germany, 13355 收起 <<
NCT01839630	-		Completed	-	China ... 展开 >> Multiple Locations, China 收起 <<
NCT01518413	Rhabdomyosarcoma and Other Sof... 展开 >>t Tissue Sarcomas Ewing's Sarcoma Family of Tumors Osteosarcoma Neuroblastoma Brain Tumors 收起 <<	Phase 1	Completed	-	United States, District of Col... 展开 >>umbia Children's National Medical Center Washington, District of Columbia, United States, 20010 United States, Maryland National Cancer Institute Bethesda, Maryland, United States, 20892 United States, Massachusetts Children's Hospital Boston/Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Pennsylvania The Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT00712790	Hepatocellular Carcinoma	Phase 1 Phase 2	Completed	-	Korea, Republic of ... 展开 >> Seoul National University Bundang Hospital Seoul, Korea, Republic of Malaysia Selayang Hospital Selangor, Malaysia Myanmar Yangon GI & Liver Centre Yangon, Myanmar Singapore Singapore General Hospital Singapore, Singapore, 169608 National Cancer Centre Singapore, Singapore, 169610 收起 <<
NCT01141478	Carcinoma, Hepatocellular	Not Applicable	Unknown	June 2018	United States, California ... 展开 >> Loma Linda University Medical Center Recruiting Loma Linda, California, United States, 92354 收起 <<
NCT01497444	Kidney Cancer ... 展开 >> Liver Cancer 收起 <<	Phase 1	Active, not recruiting	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale Scottsdale, Arizona, United States, 85259-5499 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 收起 <<
NCT00093613	Adult Anaplastic Astrocytoma ... 展开 >> Adult Anaplastic Oligodendroglioma Adult Giant Cell Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland Adult Brain Tumor Consortium Baltimore, Maryland, United States, 21231-1000 Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, North Carolina Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT01412671	-		Completed	-	Japan ... 展开 >> Multiple Locations, Japan 收起 <<
NCT01411423	-		Completed	-	Japan ... 展开 >> Multiple Locations, Japan 收起 <<
NCT01861314	Acute Myeloid Leukemia ... 展开 >> Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Active, not recruiting	-	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT01840592	Hepatocellular Carcinoma	Phase 2	Active, not recruiting	April 2019	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering West Harrison Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States, 11570 Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center Sleepy Hollow, New York, United States, 10591 收起 <<
NCT02988440	Hepatocellular Carcinoma	Phase 1	Recruiting	August 16, 2019	United States, Michigan ... 展开 >> Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Colette Zack zackc@karmanos.org Principal Investigator: Philip A. Philip Canada, Quebec Novartis Investigative Site Recruiting Montreal, Quebec, Canada, H3T 1E2 France Novartis Investigative Site Terminated Clichy, France, 92110 Germany Novartis Investigative Site Completed Essen, Germany, 45147 Hong Kong Novartis Investigative Site Active, not recruiting Hong Kong, Hong Kong Italy Novartis Investigative Site Recruiting Rozzano, MI, Italy, 20089 Japan Novartis Investigative Site Active, not recruiting Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Active, not recruiting Yokohama city, Kanagawa, Japan, 232 0024 Spain Novartis Investigative Site Completed Pamplona, Navarra, Spain, 31008 Taiwan Novartis Investigative Site Active, not recruiting Taipei, Taiwan, 10002 收起 <<
NCT01135056	Hepatocellular Carcinoma	Phase 3	Active, not recruiting	July 31, 2018	-
NCT00461851	Bladder Cancer	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Yale University, Comprehensive Cancer Center New Haven, Connecticut, United States, 06520 收起 <<
NCT00461851	-		Completed	-	-
NCT03644511	-		Not yet recruiting	December 31, 2021	Germany ... 展开 >> Many Locations Not yet recruiting Multiple Locations, Germany 收起 <<
NCT00411671	Lung Cancer	Phase 2	Completed	-	United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00411671	-		Completed	-	-
NCT00848640	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Completed	-	Egypt ... 展开 >> Egyptian Foundation For Cancer Research Cairo, Egypt, 11553 收起 <<
NCT00090545	Prostate Cancer	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 收起 <<
NCT00090545	-		Completed	-	-
NCT00126568	-		Terminated	-	-
NCT02114658	Thyroid Carcinoma	Phase 2	Completed	-	Japan ... 展开 >> Kobe, Hyogo, Japan, 650-0011 Matsumoto, Nagano, Japan, 390-8621 Bunkyo-ku, Tokyo, Japan, 113-8603 Koto-ku, Tokyo, Japan, 135-8550 Osaka, Japan, 545-8586 收起 <<
NCT00557830	-		Terminated(The study was close... 展开 >>d to enrollment when it became clear that enrollment was too slow to complete the full enrollment target within the time frame allowed.) 收起 <<	-	-
NCT00557830	Renal Cell Carcinoma	Phase 2	Terminated(The study was close... 展开 >>d to enrollment when it became clear that enrollment was too slow to complete the full enrollment target within the time frame allowed.) 收起 <<	-	United States, Arkansas ... 展开 >> Clopton Clinic Jonesboro, Arkansas, United States, 72401 United States, California Wilshire Oncology Medical Group, Inc. La Verne, California, United States, 91750 United States, Florida Advanced Medical Specialties Miami, Florida, United States, 33176 United States, Georgia Northeast Georgia Cancer Care Athens, Georgia, United States, 30607 Peachtree Hematology Oncology Consultants Atlanta, Georgia, United States, 30309 Central Georgia Cancer Care Macon, Georgia, United States, 31201 Northwest Georgia Oncology Centers Marietta, Georgia, United States, 30060 United States, Illinois Mid-Illinois Hematology and Oncology Associates, Ltd. Normal, Illinois, United States, 61761 United States, Montana Hematology Oncology Centers of the Northern Rockies Billings, Montana, United States, 59101 United States, North Carolina Gaston Hematology and Oncology Gastonia, North Carolina, United States, 28054 United States, Oregon Pacific Oncology, PC Beaverton, Oregon, United States, 97006 United States, Pennsylvania The Lancaster Cancer Center, Ltd Lancaster, Pennsylvania, United States, 17605 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 收起 <<
NCT00496756	Kidney Cancer	Phase 2	Terminated(Low accrual rate.)	-	United States, Nebraska ... 展开 >> UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-6805 收起 <<
NCT01290926	Colorectal Cancer	Phase 2	Completed	-	Belgium ... 展开 >> Cliniques Universitaires Saint Luc Woluwe Saint Lambert, Bruxelles, Belgium, 1200 Universiteit Ziekenhuis Antwerpen Antwerpen, Belgium Institut Jules Bordet Brussels, Belgium, 1000 Hopital Erasme Brussels, Belgium, 1070 Entité Jolimontoise La Louviere, Belgium Hopitaux St Joseph Liege, Belgium, 4000 CHU Ambroise Paré Mons, Belgium, 7000 收起 <<
NCT01982097	-		Completed	-	Russian Federation ... 展开 >> Multiple Locations, Russian Federation 收起 <<
NCT00126568	Anaplastic Thyroid Cancer ... 展开 >> Recurrent Thyroid Cancer 收起 <<	Phase 2	Terminated	-	United States, Ohio ... 展开 >> Case Western Reserve University Cleveland, Ohio, United States, 44106 收起 <<
NCT01730937	Adult Primary Hepatocellular C... 展开 >>arcinoma Advanced Adult Primary Liver Cancer Recurrent Adult Primary Liver Cancer 收起 <<	Phase 3	Recruiting	June 2025	-
NCT00943449	Hepatocellular Carcinoma	Phase 2	Completed	-	Germany ... 展开 >> ONKOPLUS Beratung und Hilfe für Menschen mit Krebs Berlin, Germany, 14195 Universitätsklinikum Essen (Innere Klinik/Tumorforschung und Zentrum für Innere Medizin) Essen, Germany, 45147 Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg (Klinik und Poliklinik für Innere Medizin I) Halle, Germany, 06120 Universitätsklinikum Hamburg-Eppendorf (I. Medizinische Klinik und Poliklinik) Hamburg, Germany, 20246 Universitätsklinikum Heidelberg (Medizinische Universitätsklinik/Innere Medizin IV/Nationales Centrum für Tumorerkrankungen) Heidelberg, Germany, 69120 Johannes Gutenberg-Universität Mainz (I. Medizinische Klinik und Poliklinik) Mainz, Germany, 55131 Klinikum rechts der Isar der Technischen Universität München (Medizinische Klinik und Poliklinik II/Gastroenterologie) Munich, Germany, 81675 Universitätsklinikum Tübingen (Medizinische Klinik/Innere Medizin I) Tübingen, Germany, 72076 Italy l'Azienda Ospedaliero-Universitaria di Bologna-Policlinico S. Orsola Malpighi Bologna, Italy, 40138 l'Università degli Studi di Genova (Dipartimento di Medicina Interna e Specialità Mediche) Genova, Italy, 16132 Istituto Europea di Oncologia EIO Milano, Italy, 20141 A.O.R.N. Monaldi-Cotugno-CTO Napoli, Italy, 80131 l'Azienda Ospedaliera di Padova and l'Istituto Oncologico Veneto IOV Padova, Italy l'Ente "Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone" Palermo, Italy, 12990127 L'Istituto Clinico Humanitas-Humanitas Mirasole S.p.A. Rozzano-Milano, Italy, 20089 收起 <<
NCT03009461	HepatoCellular Carcinoma ... 展开 >> Portal Vein Thrombosis 收起 <<	Phase 2	Recruiting	December 2019	China, Beijing ... 展开 >> Peking University Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Xiaodong Wang, MD 008610-88196476 wangxde@gmail.com Sub-Investigator: Guang Cao, MD Sub-Investigator: Hui Chen, MD Sub-Investigator: Jianhai Guo, MD Sub-Investigator: Haifeng Xu, MD Sub-Investigator: Peng Liu, MD Sub-Investigator: Jungang Hu, MD 收起 <<
NCT00436215	Ovarian Neoplasm ... 展开 >> Fallopian Tube Cancer Primary Peritoneal Cancer 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00436215	-		Completed	-	-
NCT00863746	Carcinoma Non... 展开 >>-Small-Cell Lung 收起 <<	Phase 3	Completed	-	-
NCT00825734	Metastatic Breast Cancer	Phase 1 Phase 2	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Ft. Myers, Florida, United States, 33916 United States, Indiana Providence Medical Group Terre Haute, Indiana, United States, 47802 RHHP/ Hope Cancer Center Terre Haute, Indiana, United States, 47802 United States, Kentucky Baptist Hospital East Louisville, Kentucky, United States, 40207 United States, Louisiana Hematology Oncology Clinic, LLP Baton Rouge, Louisiana, United States, 70806 United States, Maine Mercy Hospital Portland, Maine, United States, 04101 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 National Capital Clinical Research Consortium Bethesda, Maryland, United States, 20817 United States, Missouri St. Louis Cancer Care Chesterfield, Missouri, United States, 63044 United States, New Hampshire Portsmouth Regional Hospital Portsmouth, New Hampshire, United States, 03801 United States, New Jersey Hematology-Oncology Associates of Northern NJ Morristown, New Jersey, United States, 07962 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, South Carolina South Carolina Oncology Associates Columbia, South Carolina, United States, 29210 Spartanburg Regional Medical Center Spartanburg, South Carolina, United States United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 收起 <<
NCT00714948	Bladder Cancer ... 展开 >> URINARY BLADDER 收起 <<	Phase 2	Terminated(Lack of accrual)	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00863746	-		Completed	-	-
NCT01844947	Urothelial Carcinoma ... 展开 >> Bladder Cancer Renal Pelvis Cancer Ureter Cancer Urethra Cancer 收起 <<	Phase 1	Completed	-	Denmark ... 展开 >> Department of Oncology, Aarhus University Hospital Aarhus, Denmark, DK-8200 Department of Oncology, Rigshospitalet Copenhagen, Denmark, DK-2100 Sweden Department of Oncology, Karolinska University Hospital Stockholm, Sweden, SE-171 76 收起 <<
NCT00825734	-		Completed	-	-
NCT00392821	-		Completed	-	-
NCT00714948	-		Terminated(Lack of accrual)	-	-
NCT00839111	Colorectal Neoplasms	Phase 2	Unknown	November 2010	China, Shanghai ... 展开 >> Cancer Hospital,Fudan University Recruiting Shanghai, Shanghai, China, 200032 Contact: Yanfei Liu, Master +862164175590 ext 1107 收起 <<
NCT00613145	Refractory Malignancy	Phase 1	Completed	-	United States, Tennessee ... 展开 >> Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 收起 <<
NCT00392821	Kidney Cancer	Phase 1 Phase 2	Completed	-	United States, Florida ... 展开 >> Florida Hospital Cancer Institute Orlando, Florida, United States, 32804 United States, Georgia Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 Wellstar Cancer Research Marietta, Georgia, United States, 30060 United States, Kentucky Baptist Hospital East Louisville, Kentucky, United States, 40207 Norton Cancer Institute Louisville, Kentucky, United States, 40207 United States, Missouri Research Medical Center Kansas City, Missouri, United States, 64132 United States, New Jersey Hematology Oncology Associates of Northern NJ Morristown, New Jersey, United States, 07960 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, South Carolina South Carolina Oncology Associates, PA Columbia, South Carolina, United States, 29210 Spartanburg Regional Medical Center Spartanburg, South Carolina, United States, 29303 United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 收起 <<
NCT00595985	Gastric Cancer	Phase 2	Terminated(low response rate, ... 展开 >>no evidence of PFS or OS improved.) 收起 <<	January 2009	China, Shanghai ... 展开 >> Fudan University Cancer Hospital ShangHai, Shanghai, China, 200032 收起 <<
NCT02989870	HepatoCellular Carcinoma ... 展开 >> Unresectable HepatoCellular Carcinoma Liver Cancer 收起 <<	Phase 1	Withdrawn(No Interest. Investi... 展开 >>gator was unable to enroll any participants on study.) 收起 <<	-	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT01076010	Advanced Renal Cell Carcinoma	Phase 3	Completed	-	-
NCT01445080	Leukemia With... 展开 >> AML and FLT3-ITD Mutations 收起 <<	Phase 1 Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02187081	HCC	Not Applicable	Recruiting	December 2018	China, Chongqing ... 展开 >> Southwest Hospital Recruiting Chongqing, Chongqing, China, 400038 Contact: Xiaobin Feng Principal Investigator: Kuansheng Ma, Ph.D 收起 <<
NCT00562913	Cancer	Phase 1	Completed	-	Canada, Alberta ... 展开 >> Edmonton, Alberta, Canada, T6G 1Z2 Canada, Quebec Montreal, Quebec, Canada, H3T 1E2 收起 <<
NCT03211416	Advanced Adult Hepatocellular ... 展开 >>Carcinoma Child-Pugh Class A Stage III Hepatocellular Carcinoma Stage IIIA Hepatocellular Carcinoma Stage IIIB Hepatocellular Carcinoma Stage IIIC Hepatocellular Carcinoma Stage IV Hepatocellular Carcinoma Stage IVA Hepatocellular Carcinoma Stage IVB Hepatocellular Carcinoma 收起 <<	Phase 1 Phase 2	Recruiting	October 11, 2019	United States, New York ... 展开 >> Roswell Park Cancer Institute Recruiting Buffalo, New York, United States, 14263 Contact: Roswell Park 877-275-7724 ASKRPCI@roswellpark.org Principal Investigator: Renuka V. Iyer 收起 <<
NCT03097848	HCC	Not Applicable	Recruiting	December 31, 2018	China, Chongqing ... 展开 >> Southwest Hospital Recruiting Chongqing, Chongqing, China, 400038 Contact: kuansheng Ma, MD 收起 <<
NCT00606125	Neoplasms	Phase 1	Completed	-	United States, Connecticut ... 展开 >> New Haven, Connecticut, United States, 06511-5991 United States, Texas San Antonio, Texas, United States, 78229-3307 收起 <<
NCT00390325	Multiple Endocrine Neoplasia ... 展开 >> Recurrent Thyroid Gland Carcinoma Thyroid Gland Medullary Carcinoma 收起 <<	Phase 2	Active, not recruiting	-	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT00586105	Carcinoma, Renal Cell	Phase 3	Completed	-	China, Jiangsu ... 展开 >> Nanjing, Jiangsu, China, 210003 China Beijing, China, 100021 Shanghai, China, 200032 Shanghai, China, 200127 Taiwan Tainan, Taiwan, 70428 Taipei, Taiwan, 10002 Taipei, Taiwan, 112 Taoyuan, Taiwan, 333 收起 <<
NCT00866320	Kidney Cancer	Phase 2	Completed	-	United States, Ohio ... 展开 >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 United States, Texas Baylor Sammons Cancer Center Dallas, Texas, United States, 75246 收起 <<
NCT01915602	Carcinoma, Hepatocellular	Phase 2	Completed	-	-
NCT00866320	-		Completed	-	-
NCT01187212	Malignant Neoplasm of Stomach ... 展开 >> Effects of Chemotherapy 收起 <<	Phase 2	Completed	-	Korea, Republic of ... 展开 >> Asan Medical Center Songpa-gu, Seoul, Korea, Republic of, 138-736 收起 <<
NCT00759928	Refractory Solid Tumors	Phase 1	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Fort Myers, Florida, United States, 33916 United States, Tennessee Tennessee Oncology Nashville, Tennessee, United States, 37203 收起 <<
NCT00414388	Prostate Cancer	Phase 1 Phase 2	Completed	-	United States, Illinois ... 展开 >> Onocology Specialists, S.C Niles, Illinois, United States, 60714 Oncology Specialists, S.C Park Ridge, Illinois, United States, 60068 收起 <<
NCT00586105	-		Completed	-	-
NCT00414388	-		Completed	-	-
NCT02575339	Hepatocellular Carcinoma ... 展开 >> Liver Cancer HCC 收起 <<	Phase 1 Phase 2	Active, not recruiting	June 2020	United States, Illinois ... 展开 >> Northwestern University Feinberg School of Medicine Chicago, Illinois, United States, 60611 University of Illinois Cancer Center Chicago, Illinois, United States, 60612 United States, Indiana Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, North Carolina University of Noth Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27514 United States, Pennsylvania Penn State Cancer Institute Hershey, Pennsylvania, United States, 17033 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53705 收起 <<
NCT02450149	Refractory Solid Tumors	Not Applicable	Completed	-	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, seoul, korea, Republic of, Korea, Republic of, 135-710 收起 <<
NCT00635791	Malignant Solid Tumour ... 展开 >> Renal Cell Carcinoma Non Small Cell Lung Carcinoma 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> University of Colorado Cancer Center Aurora, Colorado, United States, 80045 收起 <<
NCT00609934	Renal Cell Carcinoma	Phase 1 Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Hosptial Toronto, Ontario, Canada, M5G2M9 收起 <<
NCT00844688	Hepatocellular Carcinoma	Phase 2	Unknown	December 2009	Pakistan ... 展开 >> Combined Military Hospital Recruiting Rawalpindi, Punjab, Pakistan, 46000 Principal Investigator: Naeem Naqi, MBBS,FCPS 收起 <<
NCT03439891	Stage III Hepatocellular Carci... 展开 >>noma AJCC v8 Stage IIIA Hepatocellular Carcinoma AJCC v8 Stage IIIB Hepatocellular Carcinoma AJCC v7 Stage IIIC Hepatocellular Carcinoma AJCC v7 Stage IV Hepatocellular Carcinoma AJCC v8 Stage IVA Hepatocellular Carcinoma AJCC v8 Stage IVB Hepatocellular Carcinoma AJCC v8 收起 <<	Phase 2	Recruiting	December 31, 2020	United States, California ... 展开 >> University of California, San Francisco Recruiting San Francisco, California, United States, 94158 Contact: Robin K. Kelley 877-827-3222 cancertrials@ucsf.edu Principal Investigator: Robin K. Kelley 收起 <<
NCT02627963	Carcinoma, Renal Cell	Phase 3	Active, not recruiting	December 2019	-
NCT02354898	Advanced Solid Tumors ... 展开 >> Hepatocellular Carcinoma 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> 5 Sites Chiba, Etc., Japan 收起 <<
NCT02400788	Hepatocellular Carcinoma	Phase 1 Phase 2	Completed	-	Japan ... 展开 >> Chiba, Japan Ishikawa, Japan Kanagawa, Japan Kochi, Japan Kyoto, Japan Osaka, Japan Saga, Japan Shizuoka, Japan Tokyo, Japan Korea, Republic of Busan, Korea, Republic of Daegu, Korea, Republic of Seoul, Korea, Republic of 收起 <<
NCT02599090	Glioblastoma ... 展开 >>Gliosarcoma 收起 <<	Phase 2	Withdrawn(Multi phase study di... 展开 >>d not progress to Phase II. Phase I registered as NCT00734526.) 收起 <<	-	-
NCT01687673	Hepatocellular Carcinoma	Phase 2	Active, not recruiting	September 2017	United States, California ... 展开 >> University of California, San Francisco San Francisco, California, United States, 94143 United States, Illinois Robert H Lurie Comprehensive Cancer Center Chicago, Illinois, United States, 60611 收起 <<
NCT00245102	Adult Angiosarcoma ... 展开 >> Adult Epithelioid Sarcoma Adult Leiomyosarcoma Adult Malignant Fibrous Histiocytoma Adult Neurofibrosarcoma Adult Synovial Sarcoma Ovarian Sarcoma Recurrent Adult Soft Tissue Sarcoma Recurrent Uterine Sarcoma Stage III Adult Soft Tissue Sarcoma Stage III Uterine Sarcoma Stage IV Adult Soft Tissue Sarcoma Stage IV Uterine Sarcoma Uterine Carcinosarcoma Uterine Leiomyosarcoma 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00473486	Carcinoma, Non-Small-Cell Lung	Phase 1 Phase 2	Terminated(Sorafenib administe... 展开 >>red in the combination with pemetrexed-carboplatin appears to enhance thrombocytopenia compared to historical data.) 收起 <<	-	Germany ... 展开 >> University of Muenster, Dept. of Medicine, Hematology / Oncology Muenster, Germany, 48145 收起 <<
NCT00494182	Metastatic Head and Neck Squam... 展开 >>ous Cell Carcinoma Metastatic Squamous Cell Carcinoma of the Hypopharynx Metastatic Squamous Cell Carcinoma of the Larynx Metastatic Squamous Cell Carcinoma of the Oral Cavity Metastatic Squamous Cell Carcinoma of the Oropharynx Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma 收起 <<	Phase 2	Active, not recruiting	April 30, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01320111	Metastatic Breast Cancer	Phase 2	Completed	-	Germany ... 展开 >> Germany Multiple Sites All Over Germany Recruiting Multiple Sites, Germany Contact: iOMEDICO AG Freiburg, Germany, 79108 收起 <<
NCT01078311	-		Unknown	February 2014	Australia, New South Wales ... 展开 >> Westmead Hospital Recruiting Westmead, New South Wales, Australia, 2145 收起 <<
NCT00245102	-		Completed	-	-
NCT03775395	Hepatocellular Carcinoma	Phase 3	Recruiting	December 1, 2021	China, Guangdong ... 展开 >> Cancer Center Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Ming Shi, MD 8620-87343115 shiming@mail.sysu.edu.cn 收起 <<
NCT00278382	Anaplastic Large Cell Lymphoma... 展开 >> Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Mantle Cell Lymphoma 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 收起 <<
NCT00533585	Lung Cancer	Phase 1	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00823290	Hepatocellular Carcinoma	Phase 1	Unknown	December 2010	Germany ... 展开 >> Department of Medicine 1, University Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Matthias Ocker, MD +49-6421-58 ext 68931 Matthias.Ocker@staff.uni-marburg.de Contact: Susanne Gahr, MD +49-9131-85 ext 35000 susanne.gahr@uk-erlangen.de Principal Investigator: Deike Strobel, MD 收起 <<
NCT01276210	Tumors Metastatic to Brain	Phase 1	Completed	-	United States, Tennessee ... 展开 >> Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 收起 <<
NCT00984282	Thyroid Neoplasms	Phase 3	Completed	-	-
NCT00984282	-		Completed	-	-
NCT03456401	Renal Cancer Cell	Phase 2	Terminated(availability of new... 展开 >> and more promising therapeutic agents than expected in the experimentation in question) 收起 <<	-	Italy ... 展开 >> Istituto Tumori Milan, Mi, Italy, 20156 收起 <<
NCT01897038	Carcinoma, Hepatocellular	Phase 1	Completed	-	United States, Florida ... 展开 >> Sarasota, Florida, United States, 34232 United States, Maryland Baltimore, Maryland, United States, 21231 United States, New York New York, New York, United States, 10065 United States, Tennessee Nashville, Tennessee, United States, 37203 United States, Texas Houston, Texas, United States, 77030 Hong Kong Pokfulam, Hong Kong Singapore Singapore, Singapore, 119228 Singapore, Singapore, 169610 Taiwan Tainan, Taiwan, 00704 Taipei, Taiwan, 100 收起 <<
NCT03164382	Liver Cancer ... 展开 >>Hepatic Carcinoma 收起 <<	Phase 3	Recruiting	December 31, 2022	China, Guangdong ... 展开 >> Minimally Invasive Interventional Division, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Recruiting Guangzhou, Guangdong, China, 500060 Contact: Ming Zhao, MD 86-20-87343272 zhaoming@sysucc.org.cn 收起 <<
NCT00627835	Locally Advanced Squamous Cell... 展开 >> Carcinomas of the Head and Neck (SCCHN) 收起 <<	Phase 1	Withdrawn(Site decided not to ... 展开 >>open this study) 收起 <<	-	Canada, British Columbia ... 展开 >> BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 收起 <<
NCT00619996	Prostate Cancer	Phase 2	Completed	-	Italy ... 展开 >> Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina ... Indirizzo: via Roma, 55 - 56100 Pisa Tel. 050-2218690 - Fax. 050-2218685 Pisa, Italy, 56100 收起 <<
NCT01159301	Adult Acute Basophilic Leukemi... 展开 >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Recurrent Adult Acute Myeloid Leukemia Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Terminated	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT01171482	Carcinoma, Hepatocellular	Phase 2	Terminated(There were problems... 展开 >> with national reimbursement policies.) 收起 <<	-	Korea, Republic of ... 展开 >> Seoul National University Hospital Seoul, Korea, Republic of 收起 <<
NCT01666756	Adult Primary Hepatocellular C... 展开 >>arcinoma Advanced Adult Primary Liver Cancer Advanced Adult Hepatocellular Carcinoma BCLC Stage B Adult Hepatocellular Carcinoma BCLC Stage C Adult Hepatocellular Carcinoma 收起 <<	Phase 1	Active, not recruiting	January 2020	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 收起 <<
NCT01624285	Adult Primary Hepatocellular C... 展开 >>arcinoma Localized Resectable Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer Recurrent Adult Primary Liver Cancer 收起 <<	Phase 2	Active, not recruiting	July 2020	-
NCT01204177	Carcinoma, Hepatocellular	Phase 2	Completed	-	Hong Kong ... 展开 >> Shatin, New Territories, Hong Kong Hong Kong, Hong Kong Korea, Republic of Jung-gu, Daegu Gwang''yeogsi, Korea, Republic of, 700-721 Goyang-si, Gyeonggido, Korea, Republic of, 410-769 Busan, Korea, Republic of, 602-739 Seoul, Korea, Republic of, 110-744 Seoul, Korea, Republic of, 120-752 Seoul, Korea, Republic of, 135-710 Seoul, Korea, Republic of, 138-736 Singapore Singapore, Singapore, 228510 Singapore, Singapore, 258499 Taiwan Kaohsiung, Taiwan, 833 Tainan, Taiwan, 736 Tainan, Taiwan Taipei, Taiwan, 100 收起 <<
NCT01008566	Adult Hepatocellular Carcinoma... 展开 >> Advanced Adult Hepatocellular Carcinoma Localized Non-Resectable Adult Liver Carcinoma Recurrent Adult Liver Carcinoma 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Pennsylvania Penn State Hershey Cancer Institute-Clinical Trials Office Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT00398814	Renal Cancer ... 展开 >>Tumors 收起 <<	Phase 1	Completed	-	-
NCT03113604	-		Withdrawn(The study has been s... 展开 >>topped because no one is) 收起 <<	-	France ... 展开 >> CHU Amiens Picardie Amiens, Picardie, France, 80054 收起 <<
NCT00044512	-		Completed	-	-
NCT00044512	Carcinoma, Hepatocellular	Phase 2	Completed	-	United States, California ... 展开 >> Los Angeles, California, United States, 90057 United States, New York New York, New York, United States, 10021-6007 Belgium Bruxelles - Brussel, Belgium, 1000 Bruxelles - Brussel, Belgium, 1070 Bruxelles - Brussel, Belgium, 1090 Gent, Belgium, 9000 Leuven, Belgium, 3000 France Lille Cedex, France, 59020 Marseille, France, 13005 Paris, France, 75020 Rennes Cedex, France, 35062 Saint Herblain, France, 44805 Israel Haifa, Israel, 31096 Jerusalem, Israel, 91120 Petach Tikva, Israel, 49100 Rehovot, Israel, 76100 Tel Aviv, Israel, 64239 Tel Hashomer, Israel, 52621 Italy Rozzano, Milano, Italy, 20089 Forlì, Italy, 47100 Milano, Italy, 20122 Pisa, Italy, 56126 Verona, Italy, 37126 收起 <<
NCT01405573	Advanced Adult Hepatocellular ... 展开 >>Carcinoma 收起 <<	Phase 3	Terminated(lack of enrolment)	-	Italy ... 展开 >> Azienda Ospedaliera G. Rummo Benevento, BN, Italy Policlinico Giaccone Palermo, PA, Italy, 90127 S. Orsola-Malpighi Bologna, Italy Ospedale Ramazzini di Carpi Carpi, Italy Osp. Civile Infermi Faenza, Italy Azienda Ospedaliera Careggi Firenze, Italy IRCCS-Azienda Ospedaliera Universitaria San Martino-IST Genova, Italy AO C. Poma Mantova, Italy Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Meldola, Italy A.O.U. G.Martino- Policlinico Universita di Messina Messina, Italy Istituto Nazionale Tumori Milano, Italy A.O.U. Federico II Napoli, Italy AOU II Università di Napoli Napoli, Italy Istituto Nazionale dei Tumori Napoli, Italy Ospedale Cardarelli Napoli, Italy Azienda Ospedaliera Universitaria di Padova Padova, Italy Istituto Oncologico Veneto Padova, Italy A.O. Ospedali Riuniti Villa Sofia-Cervello Palermo, Italy Azienda Ospedaliero Universitaria di Parma Parma, Italy Ospedale Guglielmo da Saliceto Piacenza, Italy, Italy AO S. Carlo Potenza, Italy Policlinico Universitario Tor Vergata Roma, Italy Oncologia IRCCS - Casa Sollilevo Sofferenza S. Giovanni Rotondo, Italy Azienda Ospedaliera Universitaria Arcispedal, U.O. di Oncologia Clinica Sant'Anna di Ferrara, Italy A.O. Trevigilio - Caravaggio Trevigilio, Italy 收起 <<
NCT00828074	Breast Cancer	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010-3000 South Pasadena Cancer Center Pasadena, California, United States, 91030 收起 <<
NCT02129322	Hepatocellular Carcinoma	Phase 2	Not yet recruiting	December 2019	China ... 展开 >> First affiliated hospital, Zhejiang University Not yet recruiting Hangzhou, China Contact: Weijiafang fang Principal Investigator: Weijia fang, MD 收起 <<
NCT00303797	Refractory Chronic Lymphocytic... 展开 >> Leukemia Refractory Multiple Myeloma Stage III Multiple Myeloma Stage IV Chronic Lymphocytic Leukemia Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00869570	Colorectal Cancer	Phase 1 Phase 2	Completed	-	Hungary ... 展开 >> Szent Laszlo Korhaz Budapest, Hungary, 1097 Switzerland Saint Claraspital AG Basel, Switzerland, CH-4016 Universitaetsspital-Basel Basel, Switzerland, CH-4031 Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli Bellinzona, Switzerland, 6500 Inselspital, Bern Bern, Switzerland, CH-3010 Spitalzentrum Biel Biel, Switzerland, CH-2501 Kantonsspital Bruderholz Bruderholz, Switzerland, CH-4101 Kantonsspital Graubuenden Chur, Switzerland, CH-7000 Hopital Cantonal Universitaire de Geneva HUG Geneva, Switzerland, CH-1211 Kantonsspital Luzern Luzern, Switzerland, 6000 OnkoZentrum Luzern at Klinik St. Anna Luzern, Switzerland, 6006 Kantonsspital - St. Gallen St. Gallen, Switzerland, CH-9007 SpitalSTS AG Simmental-Thun-Saanenland Thun, Switzerland, 3600 Kantonsspital Winterthur Winterthur, Switzerland, CH-8400 Onkozentrum - Klinik im Park Zurich, Switzerland, 8002 Onkozentrum Hirslanden Zurich, Switzerland, CH-8008 UniversitaetsSpital Zuerich Zurich, Switzerland, CH-8091 Stadtspital Triemli Zürich, Switzerland, 8063 收起 <<
NCT00712855	Hepatocellular Carcinoma	Phase 1	Completed	-	United States, California ... 展开 >> Cedars-Sinai Health System Los Angeles, California, United States, 90048 United States, Colorado University of Colorado Cancer Center Aurora, Colorado, United States, 80045 United States, Florida University of Florida Gainesville, Florida, United States, 32610 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania University of Pennsylvania- Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT01348503	Hepatocellular Carcinoma	Phase 1	Terminated(Treatment was ineff... 展开 >>ective) 收起 <<	-	United States, Indiana ... 展开 >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 收起 <<
NCT00828074	-		Completed	-	-
NCT02035527	Metastatic Squamous Neck Cance... 展开 >>r With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Salivary Gland Squamous Cell Carcinoma Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IVA Salivary Gland Cancer Stage IVA Squamous Cell Carcinoma of the Larynx Stage IVA Oral Cavity Squamous Cell Carcinoma Stage IVA Squamous Cell Carcinoma of the Oropharynx Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVA Verrucous Carcinoma of the Larynx Stage IVA Verrucous Carcinoma of the Oral Cavity Stage IVB Salivary Gland Cancer Stage IVB Squamous Cell Carcinoma of the Larynx Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVB Squamous Cell Carcinoma of the Oropharynx Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVB Verrucous Carcinoma of the Larynx Stage IVB Verrucous Carcinoma of the Oral Cavity Stage IVC Salivary Gland Cancer Stage IVC Squamous Cell Carcinoma of the Larynx Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVC Squamous Cell Carcinoma of the Oropharynx Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVC Verrucous Carcinoma of the Larynx Stage IVC Verrucous Carcinoma of the Oral Cavity Tongue Cancer Untreated Metastatic Squamous Neck Cancer With Occult Primary 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT01751763	-		Completed	-	China ... 展开 >> Many Locations, China 收起 <<
NCT02576509	Hepatocellular Carcinoma	Phase 3	Active, not recruiting	July 14, 2020	-
NCT00826540	-		Completed	-	-
NCT00105443	Carcinoma, Hepatocellular	Phase 3	Completed	-	-
NCT00826540	Recurrent Colon Cancer ... 展开 >> Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer 收起 <<	Phase 2	Completed	-	-
NCT00855218	Carcinoma, Hepatocellular	Phase 2	Completed	-	-
NCT00326898	Stage I Renal Cell Cancer ... 展开 >> Stage II Renal Cell Cancer Stage III Renal Cell Cancer 收起 <<	Phase 3	Completed	-	-
NCT01265576	HCC	Phase 2	Unknown	April 2016	United States, California ... 展开 >> Vicus Clinical Site Berkeley, California, United States, 94704 United States, Georgia Vicus Clinical Site Atlanta, Georgia, United States, 30318 United States, New Jersey Vicus Clinical Site New Brunswick, New Jersey, United States Vicus Clinical Site Newark, New Jersey, United States, 07103 Vicus Clinical Site Paterson, New Jersey, United States, 07503 United States, New York Vicus Clinical Site Buffalo, New York, United States, 14263 Vicus Clinical Site New York, New York, United States, 10016 United States, Pennsylvania Vicus Clinical Site Philadelphia, Pennsylvania, United States United States, Texas Vicus Clinical Site Houston, Texas, United States, 77024 Vicus Clinical Site Houston, Texas, United States, 77030 收起 <<
NCT00326898	-		Completed	-	-
NCT00105443	-		Completed	-	-
NCT01377025	Uveal Melanoma	Phase 2	Unknown	June 2017	Germany ... 展开 >> Universitätsmedizin Berlin, Charité Campus Benjamin Franklin Berlin, Germany, 12203 Universitätsklinikum Erlangen Erlangen, Germany, 91052 Univesitätsklinikum Essen Essen, Germany, 45147 收起 <<
NCT00452218	Pulmonary Arterial Hypertensio... 展开 >>n 收起 <<	Phase 1	Completed	-	United States, Illinois ... 展开 >> The University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT00855218	-		Completed	-	-
NCT01616186	Locally Metastatic Malignant N... 展开 >>eoplasm 收起 <<	Phase 2	Withdrawn	April 2016	-
NCT03434379	Carcinoma, Hepatocellular	Phase 3	Recruiting	June 29, 2022	-
NCT00244972	Advanced Malignant Neoplasm	Phase 1	Completed	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00828594	Hepatocellular Carcinoma	Phase 1	Terminated	-	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 UCLA Department of Medicine Los Angeles, California, United States, 90005 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 Korea, Republic of Novartis Investigative Site Seoul, Korea, Republic of Netherlands Novartis Investigative Site Amsterdam, Netherlands Spain Novartis Investigative Site Barcelona, Spain Novartis Invstigative Site Madrid, Spain Taiwan Novartis Investigative Site Tainan, Taiwan 收起 <<
NCT02908165	Hepatocellular Carcinoma	Phase 2	Withdrawn(A future study will ... 展开 >>be taking place using the same patient population.) 收起 <<	June 2020	United States, Connecticut ... 展开 >> Smilow Cancer Center New Haven, Connecticut, United States, 06510 收起 <<
NCT00112905	Adenocarcinoma of the Bladder ... 展开 >> Distal Urethral Cancer Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter Proximal Urethral Cancer Recurrent Bladder Cancer Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Recurrent Urethral Cancer Regional Transitional Cell Cancer of the Renal Pelvis and Ureter Squamous Cell Carcinoma of the Bladder Stage III Bladder Cancer Stage IV Bladder Cancer Transitional Cell Carcinoma of the Bladder Urethral Cancer Associated With Invasive Bladder Cancer 收起 <<	Phase 2	Terminated	-	United States, Massachusetts ... 展开 >> Eastern Cooperative Oncology Group Boston, Massachusetts, United States, 02215 收起 <<
NCT00752063	Advanced Hepatocellular Carcin... 展开 >>oma Metastatic Hepatocellular Carcinoma 收起 <<	Phase 2	Unknown	December 2008	China ... 展开 >> Queen Mary Hospital Recruiting Hong Kong, China Contact: Ida Choi, MPhil (852)28553635 cychoia@hkucc.hku.hk Principal Investigator: Ronnie Poon, MD 收起 <<
NCT00747799	Nasopharyngeal Neoplasms	Phase 2	Completed	-	China, Guangdong ... 展开 >> Cancer Center of Sun-Yat Sen University Guangzhou, Guangdong, China, 510000 收起 <<
NCT00536575	Multiple Myeloma	Phase 1 Phase 2	Completed	-	United States, Maryland ... 展开 >> Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 收起 <<
NCT00112905	-		Terminated	-	-
NCT01829035	Advanced Adult Hepatocellular ... 展开 >>Carcinoma 收起 <<	Phase 3	Completed	-	Korea, Republic of ... 展开 >> National Cancer Center, Korea Seoul, Korea, Republic of 收起 <<
NCT00536575	-		Completed	-	-
NCT00349206	Melanoma Recu... 展开 >>rrent Melanoma Stage III Melanoma Stage IV Melanoma 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02066181	Desmoid-Type Fibromatosis	Phase 3	Active, not recruiting	-	-
NCT01418729	Advanced Hepatocarcinoma	Phase 2	Completed	-	Spain ... 展开 >> Hospital Donostia, Instituto Biodonostia San Sebastian, Gipuzkoa, Spain, 20014 收起 <<
NCT00182689	Extensive Stage Small Cell Lun... 展开 >>g Cancer Recurrent Small Cell Lung Cancer 收起 <<	Phase 2	Completed	-	United States, Oregon ... 展开 >> SWOG Portland, Oregon, United States, 97239 收起 <<
NCT00788099	Advanced Solid Tumors ... 展开 >> Lymphomas 收起 <<	Phase 1	Completed	-	United States, New Jersey ... 展开 >> The Cancer Institute of New Jersey (CINJ) New Brunswick, New Jersey, United States, 08901 France Institut Gustave Roussy Villejuif, France, 94800 收起 <<
NCT00456716	Lung Cancer	Phase 2	Completed	-	United States, Washington ... 展开 >> Swedish Cancer Institute Seattle, Washington, United States, 98104 收起 <<
NCT00101400	Breast Neoplasms ... 展开 >> Breast Cancer 收起 <<	Phase 2	Completed	-	Germany ... 展开 >> Stuttgart, Baden-Württemberg, Germany, 70199 München, Bayern, Germany, 80637 Frankfurt, Hessen, Germany, 60590 Italy Bologna, Italy, 40138 Milano, Italy, 20133 Milano, Italy, 20162 Parma, Italy, 43100 收起 <<
NCT00101400	-		Completed	-	-
NCT00758381	Locally Advanced Pancreatic Ca... 展开 >>ncer 收起 <<	Phase 2	Unknown	August 2009	Italy ... 展开 >> A.O. Treviglio-Caravaggio, P.le Ospedale n1 Recruiting Treviglio, Bergamo, Italy, 24047 Sub-Investigator: sandro Barni, MD Ospedale S.Orsola Fatebenefratelli Active, not recruiting Brescia, BS, Italy, 15100 A.O. Ospedale S.Martino Recruiting Genova, GE, Italy, 16132 Sub-Investigator: Alberto Sobrero, MD A.O. san Paolo Recruiting Milano, MI, Italy, 20100 Sub-Investigator: Paolo Foa, MD Casa di Cura Igea Not yet recruiting Milano, MI, Italy, 20100 Sub-Investigator: Gianfranco Pancera, MD Ospedale S.Carlo Borromeo Not yet recruiting Milano, MI, Italy, 20123 Sub-Investigator: Donata Tabiadon, MD A.O. S.Gerardo Recruiting Monza, MI, Italy, 20052 Sub-Investigator: Paolo Bidoli, MD A.O. Universitaria Ospedali Riuniti Umberto I Recruiting Ancona, Italy, 60020 Principal Investigator: Stefano Cascinu, M.Pr Ospedali Riuniti, Largo Barozzi, 1 Recruiting Bergamo, Italy, 24128 Principal Investigator: Roberto Labianca, MD A.O.Policlinico S.Orsola Malpighi Active, not recruiting Bologna, Italy, 40138 A.O. Careggi-Università, Viale Pieraccini, 17 Recruiting Firenze, Italy, 50139 Sub-Investigator: Francesco Di Costanzo, MD Ospedale Galliera Active, not recruiting Genova, Italy, 16132 A.O. Carlo Poma - Via Albertoni, 1 Recruiting Mantova, Italy, 46100 Sub-Investigator: Enrico Aitini, MD A.O. Cà Granda, Piazza Ospedale Maggiore, 3 Recruiting Milano, Italy, 20162 Sub-Investigator: Salvatore Siena, MPr Policlinico di modena Active, not recruiting Modena, Italy, 41100 Università Campus Biomedico, Via Emilio Longoni, 83 Active, not recruiting Roma, Italy, 00155 A.O. S.Giovanni Calabita Fatebenefratelli Active, not recruiting Roma, Italy, 00186 收起 <<
NCT00699374	-		Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<	-	-
NCT00217620	Sarcoma	Phase 2	Completed	-	-
NCT00253578	Refractory Multiple Myeloma	Phase 2	Completed	-	United States, Texas ... 展开 >> Southwest Oncology Group San Antonio, Texas, United States, 78245 收起 <<
NCT00217620	-		Completed	-	-
NCT00182689	-		Completed	-	-
NCT01775501	Hepatocellular Cancer	Phase 2	Active, not recruiting	December 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02125 Brigham and Women's Hospital Boston, Massachusetts, United States, 02215 收起 <<
NCT00949182	Liver Cancer	Phase 2	Completed	-	United States, New Jersey ... 展开 >> Rutgers University Hospital Newark, New Jersey, United States, 07101 收起 <<
NCT00118170	Extranodal Marginal Zone B-cel... 展开 >>l Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Multiple Myeloma Splenic Marginal Zone Lymphoma Stage II Multiple Myeloma Stage III Adult Burkitt Lymphoma Stage III Adult Diffuse Large Cell Lymphoma Stage III Adult Diffuse Mixed Cell Lymphoma Stage III Adult Diffuse Small Cleaved Cell Lymphoma Stage III Adult Immunoblastic Large Cell Lymphoma Stage III Adult Lymphoblastic Lymphoma Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma Stage III Grade 3 Follicular Lymphoma Stage III Mantle Cell Lymphoma Stage III Marginal Zone Lymphoma Stage III Multiple Myeloma Stage III Small Lymphocytic Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Small Lymphocytic Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Waldenström Macroglobulinemia 收起 <<	Phase 1	Completed	-	United States, Illinois ... 展开 >> Cancer and Leukemia Group B (CALGB) Research Base Chicago, Illinois, United States, 60604-1104 收起 <<
NCT00126503	-		Completed	-	-
NCT00126503	Chromophobe Renal Cell Carcino... 展开 >>ma Clear Cell Renal Cell Carcinoma Papillary Renal Cell Carcinoma Recurrent Renal Cell Carcinoma Sarcomatoid Renal Cell Carcinoma Stage IV Renal Cell Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Dana-Farber Harvard Cancer Center Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 United States, Pennsylvania University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT02981498	Hepatocellular Carcinoma	Phase 2	Recruiting	April 2017	China, Guangdong ... 展开 >> Cancer Center, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Ming Shi, MD Shiming@sysu.edu.cn 收起 <<
NCT00259129	Neoplasms	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Boston, Massachusetts, United States, 02115 United States, Texas San Antonio, Texas, United States, 78229 收起 <<
NCT00390611	Ovarian Cancer	Phase 2	Completed	-	United States, Arkansas ... 展开 >> Northeast Arkansas Clinic Jonesboro, Arkansas, United States, 72401 United States, Florida Florida Cancer Specialists Fort Myers, Florida, United States, 33901 Holy Cross Hospital Ft. Lauderdale, Florida, United States, 33308 Gulfcoast Oncology Associates St. Petersburg, Florida, United States, 33705 United States, Georgia Medical College of Georgia Cancer Specialists Augusta, Georgia, United States, 30912 United States, Indiana Providence Medical Group Terre Haute, Indiana, United States, 47802 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 National Capital Clinical Research Consortium Bethesda, Maryland, United States, 20817 United States, Michigan St. Joseph Mercy Hospital Ann Arbor, Michigan, United States, 48106 Grand Rapids Clinical Oncology Program Grand Rapids, Michigan, United States, 49503 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, Oklahoma University of Oklahoma Oklahoma City, Oklahoma, United States, 73104 United States, South Carolina South Carolina Oncology Associates, PA Columbia, South Carolina, United States, 29210 United States, Tennessee Tennessee Valley Clinical Research Chattanooga, Tennessee, United States, 37411 Family Cancer Center Collierville, Tennessee, United States, 38017 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Virginia Peninsula Cancer Center Newport News, Virginia, United States, 23601 收起 <<
NCT00390611	-		Completed	-	-
NCT00989469	Metastatic Colorectal Cancer	Phase 1 Phase 2	Completed	-	France ... 展开 >> Centre Oscar Lambret Lille, France Hopital Saint Eloi Montpellier, France Centre Rene Gauducheau Nantes, France Centre Antoine Lacassagne Nice, France CHU Robert Debre Reims, France 收起 <<
NCT00265798	Gastrointestinal Stromal Tumor	Phase 2	Active, not recruiting	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 Decatur Memorial Hospital Decatur, Illinois, United States, 62526 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 62702 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00699374	Carcinoma, Hepatocellular	Phase 3	Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<	-	-
NCT01131689	Hepatocellular Carcinoma	Phase 1	Completed	-	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of 收起 <<
NCT00265798	-		Active, not recruiting	-	-
NCT00954135	Breast Cancer	Phase 2	Unknown	December 2010	Italy ... 展开 >> Breast Unit Azienda Ospedaliera Istituti Ospitalieri Cremona, Italy Azienda Ospedaliera S.Luigi Orbassano Orbassano, Italy 收起 <<
NCT00600015	Non-Small Cell Lung Cancer	Phase 2	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Fort Myers, Florida, United States, 33901 United States, Georgia Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 Wellstar Cancer Research Marietta, Georgia, United States, 30060 United States, Kansas Kansas City Cancer Centers Overland Park, Kansas, United States, 66210 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Michigan Grand Rapids Clinical Oncology Program Grand Rapids, Michigan, United States, 49503 United States, Nebraska Methodist Cancer Center Omaha, Nebraska, United States, 68114 United States, North Carolina Cancer Care of Western North Carolina Asheville, North Carolina, United States, 28801 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center Columbus, Ohio, United States, 43219 United States, South Carolina South Carolina Oncology Associates, PA Columbia, South Carolina, United States, 29210 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Family Cancer Center Collierville, Tennessee, United States, 38017 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Texas Coastal Bend Cancer Center Corpus Christi, Texas, United States, 78463 United States, Virginia Virginia Cancer Institute Richmond, Virginia, United States, 23235 收起 <<
NCT00405210	Primary Disease ... 展开 >> Prostate Cancer 收起 <<	Phase 1	Completed	-	Belgium ... 展开 >> St Pierre Ottignies, Brabant Wallon, Belgium, 1340 Cliniques Universitaires St Luc Brussels, Brussels Capital, Belgium, 1200 Notre Dame et Reine Fabiola Charleroi, Hainaut, Belgium, 6000 Clinique Universiataire de Mont Godinne Yvoir, Namur, Belgium, 5030 Sainte Elisabeth Namur, Belgium, 5000 France Hôpital Européen Georges Pompidou Paris, France, 75015 收起 <<
NCT00600015	-		Completed	-	-
NCT00303966	-		Terminated(Slow accrual)	-	-
NCT00692770	Carcinoma, Hepatocellular	Phase 3	Completed	-	-
NCT02143401	Cirrhosis Hep... 展开 >>atitis B Infection Hepatitis C Infection Metastatic Malignant Solid Neoplasm Recurrent Hepatocellular Carcinoma Recurrent Malignant Solid Neoplasm Refractory Malignant Neoplasm Stage IV Hepatocellular Carcinoma AJCC v7 Unresectable Solid Neoplasm 收起 <<	Phase 1	Recruiting	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Site Public Contact 855-776-0015 Principal Investigator: Brian A. Costello United States, California University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Edward J. Kim United States, Colorado University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Site Public Contact 720-848-0650 Principal Investigator: Sarah L. Davis United States, Florida Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Site Public Contact 855-776-0015 Principal Investigator: Brian A. Costello United States, Iowa University of Iowa/Holden Comprehensive Cancer Center Recruiting Iowa City, Iowa, United States, 52242 Contact: Site Public Contact 800-237-1225 Principal Investigator: Mohammed M. Milhem United States, Maryland University of Maryland/Greenebaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Site Public Contact 800-888-8823 Principal Investigator: Edward A. Sausville United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Site Public Contact 855-776-0015 Principal Investigator: Brian A. Costello United States, New York Columbia University/Herbert Irving Cancer Center Recruiting New York, New York, United States, 10032 Contact: Site Public Contact 212-305-6361 nr2616@cumc.columbia.edu Principal Investigator: Gulam A. Manji United States, Pennsylvania Thomas Jefferson University Hospital Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: Site Public Contact 215-955-6084 Principal Investigator: James A. Posey United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Ahmed O. Kaseb 收起 <<
NCT00692770	-		Completed	-	-
NCT00303966	Refractory Chronic Lymphocytic... 展开 >> Leukemia Stage I Chronic Lymphocytic Leukemia Stage II Chronic Lymphocytic Leukemia Stage III Chronic Lymphocytic Leukemia Stage IV Chronic Lymphocytic Leukemia 收起 <<	Phase 2	Terminated(Slow accrual)	-	United States, Illinois ... 展开 >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 收起 <<
NCT00093626	Primary Peritoneal Carcinoma ... 展开 >> Recurrent Ovarian Carcinoma 收起 <<	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> Gynecologic Oncology Group Philadelphia, Pennsylvania, United States, 19103 收起 <<
NCT00098254	Non-Small-Cell Lung Carcinoma	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01531361	Advanced Malignant Neoplasm ... 展开 >> BRAF Gene Mutation Metastatic Malignant Neoplasm Recurrent Malignant Neoplasm Refractory Malignant Neoplasm 收起 <<	Phase 1	Active, not recruiting	February 28, 2020	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00492752	Carcinoma, Hepatocellular	Phase 3	Completed	-	China, Anhui ... 展开 >> Hefei, Anhui, China, 230022 China, Guangdong Guangzhou, Guangdong, China, 510060 Guangzhou, Guangdong, China, 510515 China, Hubei Wuhan, Hubei, China, 430030 China, Jiangsu Nanjing, Jiangsu, China, 210003 Nanjing, Jiangsu, China, 210009 China, Liaoning Dalian, Liaoning, China, 116011 Dalian, Liaoning, China, 116027 China, Zhejiang Hangzhou, Zhejiang, China, 310016 China Beijing, China, 100021 Beijing, China, 100039 Chongqing, China, 400038 Shanghai, China, 200003 Shanghai, China, 200032 Tianjin, China Korea, Republic of Seoul, Seoul Teugbyeolsi, Korea, Republic of, 152-703 Daegu, Korea, Republic of, 702-701 Seoul, Korea, Republic of, 138-736 Taiwan Changhua, Taiwan, 500 Tainan, Taiwan, 736 Taipei, Taiwan, 10016 Taipei, Taiwan, 251 Taoyuan, Taiwan, 333 收起 <<
NCT01075555	Liver Cancer	Phase 3	Completed	-	France ... 展开 >> Hopital Du Bocage Dijon, France, 21000 收起 <<
NCT00632541	Metastatic Breast Cancer	Phase 2	Terminated(Significant Toxicit... 展开 >>ies Experienced) 收起 <<	-	United States, Illinois ... 展开 >> Medical & Surgical Specialists, LLC Galesburg, Illinois, United States, 61401 United States, Indiana Oncology Hematology Associates of SW Indiana Evansville, Indiana, United States, 47714 Fort Wayne Oncology & Hematology, Inc Fort Wayne, Indiana, United States, 46815 Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 Quality Cancer Center (MCGOP) Indianapolis, Indiana, United States, 46202 Arnett Cancer Care Lafayette, Indiana, United States, 47904 Horizon Oncology Center Lafayette, Indiana, United States, 47905 Medical Consultants, P.C. Muncie, Indiana, United States, 47303 Northern Indiana Cancer Research Consortium South Bend, Indiana, United States, 46601 United States, Ohio Ireland Cancer Center - University Hospitals of Cleveland Cleveland, Ohio, United States, 44106 收起 <<
NCT00492752	-		Completed	-	-
NCT00632541	-		Terminated(Significant Toxicit... 展开 >>ies Experienced) 收起 <<	-	-
NCT01264705	Hepatocellular Carcinoma ... 展开 >> Liver Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> UT Southwestern Medical Center Dallas, Texas, United States, 75390 收起 <<
NCT00622466	Breast Cancer	Phase 2	Unknown	December 2015	United States, Texas ... 展开 >> University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 收起 <<
NCT00098254	-		Completed	-	-
NCT00474929	Lymphoma Mult... 展开 >>iple Myeloma and Plasma Cell Neoplasm 收起 <<	Phase 1 Phase 2	Active, not recruiting	January 2019	United States, Iowa ... 展开 >> Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa, United States, 52242-1002 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 收起 <<
NCT00474929	-		Active, not recruiting	-	-
NCT00786110	Adrenocortical Carcinoma	Phase 2	Unknown	October 2010	Italy ... 展开 >> Department of Clinical and Biological Sciences, University of Turin Recruiting Orbassano, Italy Contact: Paola Perotti : +390119026 ext Ext. 017 Principal Investigator: Alfredo Berruti Azienda Ospedaliera di Padova Not yet recruiting Padova, Italy Contact: Franco Mantero Sub-Investigator: Franco Mantero Azienda Ospedaliera Università di Palermo Not yet recruiting Palermo, Italy Sub-Investigator: Vittorio Gebbia Policlinico Universitario Campus Biomedico- Roma Not yet recruiting Roma, Italy Contact: Daniele Santini Sub-Investigator: Daniele Santini Ist. Clin.Humanitas Not yet recruiting Rozzano, Italy Contact: Carlo Carnaghi Sub-Investigator: Carlo Carnaghi 收起 <<
NCT00908167	Acute Myeloid Leukemia ... 展开 >> Infantile Leukemia (Both AML and ALL) Myelodysplastic Syndrome Myelodysplastic/Myeloproliferative Neoplasms Biphenotypic Leukemia 收起 <<	Phase 1	Completed	-	United States, Tennessee ... 展开 >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 收起 <<
NCT00665990	Refractory Solid Tumors ... 展开 >> Leukemia 收起 <<	Phase 1	Completed	-	United States, Tennessee ... 展开 >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 收起 <<
NCT00384969	Renal Cell Carcinoma	Phase 1	Completed	-	United States, California ... 展开 >> University of California, San Francisco San Francisco, California, United States, 94115 收起 <<
NCT00126659	-		Terminated	-	-
NCT00126659	Clear Cell Renal Cell Carcinom... 展开 >>a Recurrent Renal Cell Cancer Stage IV Renal Cell Cancer 收起 <<	Phase 2	Terminated	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01817751	Glioblastoma ... 展开 >>Recurrent Adult Brain Neoplasm Malignant Glioma WHO Grade III Glioma 收起 <<	Phase 2	Recruiting	March 31, 2019	United States, Virginia ... 展开 >> Virginia Commonwealth University/Massey Cancer Center Recruiting Richmond, Virginia, United States, 23298 Contact: Alison A Ryan, NP 804-628-1936 masseysiit@vcu.edu Principal Investigator: Mark G Malkin, MD 收起 <<
NCT02564666	Hepatocellular Carcinoma	Not Applicable	Unknown	December 2017	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Korea, Republic of, 138-736 收起 <<
NCT00589550	-		Terminated(low accrual)	-	-
NCT00589550	Kidney Cancer	Phase 1	Terminated(low accrual)	-	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT01078961	Melanoma	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 收起 <<
NCT00872014	Advanced Hepatocellular Carcin... 展开 >>oma Inoperable Hepatocellular Carcinoma 收起 <<	Phase 2	Completed	-	-
NCT00657254	Neoplasm Meta... 展开 >>stasis 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Boston, Massachusetts, United States, 02115-6084 Belgium Bruxelles - Brussel, Belgium, 1000 Canada, Ontario Hamilton, Ontario, Canada, L8V 5C2 Toronto, Ontario, Canada, M5G 2M9 Germany Essen, Nordrhein-Westfalen, Germany, 45147 Herne, Nordrhein-Westfalen, Germany, 44625 收起 <<
NCT00101114	Clear Cell Renal Cell Carcinom... 展开 >>a Recurrent Renal Cell Cancer Stage III Renal Cell Cancer Stage IV Renal Cell Cancer 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Southwest Oncology Group San Antonio, Texas, United States, 78245 收起 <<
NCT00726986	Lung Cancer	Phase 2	Terminated(Extreme toxicity)	-	United States, New York ... 展开 >> Columbia Presbyterian New York, New York, United States, 10032 United States, Ohio Lake/University Ireland Cancer Center Cleveland, Ohio, United States, 44060 Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 MetroHealth Medical Center Cleveland, Ohio, United States, 44109 CCF-Fairview Hospital Cleveland, Ohio, United States, 44111 UHHS Chagrin Highlands Medical Center Cleveland, Ohio, United States, 44122 Southwest General Health Center Cleveland, Ohio, United States, 44130 UHHS Westlake Medical Center Cleveland, Ohio, United States, 44145 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 UH-Monarch Mayfield Heights, Ohio, United States, 44124 UH-Firelands Sandusky, Ohio, United States, 44870 收起 <<
NCT00098618	Clear Cell Renal Cell Carcinom... 展开 >>a Papillary Renal Cell Carcinoma Recurrent Renal Cell Cancer Stage III Renal Cell Cancer Stage IV Renal Cell Cancer 收起 <<	Phase 2	Terminated	-	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT00726986	-		Terminated(Extreme toxicity)	-	-
NCT01754987	Metastatic Hepatocellular Carc... 展开 >>inoma Advanced Liver Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 收起 <<
NCT01004003	-		Completed	-	-
NCT01004003	Carcinoma, Hepatocellular	Phase 2	Completed	-	Austria ... 展开 >> 1199.37.43001 Boehringer Ingelheim Investigational Site Wien, Austria 1199.37.43002 Boehringer Ingelheim Investigational Site Wien, Austria France 1199.37.33001 Boehringer Ingelheim Investigational Site Paris, France 1199.37.33002 Boehringer Ingelheim Investigational Site Paris, France Germany 1199.37.49008 Boehringer Ingelheim Investigational Site Berlin, Germany 1199.37.49009 Boehringer Ingelheim Investigational Site Erlangen, Germany 1199.37.49002 Boehringer Ingelheim Investigational Site Freiburg, Germany 1199.37.49001 Boehringer Ingelheim Investigational Site Hannover, Germany 1199.37.49010 Boehringer Ingelheim Investigational Site Heidelberg, Germany 1199.37.49005 Boehringer Ingelheim Investigational Site Jena, Germany 1199.37.49004 Boehringer Ingelheim Investigational Site Magdeburg, Germany 1199.37.49003 Boehringer Ingelheim Investigational Site München, Germany 1199.37.49006 Boehringer Ingelheim Investigational Site Tübingen, Germany Hungary 1199.37.36001 Boehringer Ingelheim Investigational Site Debrecen, Hungary Netherlands 1199.37.31002 Boehringer Ingelheim Investigational Site Leiden, Netherlands 1199.37.31001 Boehringer Ingelheim Investigational Site Utrecht, Netherlands Poland 1199.37.48002 Boehringer Ingelheim Investigational Site Olsztyn, Poland 1199.37.48003 Boehringer Ingelheim Investigational Site Warsaw, Poland 1199.37.48001 Boehringer Ingelheim Investigational Site Warszawa, Poland Romania 1199.37.40002 Boehringer Ingelheim Investigational Site Bucharest, Romania 1199.37.40003 Boehringer Ingelheim Investigational Site Cluj-Napoca, Romania United Kingdom 1199.37.44001 Boehringer Ingelheim Investigational Site Edgbaston, Birmingham, United Kingdom 1199.37.44005 Boehringer Ingelheim Investigational Site Glasgow, United Kingdom 1199.37.44008 Boehringer Ingelheim Investigational Site Liverpool, United Kingdom 1199.37.44002 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.37.44003 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.37.44006 Boehringer Ingelheim Investigational Site Manchester, United Kingdom 1199.37.44004 Boehringer Ingelheim Investigational Site Nottingham, United Kingdom 收起 <<
NCT00981162	Acinar Cell Adenocarcinoma of ... 展开 >>the Pancreas Duct Cell Adenocarcinoma of the Pancreas Recurrent Pancreatic Cancer Stage IV Pancreatic Cancer Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> University of Colorado at Denver Health Sciences Center Aurora, Colorado, United States, 80045 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT02856126	Hepatocellular Carcinoma	Phase 3	Recruiting	August 2018	China, Guangdong ... 展开 >> Dongguan People's Hospital Recruiting Dongguan, Guangdong, China, 523059 Contact: Wusheng Yu, MD 13827285010 yuwusheng1998@126.com Cancer Center Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Ming Shi, MD 8620-87343115 shiming@mail.sysu.edu.cn The First Affiliated Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Guosheng Tan, MD 13725254145 tgs1976@163.com Guangzhou Twelfth People 's Hospital Recruiting Guangzhou, Guangdong, China, 510620 Contact: Yuanmin Zhou, MD 15521278919 13430288977@139.com Principal Investigator: Jinghua Chen, MD Kaiping Central Hospital Recruiting Kaiping, Guangdong, China, 529300 Contact: Shijie Zhang, MD 13717287622 Shijie_9262511@163.com China, Hunan The First Affiliated Hospital of University Of South China Recruiting Hengyang, Hunan, China, 421001 Contact: Xiaoping Wu, MD 13975486015 wxp19730806@sina.com China, Shanxi The First Affiliated Hospital Of Xi'an Jiaotong University Recruiting Xi'an, Shanxi, China, 710061 Contact: Xin Zheng, MD 13649265446 183421344@qq.com 收起 <<
NCT01754987	-		Completed	-	-
NCT00387751	Recurrent Melanoma ... 展开 >> Stage III Skin Melanoma Stage IV Skin Melanoma 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Cancer Therapy and Research Center at The UT Health Science Center at San Antonio San Antonio, Texas, United States, 78229 收起 <<
NCT00387751	-		Completed	-	-
NCT00111020	Carcinoma, Renal Cell	Phase 3	Completed	-	-
NCT00522301	Fallopian Tube Cancer ... 展开 >> Ovarian Cancer Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Terminated	-	United States, New York ... 展开 >> Memorial Sloan - Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00522301	-		Terminated	-	-
NCT00663741	Gastric Cancer	Phase 1	Completed	-	Japan ... 展开 >> Kashiwa, Chiba, Japan, 277-8577 Kobe, Hyogo, Japan, 650-0017 Chuo-ku, Tokyo, Japan, 104-0045 收起 <<
NCT00096395	Recurrent Ovarian Epithelial C... 展开 >>ancer Recurrent Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT01232296	Hepatocellular Carcinoma	Phase 2	Completed	-	China, Jiangsu ... 展开 >> Novartis Investigative Site Nanjing, Jiangsu, China, 210002 China, Shanxi Novartis Investigative Site Xi'an, Shanxi, China, 710032 China, Zhejiang Novartis Investigative Site Hangzhou, Zhejiang, China, 310016 China Novartis Investigative Site Beijing, China, 100039 Hong Kong Novartis Investigative Site Hong Kong, Hong Kong Novartis Investigative Site Shatin, New Territories, Hong Kong Japan Novartis Investigative Site Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Yokohama-city, Kanagawa, Japan, 232-0024 Novartis Investigative Site OsakaSayama, Osaka, Japan, 589-8511 Korea, Republic of Novartis Investigative Site Seoul, Korea, Korea, Republic of, 03722 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 05505 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 06351 Novartis Investigative Site Seoul, Korea, Korea, Republic of, 110 744 Novartis Investigative Site Seoul, Korea, Republic of, 136-705 Singapore Novartis Investigative Site Singapore, Singapore, 308433 Taiwan Novartis Investigative Site Taipei, Taiwan, ROC, Taiwan, 112 Novartis Investigative Site Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305 Novartis Investigative Site Taichung, Taiwan, 40705 Novartis Investigative Site Taipei, Taiwan, 10048 Thailand Novartis Investigative Site Bangkok, Thailand, 10330 Novartis Investigative Site Bangkok, Thailand, 10700 Novartis Investigative Site Chiang Mai, Thailand, 50200 Novartis Investigative Site Khon Kaen, Thailand, 40002 Novartis Investigative Site Songkla, Thailand, 90110 收起 <<
NCT00794859	Mesothelioma	Phase 2	Unknown	-	United Kingdom ... 展开 >> Guy's and St Thomas' NHS Foundation Trust London, United Kingdom, SE1 9RT 收起 <<
NCT01253070	Acute Myeloid Leukemia ... 展开 >> Acute Myeloid Leukemia (Megakaryoblastic) With t(1;22)(p13.3;q13.1); RBM15-MKL1 Acute Myeloid Leukemia With a Variant RARA Translocation Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214 Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A Acute Myeloid Leukemia With Variant MLL Translocations Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Active, not recruiting	-	-
NCT01253070	-		Active, not recruiting	-	-
NCT01009593	Hepatocellular Carcinoma Non-r... 展开 >>esectable Hepatocellular Carcinoma Recurrent Carcinoma, Hepatocellular Liver Diseases Neoplasms by Histologic Type Digestive System Neoplasms Carcinoma Liver Neoplasms Neoplasms Neoplasms by Site Digestive System Diseases Adenocarcinoma Neoplasms, Glandular and Epithelial 收起 <<	Phase 3	Terminated(See termination rea... 展开 >>son in detailed description) 收起 <<	-	-
NCT00976170	Hepatocellular Carcinoma	Phase 1	Completed	-	United States, California ... 展开 >> California Pacific Medical Center San Francisco, California, United States, 94115 United States, Florida University of Miami Miami, Florida, United States United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111-2497 Taiwan National Cheng Kung University Hospital Tainan, Taiwan National Taiwan Univercity Hospital Taipei, Taiwan 收起 <<
NCT00114244	Stage IV Pancreatic Cancer	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 收起 <<
NCT00990860	Hepatocellular Carcinoma	Phase 2	Unknown	-	Taiwan ... 展开 >> E-Da hospital Kaohsiung, Taiwan Veterans General Hospital- Kaochiung Kaoshiung, Taiwan Veterans General Hospital- Taichung Taichung, Taiwan National Cheng Kung University Hospital Tainan, Taiwan Mackay Memorial Hospital Taipei, Taiwan Tri- Service General Hospital Taipei, Taiwan Veterans General Hospital- Taipei Taipei, Taiwan Chang-Gung Memorial Hospital- LinKou TaoYuan Hsien, Taiwan 收起 <<
NCT01232296	-		Completed	-	-
NCT00329641	Ciliary Body and Choroid Melan... 展开 >>oma, Medium/Large Size Extraocular Extension Melanoma Iris Melanoma Metastatic Intraocular Melanoma Recurrent Intraocular Melanoma 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Southwest Oncology Group San Antonio, Texas, United States, 78245 收起 <<
NCT00329641	-		Completed	-	-
NCT00114244	-		Completed	-	-
NCT00812175	-		Completed	-	-
NCT00791778	-		Completed	-	-
NCT00791778	Ovarian Neoplasms	Phase 2	Completed	-	-
NCT00573690	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 收起 <<
NCT00126594	Clear Cell Renal Cell Carcinom... 展开 >>a Recurrent Renal Cell Carcinoma Stage IV Renal Cell Cancer 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00558636	Carcinoma, Non-Small-Cell Lung	Phase 3	Terminated(Terminated early wh... 展开 >>en the results from Study NCT00300885 showed an overall lack of efficacy in NSCLC and increased mortality in subjects with squamous subtype.) 收起 <<	-	China, Guangdong ... 展开 >> Guangzhou, Guangdong, China, 510060 Guangzhou, Guangdong, China, 510515 China, Hong Kong Shatin, Hong Kong, China China, Jiangsu Nanjing, Jiangsu, China, 210003 China, Zhejiang Hangzhou, Zhejiang, China, (310022), Hangzhou, Zhejiang, China, 310016 China Beijing, China, 100021 Beijing, China, 100142 Beijing, China, 100730 Chongqing, China, 400038 Shanghai, China, 200032 Shanghai, China, 200433 India Mumbai, Maharashtra, India, 400012 New- Delhi, India, 110008 Korea, Republic of Gyeonggi-do, Korea, Republic of, 410-769 Seoul, Korea, Republic of, 136-705 Singapore Singapore, Singapore, 119228 Singapore, Singapore, 169610 Taiwan Changhua, Taiwan, 500 Taipei, Taiwan, 100 Thailand Bangkok, Thailand, 10330 Bangkok, Thailand 收起 <<
NCT00126594	-		Completed	-	-
NCT00558636	-		Terminated(Terminated early wh... 展开 >>en the results from Study NCT00300885 showed an overall lack of efficacy in NSCLC and increased mortality in subjects with squamous subtype.) 收起 <<	-	-
NCT03674060	Healthy, Male	Phase 1	Not yet recruiting	February 2019	-
NCT00837876	Pancreatic Cancer	Phase 2	Completed	-	United States, Kentucky ... 展开 >> Purchase Cancer Group - Paducah Paducah, Kentucky, United States, 42002 United States, Tennessee Erlanger Cancer Center at Erlanger Hospital - Baroness Chattanooga, Tennessee, United States, 37403 Baptist Regional Cancer Center at Baptist Riverside Knoxville, Tennessee, United States, 37901 Vanderbilt-Ingram Cancer Center - Cool Springs Nashville, Tennessee, United States, 37064 Vanderbilt-Ingram Cancer Center at Franklin Nashville, Tennessee, United States, 37064 Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 收起 <<
NCT01157013	Hepatocellular Carcinoma	Not Applicable	Completed	-	Spain ... 展开 >> Miguel Servet University Hospital Zaragoza, Aragon, Spain, 50009 收起 <<
NCT00586495	Carcinoma, Renal Cell	Phase 2	Completed	-	Japan ... 展开 >> Asahi, Chiba, Japan, 289-2511 Matsuyama, Ehime, Japan, 791-0280 Kurume, Fukuoka, Japan, 830-0011 Isesaki, Gunma, Japan, 372-0817 Maebashi, Gunma, Japan, 371-8511 Sapporo, Hokkaido, Japan, 003-0804 Sapporo, Hokkaido, Japan, 060-8543 Sapporo, Hokkaido, Japan, 060-8648 Sunagawa, Hokkaido, Japan, 073-0196 Tsukuba, Ibaraki, Japan, 305-8576 Morioka, Iwate, Japan, 020-8505 Tsu, Mie, Japan, 514-8507 Natori, Miyagi, Japan, 981-1293 Kashihara, Nara, Japan, 634-8522 Kurashiki, Okayama, Japan, 710-8602 Osakasayama, Osaka, Japan, 589-8511 Suita, Osaka, Japan, 565-0871 Hidaka, Saitama, Japan, 350-1298 Irima-gun, Saitama, Japan, 350-0495 Tokorozawa, Saitama, Japan, 359-8513 Hamamatsu, Shizuoka, Japan, 431-3192 Sunto, Shizuoka, Japan, 411-8777 Utsunomiya, Tochigi, Japan, 320-0834 Arakawa-ku, Tokyo, Japan, 116-8567 Bunkyo-ku, Tokyo, Japan, 113-8655 Chuo-ku, Tokyo, Japan, 104-0045 Itabashi-ku, Tokyo, Japan, 173-0003 Shinjuku-ku, Tokyo, Japan, 162-8666 Ube, Yamaguchi, Japan, 755-8505 Akita, Japan, 010-8543 Chiba, Japan, 260-8677 Chiba, Japan, 260-8717 Fukuoka, Japan, 812-0033 Fukuoka, Japan, 812-8582 Kagoshima, Japan, 890-8520 Kyoto, Japan, 602-8566 Kyoto, Japan, 606-8507 Okayama, Japan, 700-8558 Osaka, Japan, 537-8511 Tokushima, Japan, 770-8503 Yamagata, Japan, 990-9585 收起 <<
NCT00837876	-		Completed	-	-
NCT00586495	-		Completed	-	-
NCT00134069	Recurrent Colon Cancer ... 展开 >> Recurrent Rectal Cancer Stage III Colon Cancer Stage III Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> University of Colorado at Denver Health Sciences Center Aurora, Colorado, United States, 80045 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 收起 <<
NCT01215266	Bladder Cancer	Phase 2	Terminated(Slow recruitment)	-	-
NCT01466504	-		Terminated(Accrual did not mee... 展开 >>t expectations. Over nearly 2 years just 4 subjects were treated on study. The goal of 30 subjects was not attainable.) 收起 <<	-	United States, New Hampshire ... 展开 >> Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center Lebanon, New Hampshire, United States, 03756 United States, Vermont White River Junction VA Medical Center White River Junction, Vermont, United States, 05009 收起 <<
NCT00544817	Glioblastoma Multiforme	Phase 2	Completed	-	United States, Florida ... 展开 >> Florida Cancer Specialists Fort Myers, Florida, United States, 33901 United States, Georgia Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Michigan Grand Rapids Clinical Oncology Program Grand Rapids, Michigan, United States, 49503 United States, Nebraska Methodist Cancer Center Omaha, Nebraska, United States, 68114 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, South Carolina Spartanburg Regional Medical Center Spartanburg, South Carolina, United States, 29303 United States, Tennessee Tennessee Oncology Nashville, Tennessee, United States, 37203 United States, Texas South Texas Oncology and Hematology San Antonio, Texas, United States, 78258 United States, Virginia Virginia Cancer Institute Richmond, Virginia, United States, 23235 收起 <<
NCT02050919	Pleomorphic Rhabdomyosarcoma ... 展开 >> Stage IIB Adult Soft Tissue Sarcoma AJCC v7 Stage III Adult Soft Tissue Sarcoma AJCC v7 Stage IV Adult Soft Tissue Sarcoma AJCC v7 收起 <<	Phase 2	Active, not recruiting	December 31, 2018	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Portland, Oregon, United States, 97239 收起 <<
NCT00329719	-		Completed	-	-
NCT00329719	Adult Glioblastoma ... 展开 >> Adult Gliosarcoma Recurrent Adult Brain Neoplasm 收起 <<	Phase 1 Phase 2	Completed	-	-
NCT01728948	-		Completed	-	China ... 展开 >> Many Locations, China 收起 <<
NCT00544817	-		Completed	-	-
NCT00516828	Leukemia Myel... 展开 >>odysplastic Syndromes 收起 <<	Phase 1 Phase 2	Completed	-	Canada, Nova Scotia ... 展开 >> QEII Health Sciences Center Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Univ. Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec McGill University - Dept. Oncology Montreal, Quebec, Canada, H2W 1S6 收起 <<
NCT00281957	Recurrent Melanoma ... 展开 >> Stage IV Melanoma 收起 <<	Phase 2	Completed	-	-
NCT01703455	Salivary Gland Cancer	Phase 2	Unknown	January 2013	Italy ... 展开 >> IRCCS Istituto Nazionale Tumori Milano, Italy, 20133 收起 <<
NCT00281957	-		Completed	-	-
NCT01245582	Hepatic Neoplasm Malignant	Phase 3	Withdrawn	August 2015	-
NCT02240433	Hepatocellular Carcinoma	Phase 1	Active, not recruiting	February 11, 2019	Japan ... 展开 >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chiba, Japan, 277 8577 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kanagawa, Japan, 241-8515 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Suita-shi, Japan, 565-0871 收起 <<
NCT00253370	Adenocarcinoma of the Gastroes... 展开 >>ophageal Junction Metastatic Gastric Cancer Advanced Unresectable Gastric Cancer 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Eastern Cooperative Oncology Group Boston, Massachusetts, United States, 02215 收起 <<
NCT00919009	Carcinoma, Hepatocellular	Phase 2	Completed	-	Korea, Republic of ... 展开 >> National Cancer Center Seoul, Korea, Republic of 收起 <<
NCT02517736	Uveal Melanoma	Phase 2	Completed	-	France ... 展开 >> Service d'ophtalmologie, CHU de Caen Caen, France, 14000 收起 <<
NCT00253370	-		Completed	-	-
NCT00464919	Hepatocellular Carcinoma	Phase 2	Completed	-	Taiwan ... 展开 >> National Taiwan University Hospital Taipei, Taiwan, 100 收起 <<
NCT00301847	Kidney Cancer ... 展开 >> Metastatic Cancer 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> University of Chicago Cancer Research Center Chicago, Illinois, United States, 60637-1470 Decatur Memorial Hospital Cancer Care Institute Decatur, Illinois, United States, 62526 Evanston Northwestern Health Care - Evanston Hospital Evanston, Illinois, United States, 60201-1781 Ingalls Cancer Care Center at Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood, Illinois, United States, 60153 Oncology Hematology Associates of Central Illinois, PC - Peoria Peoria, Illinois, United States, 61615-7828 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 62701 United States, Indiana Fort Wayne Medical Oncology and Hematology Fort Wayne, Indiana, United States, 46885-5099 CCOP - Northern Indiana CR Consortium South Bend, Indiana, United States, 46601 United States, Michigan Oncology Care Associates, PLLC Saint Joseph, Michigan, United States, 49085 United States, Missouri David C. Pratt Cancer Center at St. John's Mercy Saint Louis, Missouri, United States, 63141 United States, Wisconsin Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT00131911	-		Completed	-	-
NCT02460991	Hepatocellular Carcinoma ... 展开 >> Hepatoma Liver Cell Carcinoma 收起 <<	Phase 3	Terminated(Slow enrollment)	-	United States, Alabama ... 展开 >> University of Alabama Hospital Birmingham, Alabama, United States, 35233 United States, California University of Southern California Los Angeles, California, United States, 90033 United States, Kentucky University of Louisville Louisville, Kentucky, United States, 40202 United States, Maryland University of Maryland Medical Center Baltimore, Maryland, United States, 21201 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02460991	-		Terminated(Slow enrollment)	-	-
NCT00238121	-		Completed	-	-
NCT01158287	Esophageal Cancer ... 展开 >> Gastric Cancer 收起 <<	Phase 2	Completed	-	Ireland ... 展开 >> Bon Secours Hospital Cork, Ireland Cork University Hospital Cork, Ireland Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital Dublin, Ireland, 24 Mater Misericordiae University Hospital Dublin, Ireland, 7 St. James's Hospital Dublin, Ireland, 8 Beaumont Hospital Dublin, Ireland, 9 University College Hospital Galway, Ireland Waterford Regional Hospital Waterford, Ireland 收起 <<
NCT00389285	Carcinoma, Renal Cell	Phase 1 Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama Birmingham, Alabama, United States, 35294 United States, Arizona Premiere Oncology of Arizona Scottsdale, Arizona, United States, 85260 United States, New Hampshire Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 收起 <<
NCT00131911	Gastrinoma Gl... 展开 >>ucagonoma Insulinoma Metastatic Gastrointestinal Carcinoid Tumor Neuroendocrine Tumor Pancreatic Polypeptide Tumor Recurrent Gastrointestinal Carcinoid Tumor Recurrent Islet Cell Carcinoma Somatostatinoma WDHA Syndrome 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT01262482	Advanced or Metastatic Gastric... 展开 >> or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment) 收起 <<	Phase 2	Completed	-	Spain ... 展开 >> Hospital Clinic de Barcelona Barcelona, Spain Hospital Sant Pau Barcelona, Spain H. Josep Trueta Girona, Spain Centro Oncológico M.D. Anderson Spain Madrid, Spain Hospital de Fuenlabrada Madrid, Spain Hospital La Paz Madrid, Spain Hospital Althaia Manresa, Spain Clínica Universitaria de Navarra Pamplona, Spain Hospital Parc Taulí Sabadell, Spain Hospital General de Valencia Valencia, Spain 收起 <<
NCT00498836	Malignant Melanoma	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Texas Cancer Therapy and Research Center, Institute for Drug Development San Antonio, Texas, United States, 78229 Norway The Norwegian Radium Hospital Oslo, Norway, NO-0310 Sweden Lund University Hospital Lund, Sweden, SE-221 85 Umeå University Hospital Umeå, Sweden Uppsala University Hospital Uppsala, Sweden, SE-751 85 收起 <<
NCT01383343	Recurrent Colon Carcinoma ... 展开 >> Recurrent Rectal Carcinoma Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer 收起 <<	Phase 1	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00101413	Cancer Carcin... 展开 >>oma, Non-Small Cell Lung 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Houston, Texas, United States, 77030 Germany Großhansdorf, Schleswig-Holstein, Germany, 22927 收起 <<
NCT00101413	-		Completed	-	-
NCT00941863	Carcinoma	Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Nashville, Tennessee, United States, 37232 United States, Wisconsin Madison, Wisconsin, United States, 53792 收起 <<
NCT00941863	-		Completed	-	-
NCT00448149	Carcinoma, Renal Cell	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> The Methodist Hospital Research Institute Houston, Texas, United States, 77030 收起 <<
NCT00119639	Kidney Diseases	Phase 1	Completed	-	-
NCT00126620	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	Canada, Ontario ... 展开 >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00238121	Recurrent Uterine Sarcoma ... 展开 >> Stage III Uterine Sarcoma Stage IV Uterine Sarcoma Uterine Carcinosarcoma 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 University of Southern California Los Angeles, California, United States, 90033-0804 United States, Illinois Decatur Memorial Hospital Decatur, Illinois, United States, 62526 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 60702 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Cancer Centre of Southeastern Ontario at Kingston General Hospital Kingston, Ontario, Canada, K7L 5P9 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00095966	Adenocarcinoma of the Pancreas... 展开 >> Recurrent Pancreatic Cancer Stage II Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 收起 <<
NCT00255658	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> Cancer Therapy and Research Center at The UT Health Science Center at San Antonio San Antonio, Texas, United States, 78229 收起 <<
NCT00865709	Metastatic Colorectal Cancer	Phase 2	Completed	-	-
NCT02977754	-		Recruiting	March 2019	Italy ... 展开 >> Istituto Clinico Humanitas Recruiting Rozzano, Milano, Italy, 20089 Contact: Egesta Lopci, MD +39 0282247542 收起 <<
NCT00326495	-		Completed	-	-
NCT00789763	Pancreatic Cancer	Phase 1	Completed	-	Spain ... 展开 >> Hospital de La Santa Creu I Sant Pau Barcelona, Spain, 08025 Hospital Clinic I Provincial Barcelona, Spain, 08036 Hospital Universitario La Paz Madrid, Spain, 28046 Hospital Universitario La Fe Valencia, Spain, 46009 收起 <<
NCT00865709	-		Completed	-	-
NCT00436579	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Terminated	-	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT01502410	-		Completed	-	-
NCT00326495	Metastatic Colorectal Cancer	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00609401	Metastatic Disease ... 展开 >> Renal Cell Carcinoma 收起 <<	Phase 2	Completed	-	Italy ... 展开 >> Istituto Tumori Milano, Italy 收起 <<
NCT01015833	Advanced Adult Hepatocellular ... 展开 >>Carcinoma Recurrent Hepatocellular Carcinoma Stage III Hepatocellular Carcinoma AJCC v7 Stage IIIA Hepatocellular Carcinoma AJCC v7 Stage IIIB Hepatocellular Carcinoma AJCC v7 Stage IIIC Hepatocellular Carcinoma AJCC v7 Stage IV Hepatocellular Carcinoma AJCC v7 Stage IVA Hepatocellular Carcinoma AJCC v7 Stage IVB Hepatocellular Carcinoma AJCC v7 Unresectable Hepatocellular Carcinoma 收起 <<	Phase 3	Active, not recruiting	-	-
NCT00919061	Extrahepatic Bile Duct Cancer ... 展开 >> Gallbladder Cancer 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01015833	-		Active, not recruiting	-	-
NCT02270788	Acute Myeloid Leukemia	Phase 1	Completed	-	United States, Tennessee ... 展开 >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 收起 <<
NCT00919061	-		Completed	-	-
NCT01502410	Childhood Hepatocellular Carci... 展开 >>noma Papillary Thyroid Cancer Previously Treated Childhood Rhabdomyosarcoma Recurrent Childhood Liver Cancer Recurrent Childhood Rhabdomyosarcoma Recurrent Thyroid Cancer Recurrent Wilms Tumor and Other Childhood Kidney Tumors 收起 <<	Phase 2	Completed	-	-
NCT00619541	Hepatocellular Carcinoma	Phase 2	Completed	-	Italy ... 展开 >> Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina ... Indirizzo: via Roma, 55 - 56100 Pisa Tel. 050-2218690 - Fax. 050-2218685 Pisa, Italy, 56100 收起 <<
NCT01234337	Breast Cancer	Phase 3	Completed	-	-
NCT01481805	-		Completed	-	Korea, Republic of ... 展开 >> Samsung medical Center Seoul, Korea, Republic of 收起 <<
NCT00217646	Adult Acute Basophilic Leukemi... 展开 >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia Adult Acute Monoblastic Leukemia Adult Acute Monocytic Leukemia Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 Adult Acute Myeloid Leukemia With Maturation Adult Acute Myeloid Leukemia With Minimal Differentiation Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL Adult Acute Myeloid Leukemia Without Maturation Adult Acute Myelomonocytic Leukemia Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA Adult Erythroleukemia Adult Pure Erythroid Leukemia Alkylating Agent-Related Acute Myeloid Leukemia Blastic Phase de Novo Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00873002	Liver Cancer	Phase 1	Terminated(Dose Limiting Toxic... 展开 >>ity) 收起 <<	-	United States, Ohio ... 展开 >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 收起 <<
NCT00727532	Hereditary Clear Cell Renal Ce... 展开 >>ll Carcinoma Kidney Cancer 收起 <<	Not Applicable	Terminated(Low Accrual)	June 2015	United States, Illinois ... 展开 >> Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois, United States, 60611-3013 收起 <<
NCT00098540	Recurrent Non-small Cell Lung ... 展开 >>Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> North Central Cancer Treatment Group Rochester, Minnesota, United States, 55905 收起 <<
NCT00096512	Metastatic Squamous Neck Cance... 展开 >>r With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Salivary Gland Squamous Cell Carcinoma Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IVA Salivary Gland Cancer Stage IVA Squamous Cell Carcinoma of the Larynx Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVA Squamous Cell Carcinoma of the Oropharynx Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVA Verrucous Carcinoma of the Larynx Stage IVA Verrucous Carcinoma of the Oral Cavity Stage IVB Salivary Gland Cancer Stage IVB Squamous Cell Carcinoma of the Larynx Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVB Squamous Cell Carcinoma of the Oropharynx Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVB Verrucous Carcinoma of the Larynx Stage IVB Verrucous Carcinoma of the Oral Cavity Stage IVC Salivary Gland Cancer Stage IVC Squamous Cell Carcinoma of the Larynx Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVC Squamous Cell Carcinoma of the Oropharynx Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVC Verrucous Carcinoma of the Larynx Stage IVC Verrucous Carcinoma of the Oral Cavity Tongue Cancer Untreated Metastatic Squamous Neck Cancer With Occult Primary 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Southwest Oncology Group (SWOG) Research Base San Antonio, Texas, United States, 78245 收起 <<
NCT00621686	Brain and Central Nervous Syst... 展开 >>em Tumors 收起 <<	Phase 2	Completed	-	-
NCT00287495	Kaposi's Sarcoma ... 展开 >> HHV-8 KSHV 收起 <<	Phase 1	Terminated	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00621686	-		Completed	-	-
NCT00217399	Recurrent Breast Cancer ... 展开 >> Stage IV Breast Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, District of Col... 展开 >>umbia Lombardi Comprehensive Cancer Center at Georgetown University Washington, District of Columbia, United States, 20057 收起 <<
NCT00889343	Colorectal Neoplasms	Phase 2	Terminated	-	-
NCT00901901	Carcinoma, Hepatocellular	Phase 3	Completed	-	-
NCT00217399	-		Completed	-	-
NCT00492297	Melanoma	Phase 2	Completed	-	France ... 展开 >> Bordeaux, France, 33000 Lyon Cedex, France, 39373 Toulouse, France, 31052 Villejuif, France, 94805 United Kingdom Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ Southampton, Hampshire, United Kingdom, SO16 6YD Northwood, Middlesex, United Kingdom, HA6 2RN Sutton, Surrey, United Kingdom, SM2 5PT London, United Kingdom, NW3 2QG London, United Kingdom, SE1 7EH London, United Kingdom, SW3 6JJ Manchester, United Kingdom, M20 4BX 收起 <<
NCT01170104	Hepatocellular Carcinoma	Phase 2	Unknown	June 2013	Korea, Republic of ... 展开 >> Chung-Ang University Hospital Recruiting Dongjak, Seoul, Korea, Republic of, 156-755 Contact: Joung-Soon Jang, M.D. 82-2-6299-1427 alsaba@daum.net Contact: In Gyu Hwang, M.D. 82-2-748-9786 higyu72@yahoo.co.kr Principal Investigator: Joung-Soon Jang, M.D. Sub-Investigator: Hyung Joon Kim, M.D. Sub-Investigator: Hyun Woong Lee, M.D. Sub-Investigator: In Gyu Hwang, M.D. 收起 <<
NCT00492297	-		Completed	-	-
NCT00526799	Ovarian Cancer	Phase 1 Phase 2	Terminated(Study closed to acc... 展开 >>rual due unfavorable interim analysis) 收起 <<	-	United States, Illinois ... 展开 >> Medical & Surgical Specialists, LLC Galesburg, Illinois, United States, 61401 United States, Indiana Oncology Hematology Associates of SW Indiana Evansville, Indiana, United States, 47714 Fort Wayne Oncology & Hematology, Inc Fort Wayne, Indiana, United States, 46815 Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 St. Vincent Hospital Cynecologic Oncology Indianapolis, Indiana, United States, 46260 Arnett Cancer Care Lafayette, Indiana, United States, 47904 Medical Consultants, P.C. Muncie, Indiana, United States, 47303 United States, New York Schwartz Gynecologic Oncology, PLLC Brightwaters, New York, United States, 11718 收起 <<
NCT01234337	-		Completed	-	-
NCT00901901	-		Completed	-	-
NCT00112671	Metastatic Transitional Cell C... 展开 >>ancer of the Renal Pelvis and Ureter Recurrent Bladder Cancer Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter Regional Transitional Cell Cancer of the Renal Pelvis and Ureter Stage III Bladder Cancer Stage IV Bladder Cancer Transitional Cell Carcinoma of the Bladder 收起 <<	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT03140332	Hepatocellular Carcinoma ... 展开 >> Perfusion Scanner 收起 <<	Not Applicable	Recruiting	February 27, 2020	France ... 展开 >> CHU Amiens Picardie Recruiting Amiens, Picardie, France, 80054 Contact: Vincent HAUTEFEUILLE, Dr +33322668206 hautefeuille.vincent@chu-amiens.fr 收起 <<
NCT00131989	Adult Acute Basophilic Leukemi... 展开 >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 收起 <<
NCT00526799	-		Terminated(Study closed to acc... 展开 >>rual due unfavorable interim analysis) 收起 <<	-	-
NCT00424385	Prostate Cancer	Phase 1	Completed	-	United States, Illinois ... 展开 >> Oncology Specialists, S.C Niles, Illinois, United States, 60714 Oncology Specialists, S.C Park Ridge, Illinois, United States, 60068 收起 <<
NCT00112671	-		Completed	-	-
NCT00424385	-		Completed	-	-
NCT00509613	Advanced Solid Tumor ... 展开 >> Refractory to Standard Therapies 收起 <<	Phase 1	Completed	-	Netherlands ... 展开 >> UMC St Radboud Nijmegen, Netherlands 收起 <<
NCT01761266	Hepatocellular Carcinoma (HCC)	Phase 3	Active, not recruiting	March 2019	-
NCT00107432	Epithelial Mesothelioma ... 展开 >> Recurrent Malignant Mesothelioma Sarcomatous Mesothelioma Stage IA Malignant Mesothelioma Stage IB Malignant Mesothelioma Stage II Malignant Mesothelioma Stage III Malignant Mesothelioma Stage IV Malignant Mesothelioma 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> Cancer and Leukemia Group B Chicago, Illinois, United States, 60606 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00478374	Hepatocellular Carcinoma	Phase 1	Completed	-	Switzerland ... 展开 >> Inselspital Bern, Switzerland, 3010 收起 <<
NCT01761266	-		Active, not recruiting	-	-
NCT03764293	Locally Advanced or Metastatic... 展开 >> and Unresectable HCC 收起 <<	Phase 3	Not yet recruiting	December 2021	-
NCT01908322	-		Completed	-	Germany ... 展开 >> Many Locations, Germany 收起 <<
NCT00119249	Stage III Melanoma ... 展开 >> Stage IV Melanoma 收起 <<	Phase 2	Completed	-	United States, New York ... 展开 >> Montefiore Medical Center Bronx, New York, United States, 10467-2490 收起 <<
NCT00573755	Breast Cancer	Phase 2	Terminated(lack of participant... 展开 >> accrual) 收起 <<	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 55259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00095459	Neoplasms	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00573755	-		Terminated(lack of participant... 展开 >> accrual) 收起 <<	-	-
NCT01124669	-		Completed	-	-
NCT00467025	Advanced Renal Cell Carcinoma	Phase 2	Completed	-	-
NCT00672178	-		Terminated(Slow accrual)	-	-
NCT00672178	Renal Cell Carcinoma	Phase 1 Phase 2	Terminated(Slow accrual)	-	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT00110994	Cancer Melano... 展开 >>ma 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Tucson, Arizona, United States, 85724 United States, Colorado Aurora, Colorado, United States, 80045 United States, Florida Lakeland, Florida, United States, 33805 United States, Illinois Park Ridge, Illinois, United States, 60068 United States, Massachusetts Boston, Massachusetts, United States, 02114 Boston, Massachusetts, United States, 02115-6084 Boston, Massachusetts, United States, 02215 United States, Missouri St. Louis, Missouri, United States, 63110-1093 United States, Nebraska Omaha, Nebraska, United States, 68114 United States, North Carolina Charlotte, North Carolina, United States, 28203 United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15232 United States, South Carolina Hilton Head Island, South Carolina, United States, 29926-2739 United States, Tennessee Nashville, Tennessee, United States, 37232-6307 United States, Texas San Antonio, Texas, United States, 78229 收起 <<
NCT01664182	Stage III Renal Cell Cancer AJ... 展开 >>CC v7 Stage IV Renal Cell Cancer AJCC v7 收起 <<	Phase 2	Active, not recruiting	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 City of Hope South Pasadena South Pasadena, California, United States, 91030 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Metro Minnesota Community Oncology Research Consortium Saint Louis Park, Minnesota, United States, 55416 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Virginia VCU Massey Cancer Center at Hanover Medical Park Mechanicsville, Virginia, United States, 23116 收起 <<
NCT00771147	-		Completed	-	Belgium ... 展开 >> Many Locations, Belgium 收起 <<
NCT03468231	Hepatocellular Carcinoma	Phase 3	Recruiting	March 9, 2020	China, Guangdong ... 展开 >> Dongguan People's Hospital Recruiting Dongguan, Guangdong, China, 523059 Contact: Wusheng Yu, MD 13827285010 yuwusheng1998@126.com Cancer Center Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Ming Shi, MD 86-2087343115 shiming@mail.sysu.edu.cn Principal Investigator: Ming Shi, MD The First Affiliated Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Guosheng Tan, MD 13725254145 tgs1976@163.com Guangzhou Twelfth People 's Hospital Recruiting Guangzhou, Guangdong, China, 510620 Contact: Yuanmin Zhou, MD 15521278919 13430288977@139.com Principal Investigator: Jinghua Chen, MD Kaiping Central Hospital Recruiting Kaiping, Guangdong, China, 529300 Contact: Shijie Zhang, MD 13717287622 Shijie_9262511@163.com China, Hunan First Affiliated Hospital of University Of South China Recruiting Hengyang, Hunan, China, 421001 Contact: Xiaoping Wu, MD 13975486015 wxp19730806@sina.com China, Shanxi The First Affiliated Hospital Of Xi'an Jiaotong University Recruiting Xi'an, Shanxi, China, 710061 Contact: Xin Zheng, MD 13649265446 183421344@qq.com 收起 <<
NCT00110994	-		Completed	-	-
NCT00430235	Adenocarcinoma of the Prostate	Phase 2	Completed	-	Canada, British Columbia ... 展开 >> BC Cancer Agency - Vancouver Centre Vancouver, British Columbia, Canada, V5Z 4E6 收起 <<
NCT02847468	Carcinoma, Hepatocellular	Not Applicable	Recruiting	March 27, 2021	France ... 展开 >> Emilie REDERSTORFF Recruiting Dijon, France, 21000 Contact: Emilie REDERSTORFF, PhD 0033 3 80 73 75 00 ext 3461 ERederstorff@cgfl.fr Contact: Sandrine TIAGO 0033 3 80 73 75 00 stiago@cgfl.fr Principal Investigator: Alexandre COCHET, MD 收起 <<
NCT00538005	Melanoma (Skin)	Phase 1 Phase 2	Unknown	-	United States, California ... 展开 >> San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas Recruiting Encinitas, California, United States, 92024 Contact: Edward F. McClay, MD 760-452-3340 emcclay@pacificoncology.com 收起 <<
NCT00661180	Chronic Myelogenous Leukemia	Phase 2	Completed	-	United States, Oregon ... 展开 >> Portland, Oregon, United States, 97239 France Lyon Cedex, France, 69437 Paris, France, 75010 Poitiers Cedex, France, 86021 收起 <<
NCT00906373	Hepatocellular Carcinoma	Phase 2	Completed	-	United States, Arizona ... 展开 >> ImClone Investigational Site Scottsdale, Arizona, United States, 85259 United States, California ImClone Investigational Site Los Angeles, California, United States, 90095 United States, Illinois ImClone Investigational Site Chicago, Illinois, United States, 60611 United States, Louisiana ImClone Investigational Site Metairie, Louisiana, United States, 70006 United States, Massachusetts ImClone Investigational Site Burlington, Massachusetts, United States, 01805 United States, New York ImClone Investigational Site New York, New York, United States, 10032 United States, Pennsylvania ImClone Investigational Site Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT00979329	-		Completed	-	Netherlands ... 展开 >> University Medical Center Nijmegen st Radboud Nijmegen, Netherlands, 6525 GH 收起 <<
NCT00906373	-		Completed	-	-
NCT01042041	Hepatocellular Carcinoma ... 展开 >> Liver Cancer Localized Unresectable Liver Cancer 收起 <<	Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> Abramson Cancer Center of The University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT00895674	-		Completed	-	-
NCT00073307	-		Completed	-	-
NCT00499525	Breast Cancer	Phase 2	Active, not recruiting	December 2021	-
NCT01108705	Carcinoma, Hepatocellular	Phase 3	Terminated	-	-
NCT01183663	Advanced Cancers	Phase 1	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00466752	Adenocarcinoma of the Prostate... 展开 >> Stage II Prostate Cancer Stage III Prostate Cancer 收起 <<	Phase 2	Completed	-	United States, Washington ... 展开 >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT00825955	Liver Cancer	Phase 3	Terminated(Efficacy endpoint m... 展开 >>et, however, overall experimental dosing regimen is not considered optimal to support further clinical development in this patient population) 收起 <<	-	-
NCT01387555	Hepatocellular Carcinoma ... 展开 >> Liver Cancer HCC 收起 <<	Phase 2	Completed	-	-
NCT00096200	Recurrent Fallopian Tube Carci... 展开 >>noma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma 收起 <<	Phase 2	Completed	-	United States, Florida ... 展开 >> Moffitt Cancer Center at Tampa General Hospital Tampa, Florida, United States, 33612 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Lake University Ireland Cancer Center Mentor, Ohio, United States, 44060 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT00858871	Hepato Cellular Carcinoma (HCC... 展开 >>) 收起 <<	Phase 3	Completed	-	-
NCT02156297	-		Recruiting	August 2019	China, Jiangsu ... 展开 >> The First Affiliated Hospital of Soochow University Recruiting Suzhou, Jiangsu, China, 215006 Contact: Jia Chen, M.D. +86 512 67781856 c_jerry_j@163.com Principal Investigator: Depei Wu, M.D., Ph.D. Sub-Investigator: Jia Chen, M.D. 收起 <<
NCT00466752	-		Completed	-	-
NCT00096200	-		Completed	-	-
NCT00492986	Carcinoma, Renal Cell	Phase 3	Completed	-	-
NCT00565968	Melanoma (Skin)	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00073307	Carcinoma, Renal Cell	Phase 3	Completed	-	-
NCT00110019	Mucosal Melanoma ... 展开 >> Recurrent Melanoma Stage IIIA Skin Melanoma Stage IIIB Skin Melanoma Stage IIIC Skin Melanoma Stage IV Skin Melanoma 收起 <<	Phase 3	Completed	-	-
NCT00661375	Carcinoma, Renal Cell	Phase 2	Completed	-	-
NCT00541021	Pancreatic Cancer	Phase 3	Unknown	-	France ... 展开 >> Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes Recruiting Marseille, France, 13273 Contact: Frederic Viret, MD 33-4-91-22-35-37 viretf@marseille.fnclcc.fr 收起 <<
NCT01308723	Carcinoma, Hepatocellular	Phase 1	Completed	-	Singapore ... 展开 >> Singapore, Singapore, 119228 Singapore, Singapore, 169610 收起 <<
NCT00732914	Renal Cell Carcinoma	Phase 3	Completed	-	Germany ... 展开 >> Urologische Klinik Mannheim, Baden-Wuerttemberg, Germany, 68167 收起 <<
NCT00792350	-		Completed	-	Austria ... 展开 >> Many Locations, Austria Germany Many Locations, Germany 收起 <<
NCT00110019	-		Completed	-	-
NCT00623402	Melanoma	Phase 2	Completed	-	Germany ... 展开 >> Dpt. of Dermatology, Humboldt University Berlin, Germany, 10117 Dept. of Dermatology, Elbe Klinikum Buxtehude, Germany, 21614 Dpt. of Dermatology, University of Hannover Hannover, Germany, 30449 Dpt. of Dermatology, University of Homburg/Saar Homburg/Saar, Germany, 66421 Dpt. of Dermatology; UK-SH Campus Kiel, Germany Kiel, Germany, D-24105 Dpt. of Dermatology, University of Cologne Koeln, Germany, D-50937 Dpt. of Dermatology, University of Mannheim Mannheim, Germany, 68163 Dpt. of Dermatology, Ludwig-Maximilian-University München, Germany, 80337 Dpt. of Dermatology, University of Tübingen Tübingen, Germany, 72076 Dpt. of Dermatology, University of Würzburg Würzburg, Germany, 97080 收起 <<
NCT00330421	Metastatic Ewing Sarcoma/Perip... 展开 >>heral Primitive Neuroectodermal Tumor Metastatic Osteosarcoma Recurrent Adult Soft Tissue Sarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Osteosarcoma Stage I Adult Soft Tissue Sarcoma Stage II Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00330421	-		Completed	-	-
NCT00417248	Non-Small Cell Lung Cancer	Phase 1 Phase 2	Terminated(Negative sorafenib ... 展开 >>results from ESCAPE trial and safety concerns of regimen) 收起 <<	-	United States, Illinois ... 展开 >> Medical & Surgical Specialists, LLC Galesburg, Illinois, United States, 61401 United States, Indiana Fort Wayne Oncology & Hematology, Inc Fort Wayne, Indiana, United States, 46815 Center for Cancer Care at Goshen Health System Goshen, Indiana, United States, 46527 Indiana University Cancer Center Indianapolis, Indiana, United States, 46202 Horizon Oncology Center Lafayette, Indiana, United States, 47905 Medical Consultants, P.C. Muncie, Indiana, United States, 47303 Northern Indiana Cancer Research Consortium South Bend, Indiana, United States, 46601 United States, Ohio Oncology Partners Network Cincinnati, Ohio, United States, 45247 收起 <<
NCT00378703	Clear Cell Renal Cell Carcinom... 展开 >>a Recurrent Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v7 收起 <<	Phase 2	Completed	-	-
NCT00589420	Prostate Cancer	Phase 2	Unknown	-	United States, Pennsylvania ... 展开 >> Abramson Cancer Center of the University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104-4283 Contact: Clinical Trials Office - Abramson Cancer Center of the Univers 800-474-9892 收起 <<
NCT00483301	Malignant Melanoma	Phase 2	Completed	-	United States, California ... 展开 >> Dr. Steven O'Day Los Angeles, California, United States, 90025 United States, Florida Mt. Sinai Medical Center Miami Beach, Florida, United States, 33140 收起 <<
NCT00417248	-		Terminated(Negative sorafenib ... 展开 >>results from ESCAPE trial and safety concerns of regimen) 收起 <<	-	-
NCT02645981	HCC	Phase 2 Phase 3	Active, not recruiting	August 2019	China, Jiangsu ... 展开 >> The PLA 81 Hospital Nanjing, Jiangsu, China, 025 China, Sichuan West China Hospital Sichuan University Chengdu, Sichuan, China, 610042 收起 <<
NCT00492258	Kidney Cancer	Phase 3	Completed	-	United Kingdom ... 展开 >> Royal Bournemouth Hospital Bournemouth, England, United Kingdom, BH7 7DW Bristol Haematology and Oncology Centre Bristol, England, United Kingdom, BS2 8ED Queen's Hospital Burton-upon-Trent, England, United Kingdom, DE13 0RB Addenbrooke's Hospital Cambridge, England, United Kingdom, CB2 2QQ Gloucestershire Oncology Centre at Cheltenham General Hospital Cheltenham, England, United Kingdom, GL53 7AN Derbyshire Royal Infirmary Derby, England, United Kingdom, DE1 2QY Dorset County Hospital Dorchester, England, United Kingdom, DT1 2JY Gloucestershire Royal Hospital Gloucester, England, United Kingdom, GL1 3NN Diana Princess of Wales Hospital Grimsby, England, United Kingdom, DN33 2BA Princess Royal Hospital at Hull and East Yorkshire NHS Trust Hull, England, United Kingdom, HU8 9HE Ipswich Hospital Ipswich, England, United Kingdom, IP4 5PD Leeds Cancer Centre at St. James's University Hospital Leeds, England, United Kingdom, LS9 7TF Leicester Royal Infirmary Leicester, England, United Kingdom, LE1 5WW Lincoln County Hospital Lincoln, England, United Kingdom, LN2 5QY Saint Bartholomew's Hospital London, England, United Kingdom, EC1A 7BE Medical Research Council Clinical Trials Unit London, England, United Kingdom, NW1 2DA Guy's Hospital London, England, United Kingdom, SE1 9RT Royal Marsden - London London, England, United Kingdom, SW3 6JJ Charing Cross Hospital London, England, United Kingdom, W6 8RF Maidstone Hospital Maidstone, England, United Kingdom, ME16 9QQ Christie Hospital Manchester, England, United Kingdom, M20 4BX Clatterbridge Centre for Oncology Merseyside, England, United Kingdom, CH63 4JY James Cook University Hospital Middlesbrough, England, United Kingdom, TS4 3BW Northern Centre for Cancer Treatment at Newcastle General Hospital Newcastle-Upon-Tyne, England, United Kingdom, NE4 6BE Mount Vernon Cancer Centre at Mount Vernon Hospital Northwood, England, United Kingdom, HA6 2RN Derriford Hospital Plymouth, England, United Kingdom, PL6 8DH Dorset Cancer Centre Poole Dorset, England, United Kingdom, BH15 2JB Portsmouth Oncology Centre at Saint Mary's Hospital Portsmouth Hants, England, United Kingdom, PO3 6AD Whiston Hospital Prescot Merseyside, England, United Kingdom, L35 5DR Berkshire Cancer Centre at Royal Berkshire Hospital Reading, England, United Kingdom, RG1 5AN Scarborough General Hospital Scarborough, England, United Kingdom, YO12 6QL Scunthorpe General Hospital Scunthorpe, England, United Kingdom, DN15 7BH Cancer Research Centre at Weston Park Hospital Sheffield, England, United Kingdom, S1O 2SJ Wexham Park Hospital Slough, Berkshire, England, United Kingdom, SL2 4HL Southampton General Hospital Southampton, England, United Kingdom, SO16 6YD University Hospital of North Staffordshire Stoke-On-Trent, England, United Kingdom, ST4 7LN Torbay Hospital Torquay, England, United Kingdom, TQ2 7AA Aberdeen Royal Infirmary Aberdeen, Scotland, United Kingdom, AB25 2ZN Velindre Cancer Center at Velindre Hospital Cardiff, Wales, United Kingdom, CF14 2TL 收起 <<
NCT00602576	Melanoma (Skin)	Phase 2	Unknown	-	United States, Pennsylvania ... 展开 >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 收起 <<
NCT00378703	-		Completed	-	-
NCT03236649	Hepatocellular Carcinoma (HCC)	Phase 3	Not yet recruiting	August 2019	-
NCT01246843	-		Completed	-	Netherlands ... 展开 >> University Medical Centre Nijmegen Nijmegen, Gelderland, Netherlands, 6500 HB 收起 <<
NCT00474786	Renal Cell Carcinoma	Phase 3	Completed	-	-
NCT02728050	Acute Biphenotypic Leukemia ... 展开 >> Acute Myeloid Leukemia de Novo Myelodysplastic Syndrome High Risk Myelodysplastic Syndrome Myelodysplastic Syndrome Myeloproliferative Neoplasm 收起 <<	Phase 1 Phase 2	Recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Anna Halpern 206-314-5944 halpern2@uw.edu Principal Investigator: Anna Halpern 收起 <<
NCT01409499	Hepatectomy H... 展开 >>epatocellular Carcinoma Sorafenib 收起 <<	Phase 4	Completed	-	China, Guangdong ... 展开 >> Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060 收起 <<
NCT00474786	-		Completed	-	-
NCT02616692	-		Completed	-	Japan ... 展开 >> Many Locations, Japan 收起 <<
NCT00095693	Anaplastic Thyroid Cancer ... 展开 >> Insular Thyroid Cancer Recurrent Thyroid Cancer Stage III Follicular Thyroid Cancer Stage III Papillary Thyroid Cancer Stage IV Follicular Thyroid Cancer Stage IV Papillary Thyroid Cancer 收起 <<	Phase 2	Terminated	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT01887717	Hepatocellular Carcinoma	Phase 3	Terminated(Poor Accrual.)	-	United States, Illinois ... 展开 >> Northwestern Medical Faculty Foundation, Div of Hematology/Oncology Chicago, Illinois, United States, 60611 United States, New York Mount Sinai School of Medicine New York, New York, United States, 10029 Belgium Cliniques Universitaires Saint-Luc Brussels, Belgium, 1200 France Paoli-Calmettes Institute Marseille, France, 13273 Italy UO Radiologia, Ospedali Riuniti di Bergamo Bergamo, Italy, 24128 Azienda Ospedaliero-Universitaria di Bologna Bologna, Italy, 40138 ASO-Santa Croce e Carle di Cuneo Cuneo, Italy, 12100 Fondazione IRCCS Ca Grande Milano, Italy, 20122 S.C Radiologia Interventistica, A.O.Ospedale Niguarda Ca Granda Milano, Italy, 20162 Fondazione Istituto Nazionale Tumori di Milano Milano, Italy, I-20133 Azienda Ospedaliera Ospedali Riuniti "Villa Sofia-Cervello" Palermo, Italy, 90147 University of Pisa Pisa, Italy, 56100 Policlinico A. Gemelli Rome, Italy, 8 - 00168 Spain Hospital Clínic Barcelona. IDIBAPS. CIBEREHD. Liver Unit Barcelona, Spain, 08036 Bulevar Sur s/n Madrid, Spain, 28041 Hospital Universitario Puerta de Hierro, Gastroenterology & Hepatology Dept Madrid, Spain, 28222 Hospital Universitari i Politecnic la Fe Valencia, Spain, 46026 United Kingdom University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom, B15 2WB Royal Free London NHS Foundation Trust London, United Kingdom, NW3 2QG 收起 <<
NCT00496301	Carcinoma, Renal Cell	Phase 2	Completed	-	Spain ... 展开 >> Hospital del Mar Barcelona, Spain, 08003 Hospital Vall d´Hebron Barcelona, Spain, 08035 Hospital de Basurto Bilbao, Spain, 48013 Hospital Santiago de Compostela Coruña, Spain, 15706 Hospital Josep Trueta Gerona, Spain, 17007 Hospital Juan Ramón Jiménez Huelva, Spain, 21005 Hospital Clínico Virgen de la Victoria Málaga, Spain, 29010 Clínica Universitaria de Navarra Pamplona, Spain, 31008 Hospital Virgen Macarena Sevilla, Spain, 41009 Hospital Xeral Cies Vigo, Spain, 36204 收起 <<
NCT00445588	Adult Giant Cell Glioblastoma ... 展开 >> Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor 收起 <<	Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, North Carolina Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT01004978	Hepatocellular Carcinoma ... 展开 >> Unresectable Hepatocellular Carcinoma 收起 <<	Phase 3	Active, not recruiting	-	-
NCT00445588	-		Completed	-	-
NCT02101593	Hepatocellular Carcinoma	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109-1023 收起 <<
NCT03340636	-		Not yet recruiting	March 2019	France ... 展开 >> Caen University Hospital Not yet recruiting Caen, France Contact: Dupont Benoit, MD, PhD 02.31 06 45 40 ext +33 dupont-be@chu-caen.fr Principal Investigator: benoit Dupont, Md, PhD 收起 <<
NCT00490685	Carcinoma, Hepatocellular	Phase 2	Completed	-	Italy ... 展开 >> Istituto Clinico Humanitas Rozzano, Milan, Italy, 20089 收起 <<
NCT00939627	Metastatic Squamous Neck Cance... 展开 >>r With Occult Primary Squamous Cell Carcinoma Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Salivary Gland Squamous Cell Carcinoma Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IVA Salivary Gland Cancer Stage IVA Squamous Cell Carcinoma of the Larynx Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVA Squamous Cell Carcinoma of the Oropharynx Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVA Verrucous Carcinoma of the Larynx Stage IVA Verrucous Carcinoma of the Oral Cavity Stage IVB Salivary Gland Cancer Stage IVB Squamous Cell Carcinoma of the Larynx Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVB Squamous Cell Carcinoma of the Oropharynx Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVB Verrucous Carcinoma of the Larynx Stage IVB Verrucous Carcinoma of the Oral Cavity Stage IVC Salivary Gland Cancer Stage IVC Squamous Cell Carcinoma of the Larynx Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVC Squamous Cell Carcinoma of the Oropharynx Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IVC Verrucous Carcinoma of the Larynx Stage IVC Verrucous Carcinoma of the Oral Cavity Tongue Cancer Untreated Metastatic Squamous Neck Cancer With Occult Primary 收起 <<	Phase 2	Completed	-	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 Suburban Hospital Bethesda, Maryland, United States, 20814 United States, Montana Billings Clinic Billings, Montana, United States, 59107-7000 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467-2490 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT00941967	Liver Cancer	Phase 2	Unknown	-	France ... 展开 >> Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Recruiting Montpellier, France, 34295 Contact: Eric Assenat, MD 33-4-6761-2593 收起 <<
NCT00452387	-		Terminated(Early stopping rule... 展开 >>) 收起 <<	-	-
NCT00452387	Metastatic Prostate Cancer	Phase 2	Terminated(Early stopping rule... 展开 >>) 收起 <<	-	United States, California ... 展开 >> Wilshire Oncology Medical Group, Inc. La Verne, California, United States, 91750 United States, Georgia Peachtree Hematology Oncology Consultants Atlanta, Georgia, United States, 30309 Central Georgia Cancer Care Macon, Georgia, United States, 31201 Northwest Georgia Oncology Centers Marietta, Georgia, United States, 30060 United States, Montana Hematology Oncology Centers of the Northern Rockies, PC Billings, Montana, United States, 59101 United States, Ohio Mid-Ohio Oncology/Hematology, Inc. Columbus, Ohio, United States, 43213 United States, Pennsylvania Lancaster Cancer Center Lancaster, Pennsylvania, United States, 17605 Pennsylvania Oncology Hematmology Associates Philadelphia, Pennsylvania, United States, 19106 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 United States, Virginia Cancer Specialists of Tidewater Chesapeake, Virginia, United States, 23320 收起 <<
NCT00939627	-		Completed	-	-
NCT00606866	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 3	Completed	-	United States, Illinois ... 展开 >> The University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT00544167	Breast Cancer	Not Applicable	Completed	-	United States, Florida ... 展开 >> Integrated Community Oncology Network Jacksonville, Florida, United States, 32256 Florida Hospital Cancer Institute Orlando, Florida, United States, 32804 United States, Kentucky Consultants in Blood Disorders and Cancer Louisville, Kentucky, United States, 40207 United States, Michigan Grand Rapids Clinical Oncology Program Grand Rapids, Michigan, United States, 49503 United States, Nebraska Methodist Cancer Center Omaha, Nebraska, United States, 68114 United States, Tennessee Chattanooga Oncology Hematology Associates Chattanooga, Tennessee, United States, 37404 Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 United States, Virginia Peninsula Cancer Institute Newport News, Virginia, United States, 23601 收起 <<
NCT00352859	Carcinoma, Renal Cell	Phase 4	Terminated	-	United States, Missouri ... 展开 >> Kansas City, Missouri, United States 收起 <<
NCT00544167	-		Completed	-	-
NCT00607438	Breast Cancer	Phase 2	Terminated(Low accrual)	-	United States, Ohio ... 展开 >> Veeda Oncology Columbus, Ohio, United States, 43215 收起 <<
NCT03212625	Hepatocellular Carcinoma	Phase 4	Active, not recruiting	January 31, 2019	Korea, Republic of ... 展开 >> Korea University Guro Hospital Seoul, Korea, Republic of, 08308 收起 <<
NCT00079612	Carcinoma, Renal Cell	Phase 2	Completed	-	United States, Illinois ... 展开 >> Chicago, Illinois, United States, 60637 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, Texas Houston, Texas, United States, 77030 San Antonio, Texas, United States, 78229 United Kingdom London, Greater London, United Kingdom, SW3 6JJ Glasgow, Strathclyde, United Kingdom, G11 6NT Sutton, Surrey, United Kingdom, SM2 5PT 收起 <<
NCT00687674	-		Terminated(Due to study design... 展开 >> (and toxicity), this trial closed to accrual prior to opening the phase II portion.) 收起 <<	-	-
NCT00454194	Lung Cancer	Phase 2	Completed	-	-
NCT00687674	Multiple Myeloma and Plasma Ce... 展开 >>ll Neoplasm 收起 <<	Phase 1 Phase 2	Terminated(Due to study design... 展开 >> (and toxicity), this trial closed to accrual prior to opening the phase II portion.) 收起 <<	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00454194	-		Completed	-	-
NCT00096434	Male Breast Cancer ... 展开 >> Recurrent Breast Cancer Stage IV Breast Cancer 收起 <<	Phase 2	Completed	-	United States, Minnesota ... 展开 >> North Central Cancer Treatment Group Rochester, Minnesota, United States, 55905 收起 <<
NCT03578874	Hepatocellular Carcinoma	Phase 2	Recruiting	December 31, 2021	Hong Kong ... 展开 >> Queen Mary Hospital Recruiting Hong Kong, Hong Kong Contact: Thomas Yau Principal Investigator: Thomas Yau, MD 收起 <<
NCT01508364	-		Completed	-	Germany ... 展开 >> Many Locations, Germany 收起 <<
NCT03755791	Hepatocellular Carcinoma	Phase 3	Recruiting	December 1, 2021	United States, California ... 展开 >> Exelixis Clinical Site #2 Recruiting Rialto, California, United States, 92377 Contact: Exelixis 888-393-5494 druginfo@exelixis.com United States, Nevada Exelixis Clinical Site #1 Recruiting Las Vegas, Nevada, United States, 89169 Contact: Exelixis 888-393-5494 druginfo@exelixis.com 收起 <<
NCT00335764	Adult Giant Cell Glioblastoma ... 展开 >> Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> University of California at Los Angeles Los Angeles, California, United States, 90095 University of California San Francisco San Francisco, California, United States, 94115 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT00875615	-		Completed	-	-
NCT00335764	-		Completed	-	-
NCT00696696	-		Completed	-	-
NCT00875615	Liver Cancer	Phase 2	Completed	-	United States, Florida ... 展开 >> University of Miami Sylvester Comprehensive Cancer Center - Miami Miami, Florida, United States, 33136 收起 <<
NCT00822848	Sarcoma	Phase 1	Completed	-	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Portland, Oregon, United States, 97239-3098 收起 <<
NCT00449033	-		Completed	-	-
NCT00696696	Pancreatic Cancer	Phase 2	Completed	-	United States, California ... 展开 >> Desert Regional Medical Center Palm Springs, California, United States, 92262 United States, New York Bellevue Hospital New York, New York, United States, 10016 New York University Cancer Center New York, New York, United States, 10016 收起 <<
NCT00876382	-		Completed	-	United States, Arkansas ... 展开 >> Northeast Arkansas Clinic Jonesboro, Arkansas, United States, 72401 United States, Florida Gulfcoast Oncology Associates St. Petersburg, Florida, United States, 33705 United States, Georgia Medical Oncology Associates of Augusta Augusta, Georgia, United States, 30901 United States, Kentucky Consultants in Blood Disorders and Cancer Louisville, Kentucky, United States, 40207 United States, Mississippi Jackson Oncology Associates Jackson, Mississippi, United States, 39202 United States, Missouri St. Louis Cancer Care Chesterfield, Missouri, United States, 63017 United States, Ohio Oncology Hematology Care Cincinnati, Ohio, United States, 45242 United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 收起 <<
NCT00449033	Carcinoma, Non-Small-Cell Lung	Phase 3	Completed	-	-
NCT01988493	Carcinoma, Hepatocellular	Phase 1 Phase 2	Active, not recruiting	October 18, 2018	-
NCT00093457	Prostate Cancer	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia British Columbia Cancer Agency - Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 British Columbia Cancer Agency - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Manitoba CancerCare Manitoba Winnipeg, Manitoba, Canada, R3E 0V9 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 London Regional Cancer Program at London Health Sciences Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT01806740	Hepatocellular Carcinoma	Phase 4	Active, not recruiting	April 2018	Korea, Republic of ... 展开 >> Guerbet Korea Seoul, Gangnam Gu, Korea, Republic of, 135-920 收起 <<
NCT02349867	Pancreatic Adenocarcinoma ... 展开 >> Stage IA Pancreatic Cancer Stage IB Pancreatic Cancer Stage IIA Pancreatic Cancer Stage IIB Pancreatic Cancer Stage III Pancreatic Cancer Recurrent Pancreatic Carcinoma 收起 <<	Phase 1	Recruiting	May 31, 2022	United States, Virginia ... 展开 >> Virginia Commonwealth University/Massey Cancer Center Recruiting Richmond, Virginia, United States, 23298 Contact: Andrew Poklepovic, MD 804-628-2321 andrew.poklepovic@vcuhealth.org Contact: Katherine Thompson, CRN 804-628-0960 masseysiit@vcu.edu Principal Investigator: Andrew Poklepovic, MD 收起 <<
NCT00494299	-		Completed	-	-
NCT00238212	Adenocarcinoma of the Extrahep... 展开 >>atic Bile Duct Adenocarcinoma of the Gallbladder Adenocarcinoma With Squamous Metaplasia of the Gallbladder Cholangiocarcinoma of the Extrahepatic Bile Duct Cholangiocarcinoma of the Gallbladder Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Squamous Cell Carcinoma of the Gallbladder Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Southwest Oncology Group San Antonio, Texas, United States, 78245 收起 <<
NCT00494299	Carcinoma, Hepatocellular	Phase 3	Completed	-	-
NCT00661830	Adenocarcinoma	Phase 2	Completed	-	Germany ... 展开 >> Klinikum der Johannes Gutenberg-Universität Mainz, I. Med. Klinik Mainz, Rheinland-Pfalz, Germany, 55131 Universitätsklinikum Jena, Klinik für Innere Medizin, Innere Medizin II D-07740 Jena, Germany Universitätsklinikum Hamburg-Eppendorf, I. Med. Klinik, Zentrum für Innere Medizin, Martinistr. 3 D-20248 Hamburg, Germany Klinikum Fulda gAG, Tumorklinik, Pacelliallee 4 D-36043 Fulda, Germany Klinikum der Johann-Wolfgang Goethe-Universität, Innere Medizin I, Theodor-Stern-Kai 7 D-60590 Frankfurt, Germany Universitätsklinikum des Saarlandes, Klinik für Innere Medizin II, Kirrberger Str., Gebäude 41 D-66421 Homburg/Saar, Germany Klinikum der Universität München, Medizinische Klinik II, Marchioninistr. 15 D-81377 München, Germany Klinikum rechts der Isar, TU München, II. Medizinische Klinik und Poliklinik, Ismaningerstr. 22 D-81675 München, Germany II. Med. Klinik, Leopoldina-Krankenhaus der Stadt Schweinfurt, Gustav-Adolf-Str. 8 D-97422 Schweinfurt, Germany Klinikum Esslingen Esslingen, Germany, 73730 Universitätsklinikum Halle, Innere Medizin I Halle, Germany, 06120 收起 <<
NCT00867321	Liver Cancer	Phase 1 Phase 2	Completed	-	-
NCT00449280	Advanced Solid Tumor	Phase 1	Completed	-	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 收起 <<
NCT01353794	-		Withdrawn	April 2018	-
NCT00661830	-		Completed	-	-
NCT00881751	-		Completed	-	-
NCT00867321	-		Completed	-	-
NCT00874874	Sarcoma	Phase 2	Unknown	-	France ... 展开 >> Centre Oscar Lambret Recruiting Lille, France, 59020 Contact: Nicolas Penel, MD 33-3-20-295-920 收起 <<
NCT02786342	-		Recruiting	January 2019	Italy ... 展开 >> Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Recruiting Meldola, FC, Italy, 47014 Contact: Andrea Casadei-Gardini, MD Oncologia medica , PO FAENZA, Ausl della Romagna Recruiting Faenza, RA, Italy, 48018 Contact: Stefano Tamberi, MD Ospedale Civile degli Infermi Recruiting Rimini, RM, Italy, 47921 Contact: Emiliano Tamburini, MD 收起 <<
NCT00121251	Recurrent Renal Cell Carcinoma... 展开 >> Stage III Renal Cell Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7 收起 <<	Phase 1 Phase 2	Completed	-	United States, New York ... 展开 >> Montefiore Medical Center - Moses Campus Bronx, New York, United States, 10467 Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York, United States, 10016 Mount Sinai Hospital New York, New York, United States, 10029 Weill Medical College of Cornell University New York, New York, United States, 10065 收起 <<
NCT00547443	Lung Cancer	Phase 1 Phase 2	Terminated(Withdrawn as the sp... 展开 >>onsor has stopped the drug for NSCLC population) 收起 <<	-	United States, Texas ... 展开 >> Arlington Cancer Center - Arlington Arlington, Texas, United States, 76012-2510 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas, Texas, United States, 75390 收起 <<
NCT00881751	Liver Cancer	Phase 2	Completed	-	United States, California ... 展开 >> USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90033-0804 California Pacific Medical Center San Francisco, California, United States, 94115 United States, New York Columbia University/ New York Presbyterian Hospital New York, New York, United States, 10032 United States, South Carolina Hollings Cancer Center at Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Tennessee Tennessee Oncology, PLLCat Sarah Cannon Cancer Center Nashville, Tennessee, United States, 37203 United States, Virginia UVA Cancer Center Charlottesville, Virginia, United States, 22908 收起 <<
NCT00634751	Pancreatic Neoplasms ... 展开 >> Bile Duct Neoplasms 收起 <<	Phase 1 Phase 2	Completed	-	United States, Wisconsin ... 展开 >> University of Wisconsin Madison, Wisconsin, United States, 53792 收起 <<
NCT03406364	Solid Tumor	Phase 1 Phase 2	Recruiting	December 31, 2019	Taiwan ... 展开 >> Tri-Service General Hospital Recruiting Taipei, Nehu District, Taiwan, 114 Contact: Candace Liu +886-2-8792-3100 ext 19391 candaceliu@metagone.com.tw 收起 <<
NCT01187199	Advanced Cancer	Phase 1	Active, not recruiting	August 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01182272	Liver Cancer	Phase 2	Unknown	-	France ... 展开 >> Hopital Beaujon Recruiting Clichy, France, 92110 Contact: Contact Person 33-1-4087-5614 sandrine.faivre@bjn.aphp.fr 收起 <<
NCT00121264	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Michigan ... 展开 >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 收起 <<
NCT00634751	-		Completed	-	-
NCT00117637	Carcinoma, Renal Cell	Phase 2	Completed	-	-
NCT00117637	-		Completed	-	-
NCT03516071	Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	May 10, 2019	China, Anhui ... 展开 >> Anhui Provincial Hospital Recruiting Hefei, Anhui, China Contact: Yueyin Pan China, Guangdong Nanfang Hospital Recruiting Guangzhou, Guangdong, China Contact: Jinlin Hou Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China Contact: Li Xu China, Heilongjiang Harbin Medical University Cancer Hospital Recruiting Harbin, Heilongjiang, China Contact: Yuxian Bai China, Henan Henan Cancer Hospital Recruiting Zhengzhou, Henan, China Contact: Xinfang Hou China, Hunan Hunan Cancer Hospital Recruiting Changsha, Hunan, China Contact: Shanzhi Gu China, Jiangsu China PLA 81st hospital Recruiting Nanjing, Jiangsu, China Contact: Shukui Qin China, Jilin The first Hospital of Jilin University Recruiting Changchun, Jilin, China Contact: Wei Li China, Liaoning Army General Hospital of Shenyang military region Recruiting Shenyang, Liaoning, China Contact: Zhendong Zheng China, Shanghai Fudan University Shanghai Cancer Center Recruiting Shanghai, Shanghai, China Contact: Zhiqiang Meng Zhongshan Hospital Recruiting Shanghai, Shanghai, China Contact: Zhenggang Ren China, Shanxi Tangdu Hospital Recruiting Xi'an, Shanxi, China Contact: Helong Zhang China, Sichuan West China Hospital West China School of Medicine Sichuan University Recruiting Chengdu, Sichuan, China Contact: Hong Zhu China, Tianjin Tianjin Medical University Cancer Institute & Hospital Recruiting Tianjin, Tianjin, China Contact: Tianqiang Song China, Zhejiang Zhejiang Cancer Hospital Recruiting Hangzhou, Zhejiang, China Contact: Jieer Ying 收起 <<
NCT02187302	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Completed	-	-
NCT01205828	Hepatocellular Carcinoma	Phase 2	Terminated(Lack of efficacy)	-	United States, District of Col... 展开 >>umbia Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington, District of Columbia, United States, 20007 收起 <<
NCT01180959	Liver Cancer	Phase 2	Active, not recruiting	April 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00410124	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 3	Completed	-	-
NCT01205828	-		Terminated(Lack of efficacy)	-	-
NCT03533582	Childhood Hepatocellular Carci... 展开 >>noma Childhood Malignant Liver Neoplasm Elevated Alpha-Fetoprotein Hepatoblastoma SMARCB1 Gene Mutation 收起 <<	Phase 2 Phase 3	Recruiting	March 31, 2025	-
NCT00410124	-		Completed	-	-
NCT00495872	Solid Tumors	Phase 1	Completed	-	United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01620216	Acute Myeloid Leukemia Arising... 展开 >> From Previous Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia 收起 <<	Phase 2	Recruiting	March 30, 2019	United States, Maryland ... 展开 >> National Heart Lung and Blood Institute Not yet recruiting Bethesda, Maryland, United States, 20824 Contact: Christopher S. Hourigan 301-803-8029 hourigan@nih.gov Principal Investigator: Christopher S. Hourigan United States, Oregon OHSU Knight Cancer Institute Not yet recruiting Portland, Oregon, United States, 97239 Contact: Marc Loriaux 503-494-9383 loriauxm@ohsu.edu Principal Investigator: Marc Loriaux United States, Texas UT Southwestern/Simmons Cancer Center-Dallas Recruiting Dallas, Texas, United States, 75390 Contact: Robert H. Collins 214-648-4155 robert.collins@utsouthwestern.edu Principal Investigator: Robert H. Collins United States, Utah Huntsman Cancer Institute/University of Utah Not yet recruiting Salt Lake City, Utah, United States, 84112 Contact: Tibor J. Kovacsovics 801-585-3229 tibor.kovacsovics@hci.utah.edu Principal Investigator: Tibor J. Kovacsovics 收起 <<
NCT02013089	Gastrointestinal Cancers	Not Applicable	Unknown	December 2017	China, Guangdong ... 展开 >> Gastrointestinal Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510655 Contact: Yanghong Deng, PhD 008613925106525 13925106525@163.com Principal Investigator: Yanhong Deng, PhD 收起 <<
NCT01556490	Unresectable Hepatocellular Ca... 展开 >>rcinoma 收起 <<	Phase 3	Active, not recruiting	April 2019	-
NCT03642236	FLT3-ITD Mutation ... 展开 >> Acute Myeloid Leukemia Brutons Tyrosine Kinase 收起 <<	Phase 2 Phase 3	Enrolling by invitation	September 2023	China, Guangdong ... 展开 >> Department of Hematology,Nanfang Hospital, Southern Medical University Guangzhou, Guangdong, China, 510515 收起 <<
NCT02435433	Hepatocellular Carcinoma	Phase 3	Recruiting	June 2020	-
NCT01441388	Carcinoma, Renal Cell ... 展开 >> Glioblastoma Carcinoma, Hepatocellular 收起 <<	Phase 1	Withdrawn(Business/Operational... 展开 >> issues) 收起 <<	November 2013	-
NCT03298451	Hepatocellular Carcinoma	Phase 3	Recruiting	January 29, 2021	-
NCT02184416	-		Recruiting	July 20, 2019	-
NCT01964235	Advanced Hepatocellular Carcin... 展开 >>oma 收起 <<	Phase 2	Withdrawn(Study was cancelled ... 展开 >>by Sponsor.) 收起 <<	July 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Mass General Hospital Boston, Massachusetts, United States, 02115 United States, Missouri Research Medical Center Onc Dept Kansas City, Missouri, United States, 64132 Australia, New South Wales Novartis Investigative Site Kogarah, New South Wales, Australia, 2217 Australia, Victoria Novartis Investigative Site Heidelberg, Victoria, Australia, 3084 France Novartis Investigative Site Clichy, France, 92110 Novartis Investigative Site LILLE Cedex, France, 59037 Novartis Investigative Site Montpellier Cedex 5, France, 34298 Novartis Investigative Site Nice Cedex 3, France, 06202 Germany Novartis Investigative Site Essen, Germany, 45147 Novartis Investigative Site Würzburg, Germany, 97080 Hong Kong Novartis Investigative Site Hong Kong SAR, Hong Kong Novartis Investigative Site Hong Kong, Hong Kong Spain Novartis Investigative Site Cordoba, Andalucia, Spain, 14004 Switzerland Novartis Investigative Site Bern, Switzerland, 3010 Novartis Investigative Site Genève, Switzerland, 1211 收起 <<
NCT02940496	Malignant Neoplasms of Digesti... 展开 >>ve Organs Advanced Liver Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01248247	Lung Cancer	Phase 2	Active, not recruiting	June 2019	United States, Connecticut ... 展开 >> Yale Universtiy New Haven, Connecticut, United States, 06520 United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01190241	Advanced Solid Tumors ... 展开 >> Inoperable Metastasis 收起 <<	Not Applicable	Unknown	-	Netherlands ... 展开 >> Medical Center Alkmaar Alkmaar, Netherlands, 1815 JD VU University Medical Center Amsterdam, Netherlands, 1081 HV 收起 <<
NCT01035229	-		Completed	-	-
NCT01035229	Carcinoma	Phase 3	Completed	-	-
NCT01582009	Clear Cell Renal Cell Carcinom... 展开 >>a Recurrent Renal Cell Cancer Stage III Renal Cell Cancer Stage IV Renal Cell Cancer 收起 <<	Phase 1 Phase 2	Terminated(pts off study, PI l... 展开 >>eft institute) 收起 <<	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 University of Rochester Medical Center Rochester, New York, United States, 14642 收起 <<
NCT03499626	Advanced/ Metastatic Hepatocel... 展开 >>lular Carcinoma 收起 <<	Phase 1 Phase 2	Recruiting	May 5, 2021	Singapore ... 展开 >> National University Hospital Recruiting Singapore, Singapore, 119228 Contact: Raghav Sundar (65) 6779 5555 raghav_sundar@nuhs.edu.sg 收起 <<
NCT02089763	Hepatocellular Carcinoma	Phase 2	Terminated(Early termination f... 展开 >>or futility) 收起 <<	-	Hong Kong ... 展开 >> Prince of Wales Hospital, the Chinese University of Hong Kong Hong Kong, Hong Kong 收起 <<
NCT01582009	-		Terminated(pts off study, PI l... 展开 >>eft institute) 收起 <<	-	-
NCT01197170	Solid Tumors ... 展开 >>Advanced Cancer 收起 <<	Phase 1	Active, not recruiting	September 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01449825	-		Completed	-	-
NCT02029157	Liver Cancer	Phase 3	Completed	-	Japan ... 展开 >> Cancer Centers in Japan Tokyo, Japan 收起 <<
NCT03163992	Hepatocellular Carcinoma	Phase 2	Recruiting	December 2019	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Sung Ju Park 234106820 Principal Investigator: Jeeyun Lee, M.D., Ph.D. 收起 <<
NCT01953406	Hepatocellular Carcinoma ... 展开 >> Lung Metastasis 收起 <<	Phase 2	Withdrawn(No participants were... 展开 >> enrolled. Therefore, we stop this study, prematurely.) 收起 <<	-	Korea, Republic of ... 展开 >> Seoul National University Hospital Seoul, Korea, Republic of 收起 <<
NCT01209299	-		Completed	-	-
NCT00900536	-		Completed	-	United Kingdom ... 展开 >> Addenbrooke's Hospital Cambridge, England, United Kingdom, CB2 2QQ 收起 <<
NCT01195649	-		Completed	-	Taiwan ... 展开 >> Many Locations, Taiwan 收起 <<
NCT03563170	Hepatocellular Carcinoma Non-r... 展开 >>esectable Hepatocellular Carcinoma Recurrent 收起 <<	Phase 1 Phase 2	Recruiting	December 30, 2022	United States, California ... 展开 >> Chan Soon-Shiong Institute for Medicine Recruiting El Segundo, California, United States, 90245 收起 <<
NCT02015728	Recurrent Childhood Brain Tumo... 展开 >>r 收起 <<	Not Applicable	Unknown	December 2017	United States, Washington ... 展开 >> Seattle Children's Seattle, Washington, United States, 98105 收起 <<
NCT01246986	Carcinoma, Hepatocellular	Phase 2	Active, not recruiting	December 3, 2018	-
NCT00791544	Liver Carcinoma	Phase 1 Phase 2	Terminated(Company decision to... 展开 >> discontinue the AVE1642 development program, not due to any safety or efficacy concerns) 收起 <<	-	France ... 展开 >> Sanofi-Aventis Administrative Office Paris, France 收起 <<
NCT00829231	Liver Disease	Phase 1	Completed	-	United States, Florida ... 展开 >> Miami, Florida, United States, 33014 Orlando, Florida, United States, 32809 United States, Tennessee Knoxville, Tennessee, United States, 37920 收起 <<
NCT02372162	-		Active, not recruiting	July 2019	Germany ... 展开 >> University Hospital Tuebingen, BW, Germany, D-72076 收起 <<
NCT02973204	-		Recruiting	October 2020	Denmark ... 展开 >> Department of Hepatology and Gastroenterology Recruiting Aarhus, Aarhus C, Denmark, 8000 Contact: Stine Karlsen, MD, Phd Student +4522793193 stinkarl@rm.dk Contact: Jens Kelsen, Consultant, PhD +4530562682 jenskels@rm.dk Principal Investigator: Stine Karlsen, MD, Phd student 收起 <<
NCT02303444	-		Active, not recruiting	July 31, 2020	-
NCT00110344	Carcinoma, Renal Cell	Phase 2	Terminated	-	United States, Massachusetts ... 展开 >> Boston, Massachusetts, United States, 02115-6084 收起 <<
NCT01576185	-		Completed	-	United States, California ... 展开 >> Children's Oncology Group Monrovia, California, United States, 91006-3776 收起 <<
NCT00920816	Kidney Neoplasms	Phase 3	Active, not recruiting	May 30, 2021	-
NCT03630120	Thyroid Cancer ... 展开 >> Thyroid Cancer, Medullary Differentiated Thyroid Cancer Papillary Thyroid Cancer Follicular Thyroid Cancer Poorly Differentiated Thyroid Gland Carcinoma 收起 <<	Phase 2	Recruiting	December 2023	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 收起 <<
NCT02794337	Carcinoma, Hepatocellular	Phase 2 Phase 3	Recruiting	January 2022	India ... 展开 >> Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre Recruiting Navi Mumbai, Maharashtra, India, 410210 Contact: Supriya Chopra, MD,DNB 022-27405000 ext 5510 schopra@actrec.gov.in Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre Recruiting Navi Mumbai, Maharashtra, India, 410210 Contact: Dr Supriya Chopra, MD 91-22-27405000 ext 5491 schopra@actrec.gov.in Principal Investigator: Supriya Chopra, MD 收起 <<
NCT03132454	Hematopoietic/Lymphoid Cancer ... 展开 >> Acute Myeloid Leukemia Acute Lymphoblastic Leukemia 收起 <<	Phase 1	Recruiting	July 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact tkadia@mdanderson.org 收起 <<
NCT00920816	-		Active, not recruiting	-	-
NCT01752933	Hepatocellular Carcinoma	Phase 2	Completed	-	-
NCT03645980	Hepatocellular Carcinoma	Phase 1 Phase 2	Recruiting	August 31, 2022	Germany ... 展开 >> Universitätsmedizin Mainz, I. Med. Klinik und Poliklinik Recruiting Mainz, Germany, 55131 Contact: Jens U Marquardt, Dr.med. +49 6131 17 ext 6863 marquarj@uni-mainz.de 收起 <<
NCT01655693	Carcinoma, Hepatocellular	Phase 3	Active, not recruiting	January 2019	-
NCT01658878	Hepatocellular Carcinoma	Phase 1 Phase 2	Active, not recruiting	December 26, 2019	-
NCT01381614	-		Completed	-	-
NCT00979381	-		Completed	-	Netherlands ... 展开 >> University Medical Center Nijmegen st Radboud Nijmegen, Netherlands, 6525 GH 收起 <<
NCT00543504	Advanced Cancer	Phase 1	Active, not recruiting	October 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02115373	Carcinoma, Hepatocellular	Phase 1 Phase 2	Completed	-	Germany ... 展开 >> Please contact the Merck KGaA Communication Center located in Darmstadt, Germany 收起 <<
NCT02406521	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 1	Active, not recruiting	December 2018	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00987935	Carcinoma, Hepatocellular	Phase 2	Completed	-	Korea, Republic of ... 展开 >> 1199.39.82001 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82002 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82003 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82004 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82005 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82006 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of Taiwan 1199.39.88606 Boehringer Ingelheim Investigational Site Changhua, Taiwan 1199.39.88609 Boehringer Ingelheim Investigational Site Kaohsiung, Taiwan 1199.39.88610 Boehringer Ingelheim Investigational Site Kaohsiung, Taiwan 1199.39.88605 Boehringer Ingelheim Investigational Site Taichung, Taiwan 1199.39.88608 Boehringer Ingelheim Investigational Site Tainan City, Taiwan 1199.39.88602 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1199.39.88601 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1199.39.88603 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1199.39.88604 Boehringer Ingelheim Investigational Site Taoyuan County, Taiwan 1199.39.88607 Boehringer Ingelheim Investigational Site Yunlin County, Taiwan 收起 <<
NCT01191385	-		Withdrawn(Study is officially ... 展开 >>cancelled bevore FPFV.) 收起 <<	December 2013	-
NCT00199160	Head and Neck Neoplasms	Phase 2	Completed	-	Belgium ... 展开 >> Jules Bordet Institute Brussels, Belgium, 1000 收起 <<
NCT01621906	Metastatic Breast Cancer to th... 展开 >>e Brain 收起 <<	Not Applicable	Recruiting	June 2019	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Cancer Center Recruiting Basking Ridge, New Jersey, United States Contact: Andrew Seidman, MD 646-888-5445 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Andrew Seidman, MD 646-888-5445 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Andrew Seidman, MD 646-888-5445 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Andrew Seidman, MD 646-888-5445 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Andrew Seidman, MD 646-888-5445 Contact: Heiko Schoder, MD 212-639-2079 Principal Investigator: Andrew Seidman, MD Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Andrew Seidman, MD 646-888-5445 收起 <<
NCT00987935	-		Completed	-	-
NCT02220088	Hepatocellular Carcinoma	Phase 2 Phase 3	Completed	-	China, Guangdong ... 展开 >> Cancer Center Sun Yat-sen University Guangzhou, Guangdong, China, 510060 收起 <<
NCT00678392	Kidney Neoplasms	Phase 3	Completed	-	-
NCT03605706	Advanced Hepatocellular Carcin... 展开 >>oma 收起 <<	Phase 3	Recruiting	December 2021	China, Jiangsu ... 展开 >> 81 Hospital Nanjing Recruiting Nanjing, Jiangsu, China, 210002 Contact: Shukui Qin, MD +862580864542 收起 <<
NCT02178358	Hepatocellular Carcinoma	Phase 2	Active, not recruiting	December 31, 2018	China ... 展开 >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Beijing, China, 100036 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bengbu, China, 233004 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Changchun, China, 130012 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hangzhou, China, 310016 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hefei, China, 230022 Hong Kong For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hong Kong, Hong Kong For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kowloon, Hong Kong Korea, Republic of For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Incheon, Korea, Republic of, 405-760 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Seoul, Korea, Republic of, 135 720 Taiwan For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gwei Shan Township, Taiwan, 333 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Liouying/Tainan, Taiwan, 736 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Puzih City, Taiwan, 613 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tainan, Taiwan, 70403 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Taipei, Taiwan, 11217 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Taoyuan, Taiwan, 33378 Thailand For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bangkok, Thailand, 10330 收起 <<
NCT00974896	Advanced Malignancy ... 展开 >> Advanced Solid Tumors Cancer Solid Tumors Tumors 收起 <<	Phase 1	Completed	-	-
NCT01375569	Hepatocellular Carcinoma ... 展开 >> Hepatocellular Cancer Carcinoma, Hepatocellular 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01897610	Advanced Hepatocellular Carcin... 展开 >>oma 收起 <<	Phase 2	Completed	-	Korea, Republic of ... 展开 >> Inha University Hospital Incheon, Korea, Republic of, 400-711 Yonsei University Health System Seoul, Korea, Republic of, 120-752 Korea University Anam Hospital Seoul, Korea, Republic of, 136-750 The Catholic University of Korea, Seoul ST. Mary's Hospital Seoul, Korea, Republic of, 137-701 收起 <<
NCT02867891	-		Completed	-	-
NCT01381601	-		Completed	-	-
NCT00678392	-		Completed	-	-
NCT02209441	-		-	-	-
NCT01324076	Liver Cancer	Phase 3	Unknown	-	United Kingdom ... 展开 >> Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust Recruiting Birmingham, England, United Kingdom, B15 2TH Contact: Contact Person 44-121-472-1311 Bristol Royal Infirmary Recruiting Bristol, England, United Kingdom, BS2 8HW Contact: Contact Person 44-117-923-0000 Aintree University Hospital Recruiting Liverpool, England, United Kingdom, L9 7AL Contact: Contact Person 44-151-525-5980 Royal Free Hospital Recruiting London, England, United Kingdom, NW3 2QG Contact: Contact Person 44-20-7794-0500 King's College Hospital Recruiting London, England, United Kingdom, SE5 9RS Contact: Contact Person 44-20-3299-9000 Royal Marsden - London Recruiting London, England, United Kingdom, SW3 6JJ Contact: Contact Person 44-20-7352-8171 Queen's Medical Centre Recruiting Nottingham, England, United Kingdom, NG7 2UH Contact: Contact Person 44-115-924-9924 Southampton General Hospital Recruiting Southampton, England, United Kingdom, SO16 6YD Contact: Contact Person 44-23-8079-8751 收起 <<
NCT00673361	Melanoma	Phase 2	Terminated	-	-
NCT01375569	-		Completed	-	-
NCT03730675	Hepatocellular Carcinoma ... 展开 >> Portal Vein Tumor Thrombosis 收起 <<	Not Applicable	Not yet recruiting	November 2021	-
NCT00673361	-		Terminated	-	-
NCT01222676	Bladder Cancer	Phase 2	Unknown	-	Italy ... 展开 >> Fondazione Istituto Nazionale dei Tumori Recruiting Milan, Italy, 20133 Contact: Contact Person 39-2-2390-2359 roberto.salvioni@istitutotumori.mi.it 收起 <<
NCT00687596	Hepatocellular Carcinoma	Phase 2	Terminated(Terminated due to s... 展开 >>afety concerns) 收起 <<	-	Italy ... 展开 >> I.R.C.C.S. San Matteo University Hospital Golgi, Pavia, Italy, 27100 收起 <<
NCT02939807	Carcinoma, Hepatocellular	Phase 2	Recruiting	May 2021	United States, South Carolina ... 展开 >> Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29425 Contact: Lindsay Hunt 843-792-9321 hcc-clinical-trials@musc.edu Principal Investigator: Carolyn Britten, MD 收起 <<
NCT01774344	-		Active, not recruiting	-	-
NCT01636284	Hepatocellular Carinoma	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale, Arizona, United States, 85259 United States, Texas University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229 Korea, Republic of Pusan National University Hospital Pusan, Korea, Republic of Pusan National University Yangsan Hospital Yangsan, Korea, Republic of Spain University Clinic of Navarra Navarra, Spain 收起 <<
NCT00108953	Carcinoma, Hepatocellular	Phase 2	Completed	-	-
NCT01908426	Hepatocellular Carcinoma	Phase 3	Active, not recruiting	October 2018	-
NCT03275376	Overall Survival ... 展开 >> Tumor Responses 收起 <<	Phase 2	Recruiting	December 21, 2023	Taiwan ... 展开 >> Taichung Veterans General Hospital Recruiting Taichung, Taiwan, 40705 Contact: Teng-Yu Lee, PhD 4-23592525 ext 3301 tylee@vghtc.gov.tw 收起 <<
NCT02436902	Hepatocellular Carcinoma	Phase 3	Recruiting	August 2019	China, Guangxi ... 展开 >> Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University Recruiting Nanning, Guangxi, China, 530021 Contact: Bang-De Xiang, MD,PhD 86-771-5330855 xiangbangde@163.com 收起 <<
NCT01774344	Carcinoma, Hepatocellular	Phase 3	Active, not recruiting	February 28, 2019	-
NCT01140347	Hepatocellular Carcinoma	Phase 3	Completed	-	-
NCT00811759	Melanoma (Skin)	Phase 1 Phase 2	Unknown	-	France ... 展开 >> Institut Gustave Roussy Villejuif, France, F-94805 收起 <<
NCT01140347	-		Completed	-	-
NCT01498952	Unresectable or Metastatic Hep... 展开 >>atocellular Carcinoma (HCC) 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Research Site Oxnard, California, United States United States, Colorado Research Site Golden Springs, Colorado, United States United States, Nevada Research Site Las Vegas, Nevada, United States 收起 <<
NCT01357486	Hepatocellular Carcinoma ... 展开 >> CHILD B 收起 <<	Phase 2	Completed	-	France ... 展开 >> CH d'Abbeville Abbeville, France, 80142 CH Pays d'Aix Aix-en-provence, France, 13616 CH d'Auxerre Auxerre, France, 89011 CH de la Côte Basque Bayonne, France, 64109 AP-HP- Hôpital Jean-Verdier Bondy, France, 93143 CHU de Bordeaux Bordeaux, France, 33075 CH Duchenne Boulogne Sur Mer, France, 62321 CH de Béziers Béziers, France, 34525 AP-HP Hôpital Henri Mondor Creteil, France, 94010 CHU Le Bocage Dijon, France, 21079 CH Départemental Vendée La Roche-sur-yon, France, 85925 CH Le Mans Le Mans, France, 72037 CH de Bretagne Sud Lorient, France, 56100 Hôpital privé Jean Mermoz Lyon, France, 69008 AP-HM Hôpital de la Timone Marseille, France, 13385 CH de Meaux Meaux, France, 77104 CH Mont de Marsan Mont-de-marsan, France, 40024 CHU de Nancy Hôpital Brabois Nancy, France, 54511 CHU de Nantes Hôpital de l'Hotel Dieu Nantes, France, 44093 CHU Nîmes Nimes, France, 30029 CHR d'Orléans - Hôpital La Source Orleans, France, 45067 Groupe Hospitalier Paris Saint Joseph Paris, France, 75014 CH Perpignan Perpignan, France, 66046 CHU de Bordeaux, Hôpital du Haut Lévèque Pessac, France, 33604 CH de la Région d'Annecy Pringy, France, 74374 Centre Eugène Marquis Rennes, France, 35042 Clinique Mathilde Rouen, France, 76000 Clinique Armoricaine de Radiologie Saint Brieuc, France, 22015 CH Saint-Malo Saint Malo, France, 35400 Centre René Gauducheau CLCC Nantes Atlantique Saint-herblain, France, 44805 CH Gaston Ramon Sens, France, 89100 Centre Régional de Lutte contre le Cancer Centre Paul Strauss Strasbourg, France, 67065 Hôpitaux Universitaires de Strasbourg Hôpital civil Strasbourg, France, 67091 Hôpitaux Universitaires de Strasbourg, Hôpital Hautepierre Strasbourg, France, 67098 CHRU de Tours Tours, France, 37044 收起 <<
NCT00406601	Sarcoma, Soft Tissue	Phase 2	Completed	-	Italy ... 展开 >> Istituto Clinico Humanitas Rozzano, Milan, Italy, 20089 收起 <<
NCT00727233	Neurofibromatosis Type I ... 展开 >> Plexiform Neurofibroma 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> Children's Hospital of Alabama Birmingham, Alabama, United States, 35233 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00108953	-		Completed	-	-
NCT03389126	Carcinoma, Hepatocellular	Phase 2	Recruiting	March 31, 2020	Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 03080 Contact: Kyung-Hun Lee, MD, PhD 82-2-2072-7207 kyunghunlee@snu.ac.kr 收起 <<
NCT00801385	Lung Cancer	Phase 2	Unknown	-	Korea, Republic of ... 展开 >> Yonsei Cancer Center at Yonsei University Medical Center Recruiting Seoul, Korea, Republic of, 120-752 Contact: Joo-Hang Kim, MD 82-2-2228-8131 kjhang@yuhs.ac 收起 <<
NCT00532064	-		Terminated(Terminated per PI's... 展开 >> request) 收起 <<	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01011010	Liver Cancer	Phase 1	Completed	-	United States, North Carolina ... 展开 >> Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States, 27157-1096 收起 <<
NCT03008512	Carcinoma, Hepatocellular	Phase 2	Recruiting	October 2021	Korea, Republic of ... 展开 >> Gachon University Gil Medical Center Recruiting Incheon, Korea, Republic of Contact: Young Saing Kim, MD +82-32-460-3231 zoomboom@gilhospital.com 收起 <<
NCT00667589	Hand-foot Skin Reaction ... 展开 >> Rash 收起 <<	Phase 2	Terminated(Study was halted du... 展开 >>e to poor subject accrual.) 收起 <<	-	United States, Illinois ... 展开 >> Northwestern University Feinberg School of Medicine, Department of Dermatology Chicago, Illinois, United States, 60611 收起 <<
NCT00667589	-		Terminated(Study was halted du... 展开 >>e to poor subject accrual.) 收起 <<	-	-
NCT00111007	Melanoma	Phase 3	Completed	-	-
NCT01371981	Acute Myeloid Leukemia ... 展开 >> Leukemia Cutis Myeloid Neoplasm Myeloid Sarcoma Untreated Adult Acute Myeloid Leukemia Untreated Childhood Myeloid Neoplasm 收起 <<	Phase 3	Active, not recruiting	-	-
NCT01777594	Advanced Adult Hepatocellular ... 展开 >>Carcinoma 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Mary Crowley Cancer Research Center Dallas, Texas, United States, 75230 Oncology Consultants, PA Houston, Texas, United States, 77030 University of Texas Health Sciences Center at Houston, Memorial Hermann Cancer Center Houston, Texas, United States, 77030 The University of Texas Health Science Center at San Antonio San Antonio, Texas, United States, 78229-3900 收起 <<
NCT00111007	-		Completed	-	-
NCT01012011	-		Completed	-	Korea, Republic of ... 展开 >> Many Locations, Korea, Republic of 收起 <<
NCT00492505	Melanoma (Skin)	Phase 2	Unknown	-	United States, California ... 展开 >> San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas Recruiting Encinitas, California, United States, 92024 Contact: Edward F. McClay, MD 760-452-3340 emcclay@pacificoncology.com 收起 <<
NCT00493636	-		Completed	-	-
NCT01069328	Carcinoma, Non-Small-Cell Lung... 展开 >> Lung Cancer 收起 <<	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Rochester, Minnesota, United States, 55905 United States, Texas Houston, Texas, United States, 77030 收起 <<
NCT00861419	Advanced Solid Tumors	Phase 1	Completed	-	-
NCT00493636	Breast Cancer	Phase 2	Completed	-	-
NCT03511703	Hepatocellular Carcinoma	Phase 2	Not yet recruiting	June 30, 2019	-
NCT02665065	Acute Myeloid Leukemia ... 展开 >> Leukemia, Acute Myeloid Myeloid Leukemia, Acute Leukemia, Myeloid, Acute Acute Myelogenous Leukemia Leukemia, Acute Myelogenous Myelogenous Leukemia, Acute 收起 <<	Phase 3	Recruiting	June 2020	United States, Arizona ... 展开 >> Banner MD Anderson Cancer Center Recruiting Gilbert, Arizona, United States United States, Connecticut Yale Cancer Center Recruiting New Haven, Connecticut, United States United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States United States, Illinois Loyola University Medical Center Recruiting Maywood, Illinois, United States United States, Kansas The University of Kansas Cancer Center Recruiting Westwood, Kansas, United States United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States United States, New York Roswell Park Cancer Institute Recruiting Buffalo, New York, United States Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States Stony Brook University Recruiting Stony Brook, New York, United States United States, Ohio University Hospital of Cleveland Seidman Cancer Center Recruiting Cleveland, Ohio, United States The Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States United States, Texas Baylor Charles A. Sammons Cancer Center Recruiting Dallas, Texas, United States MD Anderson Cancer Center Recruiting Houston, Texas, United States United States, Washington Fred Hutchinson Cancer Research Center Recruiting Seattle, Washington, United States United States, Wisconsin Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States Canada, Ontario University of Ottawa Recruiting Ottawa, Ontario, Canada 收起 <<
NCT02135874	Acute Bilineal Leukemia ... 展开 >> Acute Biphenotypic Leukemia Acute Leukemia of Ambiguous Lineage Acute Undifferentiated Leukemia Mixed Phenotype Acute Leukemia Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified Recurrent Mixed Phenotype Acute Leukemia 收起 <<	Phase 2	Recruiting	October 30, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Elias Jabbour 713-792-4764 Principal Investigator: Elias Jabbour 收起 <<
NCT03017326	Hepatoblastoma ... 展开 >> Carcinoma, Hepatocellular 收起 <<	Phase 3	Recruiting	December 2022	United Kingdom ... 展开 >> Royal Aberdeen Children's Hospital Recruiting Aberdeen, United Kingdom, AB25 2ZG Contact: Hugh Bishop, MBChB Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Amos Burke, MB ChB amos.burke@addenbrookes.nhs.uk 收起 <<
NCT02788201	Urothelial Carcinoma ... 展开 >> Bladder Cancer Urinary Bladder Neoplasms 收起 <<	Phase 2	Recruiting	July 1, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT03318562	Triple Negative Breast Cancer ... 展开 >> Hepatocellular Carcinoma 收起 <<	Phase 2	Terminated(The study was termi... 展开 >>nated due to change in focus of the development program) 收起 <<	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 United States, Missouri Kansas City Research Institute Kansas City, Missouri, United States, 64131 收起 <<
NCT00698659	-		Terminated	-	Singapore ... 展开 >> National University Hospital Singapore, Singapore 收起 <<
NCT03768375	Cholangiocarcinoma of the Extr... 展开 >>ahepatic Bile Duct Gallbladder Cancer 收起 <<	Phase 2	Recruiting	December 30, 2021	China, Shanghai ... 展开 >> Xinhua Hospital Recruiting Shanghai, Shanghai, China, 200092 Contact: Yingbin Liu, PHD 13918803900 laoniulyb@163.com Principal Investigator: yingbin liu, PHD 收起 <<
NCT03251612	Colorectal Cancer Metastatic	Phase 2	Recruiting	December 2020	Denmark ... 展开 >> Department of Oncology, Aalborg University Hospital Not yet recruiting Aalborg, Denmark Contact: Mette Yilmaz, MD m.yilmaz@rn.dk Department of Oncology, Rigshospitalet Not yet recruiting Copenhagen, Denmark Contact: Lone N Petersen, MD Lone.Noergaard.Petersen@regionh.dk Departmen of Oncology, Vejle Hospital Recruiting Vejle, Denmark Contact: Lars H Jensen, MD lars.henrik.jensen@rsyd.dk Germany Universitätsklinikum Hamburg - Eppendorf, Universitäres Cancer Center Hamburg (UCCH) Not yet recruiting Hamburg, Germany Contact: Andreas Block, MD block@uke.de 收起 <<
NCT03413176	-		Completed	-	France ... 展开 >> AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM. Paris, France, 75013 收起 <<
NCT00498966	Kidney Cancer	Phase 2	Completed	-	United States, Kentucky ... 展开 >> Investigative Site Louisville, Kentucky, United States, 40202 United States, New Jersey Investigative Site Morristown, New Jersey, United States, 07962 United States, New York Investigative Site Armonk, New York, United States, 10504 收起 <<
NCT03586973	Advanced Hepatocellular Carcin... 展开 >>oma 收起 <<	Phase 2	Recruiting	March 31, 2021	Japan ... 展开 >> Aichi Cancer Center Hospital Recruiting Nagoya, Aichi, Japan National Cancer Center Hospital East Not yet recruiting Kashiwa, Chiba, Japan Iizuka Hospital Recruiting Iizuka, Fukuoka, Japan Kurume University Hospital Not yet recruiting Kurume, Fukuoka, Japan Sapporo-Kosei General Hospital Recruiting Sapporo, Hokkaido, Japan Kanazawa University Hospital Recruiting Kanazawa, Ishikawa, Japan Kanagawa Cancer Center Recruiting Yokohama, Kanagawa, Japan Yokohama City University Medical Center Not yet recruiting Yokohama, Kanagawa, Japan Kindai University Hospital Recruiting Osakasayama, Osaka, Japan National Cancer Center Hospital Recruiting Chuo-ku, Tokyo, Japan Kyorin University Hospital Recruiting Mitaka, Tokyo, Japan Japanese Red Cross Musashino Hospital Active, not recruiting Musashino, Tokyo, Japan Chiba University Hospital Recruiting Chiba, Japan Hiroshima University Hospital Active, not recruiting Hiroshima, Japan Okayama University Hospital Not yet recruiting Okayama, Japan Osaka City University Hospital Recruiting Osaka, Japan Osaka International Cancer Institute Not yet recruiting Osaka, Japan 收起 <<
NCT02111889	Disseminated Malignant Neoplas... 展开 >>m 收起 <<	Not Applicable	Completed	-	Netherlands ... 展开 >> VU University Medical Center Amsterdam, Noord-Holland, Netherlands, 1081 HV 收起 <<
NCT01507740	-		Terminated(Study was stopped 0... 展开 >>4.10.2014 prematurly after recruitment of HCC and RCC patients. NSCLC (2 of 10 patients planned) and CRC patients recruitment was stopped) 收起 <<	-	Austria ... 展开 >> University Hospital Innsbruck, Internal Medicine V, Hematology Oncology Innsbruck, Austria, A-6020 收起 <<
NCT02086734	-		Completed	-	Germany ... 展开 >> Urologische Klinik und Poliklinik der Universität München München, Bavaria, Germany, 81377 收起 <<
NCT01810744	Metastatic Colorectal Cancer ... 展开 >> Glioblastoma Bevacizumab Capillaroscopy 收起 <<	Not Applicable	Active, not recruiting	June 2018	France ... 展开 >> Centre Georges François Leclerc Dijon, France, 21079 收起 <<
NCT00960167	Hepatocellular Carcinoma	Phase 1	Unknown	-	Taiwan ... 展开 >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Jason Chia-Hsien Cheng, Ph.D. 886-2-2312-3456 ext 66696 jasoncheng@ntu.edu.tw 收起 <<
NCT02452853	Hepatocellular Carcinoma	Phase 2	Unknown	May 2018	-
NCT01391962	Sarcoma, Alveolar Soft Part	Phase 2	Recruiting	December 15, 2019	United States, California ... 展开 >> Santa Monica Oncology Center Recruiting Santa Monica, California, United States, 90403 Contact: Shivaani Kummar, M.D. 301-435-5402 kummars@mail.nih.gov United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office (888) NCI-1937 United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030-4096 Canada, Ontario Princess Margaret Cancer Center Recruiting Toronto, Ontario, Canada, M5G2M9 收起 <<
NCT01381211	Hepatocellular Carcinoma	Phase 2	Unknown	December 2016	Belgium ... 展开 >> University Hospital Ghent Recruiting Ghent, Belgium, 9000 Contact: L Defreyne, PhD, MD (0)9/332 2938 ext +32 luc.defreyne@ugent.be Principal Investigator: L Defreyne, PhD, MD 收起 <<
NCT02428543	Acute Myeloid Lukemia	Phase 1 Phase 2	Recruiting	September 2020	France ... 展开 >> Dr Abdelaziz CHAIB Recruiting Aix-en-Provence, France, 13600 Contact: Abdelaziz CHAIB achaib@ch-aix.fr Principal Investigator: Abdelaziz CHAIB Chu Amiens Recruiting Amiens, France, 80054 Contact: MAROLLEAU Jean Pierre Principal Investigator: MAROLLEAU Jean Pierre CHU d'Angers Recruiting Angers, France, 49033 Contact: Martine GARDEMBAS Magardembas@chu-angers.fr Principal Investigator: Martine GARDEMBAS Hôpital VICTOR DUPOUY Recruiting Argenteuil, France, 95107 Contact: AL JIJAKLI Ahmad ahmad.aljijakli@ch-argenteuil.fr Principal Investigator: AL JIJAKLI Ahmad Dr Edouard RANDIAMALALA Recruiting Bayonne, France, 64100 Contact: Edouard RANDIAMALALA erandiamalala@ch-cotebasque.fr Principal Investigator: Edouard RANDIAMALALA CHU de Besançon Recruiting Besançon, France, 25030 Contact: Fabrice LAROSA flarosa@chu-besançon.fr Principal Investigator: Fabrice LAROSA Dr Thorsten BRAUN Recruiting Bobigny, France, 93000 Contact: Thorsten BRAUN thorsten.braun@aphp.fr Principal Investigator: Thorsten BRAUN CHU Boulogne Sur Mer Recruiting Boulogne Sur Mer cedex, France, 62321 Contact: CHOUFI Bachra b.choufi@ch-boulogne.fr Principal Investigator: CHOUFI Bachra Chr Clemenceau Recruiting Caen Cedex, France, 14033 Contact: REMAN Oumédaly reman-o@chu-caen.fr Principal Investigator: REMAN Oumédaly Hôpital d'Instruction des Armées PERCY Recruiting Clamart, France, 92141 Contact: Jean Valère MALFUSSON jvmalf@free.fr Principal Investigator: Jean Valère MALFUSSON Dr Stéphanie HAÏAT Recruiting Corbeil-essonnes, France, 91100 Contact: Stéphanie HAÏAT Principal Investigator: Stéphanie HAÏAT Hôpital Henri Mondor Recruiting Créteil, France, 94010 Contact: PAUTAS Cécile cecile.pautas@hmn.aphp.fr Principal Investigator: PAUTAS Cécile CHU de Dijon Not yet recruiting Dijon, France, 21079 Contact: CAILLOT Denis denis.caillot@chu-dijon.fr Principal Investigator: CAILLOT Denis Centre hospitalier de Versailles Recruiting Le Chesnay cedex, France, 78157 Contact: Rousselot Philippe 003339638622 phrousselot@ch-versailles.fr Principal Investigator: Rousselot Philippe Hôpital Claude Huriez Recruiting Lille cedex, France, 59037 Contact: QUESNEL Bruno bquesnel@chru-lille.fr Principal Investigator: QUESNEL Bruno CHRU Dupuytren Not yet recruiting Limoges cedex, France, 87042 Contact: TURLURE Pascal pascal.turlure@chu-limoges.fr Principal Investigator: TURLURE Pascal Hôpital Edouard Herriot Recruiting Lyon cedex 03, France, 69437 Contact: THOMAS Xavier xavier.thomas@chu-lyon.fr Principal Investigator: THOMAS Xavier Dr Regis COSTELLO Recruiting Marseille, France, 13000 Contact: Regis COSTELLO regis.costello@ap-hm.fr Principal Investigator: Regis COSTELLO Centre Hospitalier de Meaux Recruiting Meaux, France, 77104 Contact: FRAYFER Jamilé j-frayfer@ch-meaux.fr Principal Investigator: FRAYFER Jamilé Dr Mario OJEDA-URIBE Recruiting Mulhouse, France, 68000 Contact: Mario OJEDA-URIBE ojedam@ch-mulhouse.fr Principal Investigator: Mario OJEDA-URIBE Dr Jacques DELAUNAY Recruiting Nantes, France, 44000 Contact: Jacques DELAUNAY jacques.delaunay@chu-nantes.fr Principal Investigator: Jacques DELAUNAY CHU Nice, Hôpital Archet 1 Recruiting Nice cedex 3, France, 06202 Contact: MANNONE Lionel mannone.l@chu-nice.fr Principal Investigator: MANNONE Lionel CHU de Nîmes Recruiting Nîmes, France, 30029 Contact: Eric JOURDAN eric.jourdan@chu-nimes.fr Principal Investigator: Eric Jourdan Hôpital Saint Antoine Recruiting Paris cedex 12, France, 75751 Contact: ISNARD Françoise francoise.isnard@sat.aphp.fr Principal Investigator: ISNARD Françoise Hôpital Necker Enfants Malades Recruiting Paris cedex 15, France, 75743 Contact: SUAREZ Felipe felipe.suarez@nck.aphp.fr Principal Investigator: SUAREZ Felipe Hôpital Saint Louis Recruiting Paris, France, 75010 Contact: RAFFOUX Emmanuel emmanuel.raffoux@sls.ap-hop-paris.fr Principal Investigator: RAFFOUX Emmanuel Hôpital La Pitié Salpêtrière Recruiting Paris, France, 75013 Contact: UZUNOV Madalina madalina.uzunov@psl.aphp.fr Principal Investigator: UZUNOV Madalina Dr Laurence SANHES Suspended Perpignan, France, 66000 Dr Arnaud PIGNEUX Recruiting Pessac, France, 33604 Contact: Arnaud PIGNEUX arnaud.pigneux@chu-bordeaux.fr Principal Investigator: Arnaud PIGNEUX Centre Hospitalier René Dubos Recruiting Pontoise Cedex, France, 95303 Contact: VAIDA Iona Dana ioana.vaida@ch-pontoise.fr Principal Investigator: VAIDA Iona Dana Marc BERNARD Recruiting Rennes, France, 35000 Contact: Marc BERNARD marc.bernard@chu-rennes.fr Principal Investigator: Marc BERNARD Dr Emilie LEMASLE Recruiting Rouen, France, 76000 Contact: Emilie LEMASLE emilie.lemasle@chb.unicancer.fr Principal Investigator: Emilie LEMASLE Centre Hospitalier René Huguenin Suspended Saint Cloud, France, 92210 Institut de Cancérologie de la Loire Recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Emmanuelle TAVERNIER-TARDY emmanuelle.tavernier@icloire.fr Principal Investigator: Emmanuelle TAVERNIER-TARDY Dr Réda GARIDI Recruiting Saint-Quentin, France, 02100 Contact: Réda GARIDI Principal Investigator: Réda GARIDI Dr Christian RECHER Recruiting Toulouse, France, 31000 Contact: Christian RECHER Principal Investigator: Christian RECHER Centre Hospitalier de Valenciennes Recruiting Valenciennes, France, 59322 Contact: FERNANDES José fernandes-j@ch-valenciennes.fr Principal Investigator: FERNANDES José 收起 <<
NCT03091465	-		Completed	-	-
NCT01372813	-		Terminated(Terminated for insu... 展开 >>fficient accrual.) 收起 <<	-	-
NCT02426450	Hepatocellular Carcinoma	Phase 2	Unknown	April 2017	China, Guangdong ... 展开 >> Zhen-Wei Peng Guangzhou, Guangdong, China, 510080 收起 <<
NCT01322477	-		Unknown	-	Israel ... 展开 >> Hadassah Hebrew University Medical Center Not yet recruiting Jerusalem, Israel Contact: Marina Orevi, MD 0508946211 marinaor@hadassah.org.il Contact: Roland Chisin, MD chisin@hadassah.org.il 收起 <<
NCT01372813	Advanced Clear Cell Renal Carc... 展开 >>inoma 收起 <<	Phase 2	Terminated(Terminated for insu... 展开 >>fficient accrual.) 收起 <<	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02847377	Carcinoma, Non-Small-Cell Lung	Early Phase 1	Recruiting	March 27, 2019	France ... 展开 >> CGFL Recruiting Dijon, France, 21079 收起 <<
NCT03097601	-		Active, not recruiting	December 30, 2019	France ... 展开 >> Centre Antoine LACASSAGNE Nice, France, 06189 收起 <<
NCT03630640	Hepatocellular Carcinoma	Phase 2	Recruiting	September 30, 2020	France ... 展开 >> Hôpital Jean Verdier Recruiting Bondy, France, 93140 Contact: Pierre NAHON, MD,PhD 01 48 02 62 99 ext 0033 pierre.nahon@aphp.fr Contact: Olivier SEROR, MD,PhD 01 48 02 58 68 ext 0033 olivier.seror@aphp.fr 收起 <<
NCT01538238	Locally Advanced or Metastatic... 展开 >> Non-clear Cell Type Renal Cell Carcinoma 收起 <<	Phase 2	Completed	-	Korea, Republic of ... 展开 >> Samsung medical Center Seoul, Korea, Republic of 收起 <<
NCT03322280	Hepatocellular Carcinoma ... 展开 >> Portal Vein Occlusion Tumor Thrombus 收起 <<	Not Applicable	Enrolling by invitation	June 30, 2022	China, Guangdong ... 展开 >> The 2nd Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China, 510260 收起 <<
NCT02711007	Osteosarcoma ... 展开 >>Metastasis 收起 <<	Phase 2 Phase 3	Completed	-	China, Beijing ... 展开 >> Peking University People's Hospital Beijing, Beijing, China, 100044 收起 <<
NCT01167374	Hepatocellular Carcinoma	Not Applicable	Recruiting	August 2020	Germany ... 展开 >> University Hospital of Heidelberg, Radiation Oncology Recruiting Heidelberg, Germany, 69120 Principal Investigator: Jürrgen Debus, MD PHD 收起 <<
NCT02056587	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 4	Completed	-	Russian Federation ... 展开 >> Tatarstan Regional Cancer Center Kazan, Tatarstan, Russian Federation, 420029 Altai Regional Cancer Center Barnaul, Russian Federation N.N. Blokhin Russian Cancer Research Center Moscow, Russian Federation, 115478 收起 <<
NCT02738697	Carcinoma, Hepatocellular	Phase 3	Recruiting	December 2021	China, Guangdong ... 展开 >> SUN YAT-SEN University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Rong-Ping Guo, M.D. 00862087342266 guorp@sysucc.org.cn Contact: Wei Wei, Ph.D. M.D. 00862087343790 weiwei@sysucc.org.cn 收起 <<
NCT02877368	-		Completed	-	France ... 展开 >> Chu de Reims Reims, France, 51092 收起 <<
NCT02772029	Hepatocellular Carcinoma	Phase 1 Phase 2	Unknown	September 2017	-
NCT02857712	Salivary Gland Cancers	Phase 2	Active, not recruiting	June 2019	Italy ... 展开 >> Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy, 20133 收起 <<
NCT02448056	-		Not yet recruiting	May 2025	Taiwan ... 展开 >> National Taiwn University Hospital Recruiting Taipei, Taiwan, 100 Contact: Ja-Der Liang, Master 886-2-23123456 jdliangntu@ntu.edu.tw 收起 <<
NCT03229512	Hand Foot Skin Reaction	Early Phase 1	Recruiting	December 2018	United States, Illinois ... 展开 >> Department of Dermatology, Northwestern University Feinberg School of Medicine Recruiting Chicago, Illinois, United States, 60611 Contact: Jennifer N Choi, MD 312-695-8106 jennifer.choi@northwestern.edu Contact: Linda Serrano, MD 312-503-5903 linda.serrano@northwestern.edu Principal Investigator: Jennifer N Choi, MD Sub-Investigator: Linda Serrano, MD Northwestern Memorial Hospital Recruiting Chicago, Illinois, United States, 60611 Contact: Jennifer N Choi, MD 312-695-8106 jennifer.choi@northwestern.edu Contact: Linda Serrano, MD 312-503-5903 linda.serrano@northwestern.edu Principal Investigator: Jennifer N Choi, MD Sub-Investigator: Linda Serrano, MD 收起 <<
NCT02290977	Hepatocellular Carcinoma ... 展开 >> Portal Vein Tumor Thrombosis 收起 <<	Phase 2	Unknown	April 2016	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Yong Han Paik, MD, PhD yh.paik@samsung.com Principal Investigator: Yong-Han Paik, MD, PhD Sub-Investigator: Hee Chul Park, MD, PhD Sub-Investigator: Ju-Yeon Cho, MD Sub-Investigator: Jeong Il Yu, MD 收起 <<
NCT00782275	Renal Cell Carcinoma ... 展开 >> Kidney Cancer 收起 <<	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Tennessee Vanderbilt Univeristy Medical Center Nashville, Tennessee, United States, 37232 收起 <<
NCT00715182	Advanced/ Metastatic Renal Cel... 展开 >>l Cancer 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Novartis Investigative Site San Francisco, California, United States United States, North Carolina Novartis Investigative Site Durham, North Carolina, United States, 27710 United States, Washington Novartis Investigative Site Seattle, Washington, United States, 98109-1023 France Novartis Investigative Site Bordeaux Cedex, France, 33075 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Hannover, Germany, 30625 Novartis Investigative Site München, Germany, 81675 Netherlands Novartis Investigative Site Rotterdam, Netherlands, 3075 EA Spain Novartis Investigative Site Madrid, Spain, 28041 Taiwan Novartis Investigative Site Taipei, Taiwan, ROC, Taiwan, 112 Novartis Investigative Site Taichung, Taiwan, 40705 Novartis Investigative Site Taipei, Taiwan, 10002 收起 <<
NCT01339962	-		Completed	-	Denmark ... 展开 >> University of Copenhagen Herlev Hospital Herlev, Denmark, 2730 收起 <<
NCT03359018	Progression-free Survival ... 展开 >> Overall Survival Clinical Benefit Rate Toxicity 收起 <<	Phase 2	Active, not recruiting	March 1, 2020	China ... 展开 >> Musculoskeletal Tumor Center of Peking University People's Hospital Beijing, China, 100044 Peking University Shougang Hospital Beijing, China, 100144 收起 <<
NCT02571946	Liver Neoplasm ... 展开 >> Portal Vein Tumor Thrombosis Proton Therapy 收起 <<	Not Applicable	Recruiting	September 2022	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Hee Chul Park, M.D., Ph.D. 82-2-3410-2612 hee.ro.park@samsung.com Principal Investigator: Hee Chul Park, M.D., Ph.D. Sub-Investigator: Doo Ho Choi, M.D., Ph.D. Sub-Investigator: Jeong Il Yu, M.D. Sub-Investigator: Won Ki Kang, M.D., Ph.D. Sub-Investigator: Ho Yeong Lim, M.D., Ph.D. Sub-Investigator: Young Suk Park, M.D., Ph.D. Sub-Investigator: Joon Oh Park, M.D., Ph.D. Sub-Investigator: Se Hoon Park, M.D., Ph.D. Sub-Investigator: Jeeyun Lee, M.D., Ph.D. 收起 <<
NCT00538772	-		Withdrawn	-	Canada, British Columbia ... 展开 >> BC Cancer Agency - Centre for Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BC Cancer Agency - Vancouver Vancouver, British Columbia, Canada, V5Z 4E6 BC Cancer Agency - Vancouver Island Victoria, British Columbia, Canada, V8R 6V5 收起 <<
NCT02632864	Liver Neoplasm ... 展开 >> Proton Therapy 收起 <<	Phase 2	Recruiting	November 2022	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Joon Hyeok Lee, MD, PhD 82-2-3410-3409 gijhlee.lee@samsung.com Contact: Hee Chul Park, MD, PhD 82-2-3410-2612 hee.ro.park@samsung.com Sub-Investigator: Jeong Il Yu, MD 收起 <<
NCT00782275	-		Completed	-	-
NCT01911000	Carcinoma. Hepatocellular	Phase 2	Completed	-	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT03048877	Differentiated Thyroid Cancer	Phase 3	Recruiting	December 2019	China, Jiangsu ... 展开 >> Nanjing PLA 81 Hospital Recruiting Nanjing, Jiangsu, China Contact: Shukui Qin, Prof. M.D. +86-26-84453932 qinsk@csco.org.cn China Peking Union Medical College Hospital Recruiting Peking, China, 100730 Contact: Lin Yansong, MD +86-10-69155610 linys@pumch.cn 收起 <<
NCT03066557	Hepatocellular Carcinoma	Not Applicable	Not yet recruiting	December 31, 2018	-
NCT03164057	Acute Myeloid Leukemia ... 展开 >> Myelodysplastic Syndromes 收起 <<	Phase 2	Recruiting	June 2027	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Recruiting Duarte, California, United States, 91010 Contact: Weili Sun, MD,PhD 800-826-4673 weilisun@coh.org Principal Investigator: Weili Sun, MD,PhD Children's Hospital of Central California Recruiting Madera, California, United States, 93636 Contact: Faisal Razzaqi, MD 866-353-5437 frazzaqi@valleychildrens.org Principal Investigator: Faisal Razzaqi, MD Children's Hospital of Orange County Recruiting Orange, California, United States, 92968 Contact: Jamie Frediani, MD 714-509-4348 jfrediani@choc.org Principal Investigator: Jamie Frediani, MD Lucile Packard Children's Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Norman J. Lacayo, MD 650-497-8953 lacayon@stanford.edu Principal Investigator: Norman J. Lacayo, MD Rady Children's Hospital and Health Center Recruiting San Diego, California, United States, 92123 Contact: Deborah Schiff, MD 858-966-5983 dschiff@chsd.org Principal Investigator: Deborah Schiff, MD United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Tanja A. Gruber, MD, PhD 866-278-5833 tanja.gruber@stjude.org Contact: Referral Office 866-278-5833 referralinfo@stjude.org Principal Investigator: Tanja A. Gruber, MD, PhD United States, Texas Cook Children's Medical Center Recruiting Fort Worth, Texas, United States, 76104 Contact: Kenneth M. Heym, MD 682-885-4007 kenneth.heym@cookchildrens.org Principal Investigator: Kenneth M. Heym, MD 收起 <<
NCT00936858	Thyroid Cancer	Phase 2	Active, not recruiting	December 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Mt. Sinai Medical Center New York, New York, United States, 10029 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02716012	Hepatocellular Carcinoma ... 展开 >> Liver Cancer 收起 <<	Phase 1	Recruiting	December 2019	Singapore ... 展开 >> National Cancer Centre Not yet recruiting Singapore, Singapore Principal Investigator: Dr Han Chong Toh National University Hospital Not yet recruiting Singapore, Singapore Principal Investigator: Dr Cheng Ean Chee Taiwan National Taiwan University Hospital Recruiting Taipei, Taiwan Principal Investigator: Professor Kai-Wen Huang United Kingdom University Hospitals Birmingham NHS Foundation Trust Recruiting Birmingham, United Kingdom Principal Investigator: Dr yuk-Ting Ma Cambridge University Hospitals NHS Trust Recruiting Cambridge, United Kingdom Principal Investigator: Dr Bristi Basu The Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom Principal Investigator: Professor Jeff Evans Clatterbridge Cancer Centre NHS Foundation Trust Recruiting Liverpool, United Kingdom Principal Investigator: Professor Daniel Palmer Guy's and St. Thomas' NHS Foundation Trust Recruiting London, United Kingdom Principal Investigator: Dr Debashis Sarker Imperial College Healthcare NHS Trust Recruiting London, United Kingdom Principal Investigator: Professor Long R Jiao University College London Hospitals NHS Foundation Trust Recruiting London, United Kingdom Principal Investigator: Professor Tim Meyer Newcastle upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle, United Kingdom Principal Investigator: Professor Ruth Plummer 收起 <<
NCT01798446	Renal Cell Carcinoma ... 展开 >> Nonclear Cell Temsirolimus Resistance 收起 <<	Phase 2	Unknown	December 2016	Korea, Republic of ... 展开 >> Seou National University Hospital Recruiting Seoul, Korea, Republic of, 110744 Contact: Se-Hoon Lee, MD, PhD 82220722199 shlee119@snu.ac.kr Principal Investigator: Se-Hoon Lee, MD, PhD Sub-Investigator: Dae Seog Heo, MD, PhD Sub-Investigator: Dong-Wan Kim, MD, PhD Sub-Investigator: Tae Min Kim, MD, PhD Sub-Investigator: Bhumsuk Keam, MD 收起 <<
NCT01105364	Kidney Cancer ... 展开 >> Metastatic Cancer 收起 <<	Not Applicable	Unknown	-	France ... 展开 >> Centre Hospitalier Universitaire Bretonneau de Tours Recruiting Tours, France, 37044 Contact: Contact Person 33-2-4747-4776 收起 <<
NCT01771458	Reccurent/Metastatic Solid Tum... 展开 >>or Disease 收起 <<	Phase 2	Unknown	December 2016	France ... 展开 >> Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc Dijon, France, 21079 Centre Leon Berard Lyon, France, 69373 Institut Paoli Calmettes Marseille, France, 13009 Insitut Curie Paris, France, 75248 Institut Curie Hopital Rene Huguenin Saint-cloud, France, 92210 Institut de cancérologie de l'Ouest Centre René Gauducheau Saint-herblain, France, 44000 Institut Claudius Régaud Toulouse, France, 31052 Centre Alexis Vautrin Vandoeuvre Les Nancy, France, 54500 收起 <<
NCT02702414	Hepatocellular Carcinoma	Phase 2	Recruiting	May 30, 2021	-
NCT02558387	Recurrent or Metastatic Saliva... 展开 >>ry Gland Cancer of the Head and Neck 收起 <<	Phase 2	Unknown	January 2017	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT02544737	Esophageal Cancer ... 展开 >> Metastatic Esophageal Cancer Apatinib 收起 <<	Phase 2	Unknown	December 2017	China, Zhejiang ... 展开 >> Hangzhou Cancer Hospital Recruiting Hangzhou, Zhejiang, China, 310000 Contact: Shixiu Wu, MD +8657186826086 wushixiu@medmail.com.cn Contact: Tao Song, Dr +8657186826086 taosong01@hotmail.com 收起 <<
NCT01545804	Liver Cancer	Phase 2	Completed	-	Taiwan ... 展开 >> National Taiwan University Hospital Taipei, Taiwan, 100 收起 <<
NCT01390519	-		Completed	-	Norway ... 展开 >> Novartis Investigative Site Kristiansand, Norway, 4615 Novartis Investigative Site Tromsø, Norway, 9038 Novartis Investigative Site Trondheim, Norway, 7006 收起 <<
NCT00923130	Renal Cell Carcinoma	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 United States, South Carolina University of South Carolina Charleston, South Carolina, United States, 29425 收起 <<
NCT03732547	Carcinoma, Hepatocellular	Phase 2	Recruiting	October 22, 2023	China, Zhejiang ... 展开 >> The second affiliated hospital of Zhejiang University Recruiting Hangzhou, Zhejiang, China, 310000 Contact: Liang Wen, MD PhD +8619967413613 11518214@zju.edu.cn 收起 <<
NCT01949194	Metastatic Colorectal Cancer	Phase 2	Active, not recruiting	December 2018	Canada, New Brunswick ... 展开 >> The Moncton Hospital (Horizon Health Network) Moncton, New Brunswick, Canada, E1C 6Z8 Canada, Quebec Jewish General Hospital Montreal, Quebec, Canada, H3T 1E2 St-Mary's Hospital Centre Montreal, Quebec, Canada, H3T 1M5 McGill University Health Centre Montréal, Quebec, Canada, H4A 3J1 Canada Hopital Maisonneuve-Rosemont Montreal, Canada, H1T 2M4 收起 <<
NCT03648073	Hepatocellular Carcinoma	Phase 1 Phase 2	Not yet recruiting	December 3, 2019	-
NCT01747642	Quality of Life	Phase 2 Phase 3	Unknown	June 2014	Bangladesh ... 展开 >> Farabi General Hospital Recruiting Dhaka, Bangladesh, 1215 Contact: Mamun A Mahtab, MD, FACG +8801711567275 shwapnil@agni.com Contact: Helal Uddin, BSc +880-1819251514 crobangladesh@gmail.com Principal Investigator: Mamun A Mahtab, MD, FACG Sub-Investigator: Lovely Begum, BPharm 收起 <<
NCT02789137	-		Recruiting	October 30, 2018	Spain ... 展开 >> Hospital Arquitecto Marcide de Ferrol Recruiting Ferrol, A Coruña, Spain, 15405 Hospital Asil de Granollers Recruiting Granollers, Barcelona, Spain, 08402 Hospital Parc Taulí Recruiting Sabadell, Barcelona, Spain, 08208 Hospital Galdakano Recruiting Usansolo, Bizkaia, Spain, 48960 Complejo Hospitalario la Mancha Centro Recruiting Alcazar de San Juan, Ciudad REAL, Spain, 13600 Hospital Universitari Son Espases Recruiting Palma, Mallorca, Spain, 07120 H. Universitario Infanta Cristina Recruiting Badajoz, Spain, 06006 Hospital Vall de Hebrón Recruiting Barcelona, Spain, 08035 Hospital Universitario Ciudad Real Recruiting Ciudad Real, Spain, 13005 H. Reina Sofía de Cordoba Recruiting Córdoba, Spain, 14004 Hospital de Cabueñes Not yet recruiting Gijón, Spain, 33394 ICO Girona (Hospital Dr.Josep Trueta) Recruiting Girona, Spain, 17007 Hospital Universitario de Guadalajara Not yet recruiting Guadalajara, Spain, 19002 Complejo Hospitalario de Jaén Recruiting Jaén, Spain, 23007 Complejo Hospitalario de León Recruiting León, Spain, 24071 Complejo Hospitalario Ourense. Hospital Santa María Nai Recruiting Ourense, Spain, 32005 Hospital General de Asturias Not yet recruiting Oviedo, Spain, 33011 Complejo Hospitalario de Navarra Recruiting Pamplona, Spain, 31008 Hospital Universitario Canarias Not yet recruiting Santa Cruz de Tenerife, Spain, 38320 Hospital de Sant Pau i Santa Tecla Recruiting Tarragona, Spain, 43003 Hospital Virgen de la Salud Recruiting Toledo, Spain, 45071 Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain, 46011 H Clínico Zaragoza Recruiting Zaragoza, Spain, 50009 收起 <<
NCT01567930	Unresectable or Metastatic Hep... 展开 >>atocellular Carcinoma 收起 <<	Phase 2	Unknown	March 2013	United States, Tennessee ... 展开 >> Boston Baskin Cancer Foundation Recruiting Memphis, Tennessee, United States, 38120 收起 <<
NCT01498458	Metastatic Breast Cancer	Phase 1	Completed	-	Germany ... 展开 >> GBG Forschungs GmbH Neu-Isenburg, Germany, 63263 收起 <<
NCT00923130	-		Completed	-	-
NCT02942329	Gastric Cancer ... 展开 >> Hepatocellular Carcinoma 收起 <<	Phase 1 Phase 2	Recruiting	October 2018	China, Beijing ... 展开 >> The Affiliated Hospital of the Chinese Academy of Military Medical Sciences Recruiting Beijing, Beijing, China, 100071 Contact: Jian-Ming Xu, M.D. +861066947176 jmxu2003@yahoo.com Principal Investigator: Jian-Ming Xu, M.D. Sub-Investigator: Yun Zhang, M.D. 收起 <<
NCT00282048	Kidney Neoplasms ... 展开 >> Carcinoma, Renal Cell 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> Pfizer Investigational Site Chicago, Illinois, United States, 60637 United States, New York Pfizer Investigational Site Bronx, New York, United States, 10466 United States, Ohio Pfizer Investigational Site Cleveland, Ohio, United States, 44195 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19111-2497 United States, Wisconsin Pfizer Investigational Site Madison, Wisconsin, United States, 53792 收起 <<
NCT02338570	Renal Cell Carcinoma	Phase 4	Terminated(Stopped on November... 展开 >> 16th 2016, because of recruitment failure.) 收起 <<	-	Italy ... 展开 >> Spedali Civili Brescia, Italy Ospedale A Perrino Brindisi, Italy Istituto Europeo di Oncologia Milano, Italy Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale Napoli, Italy AOU Maggiore della Carità Novara, Italy Casa di Cura La Maddalena Palermo, Italy Unicampus Biomedico Roma, Italy AOU San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy 收起 <<
NCT02751827	-		Recruiting	February 2019	France ... 展开 >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Antoine ITALIANO, MD,PhD Principal Investigator: Antoine ITALIANO, MD,PhD Centre Léon Bérard Not yet recruiting Lyon Cedex 08, France, 69373 Contact: Jean-Yves BLAY, MD, PhD Principal Investigator: Jean-Yves BLAY, MD, PhD 收起 <<
NCT01265810	Oral Complaints ... 展开 >> Renal Cell Carcinoma Hepatocellular Carcinoma Gastrointestinal Stromal Tumors 收起 <<	Phase 3	Completed	-	Netherlands ... 展开 >> The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Amsterdam, Netherlands, 1066 CX Leiden University Medical Centre (LUMC) Leiden, Netherlands, 2300 RC 收起 <<
NCT00282048	-		Completed	-	-
NCT00717756	Liver Cancer	Phase 2	Completed	-	United States, New York ... 展开 >> Montefiore Medical Center Bronx, New York, United States, 10467 United States, Rhode Island Memorial Hospital of Rhode island Pawtucket, Rhode Island, United States, 02860 Lifespan Hospitals Providence, Rhode Island, United States, 02903 收起 <<
NCT00448721	Renal Cell Carcinoma	Phase 2	Completed	-	United States, California ... 展开 >> Investigative Site Duarte, California, United States, 91010 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Pennsylvania Investigative Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Investigative Site Nashville, Tennessee, United States, 37232 收起 <<
NCT01498458	-		Completed	-	-
NCT01910909	Localized Non-Resectable Adult... 展开 >> Hepatocellular Carcinoma 收起 <<	Not Applicable	Recruiting	October 2018	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Hee Chul Park, M.D., Ph.D. 82-2-3410-2612 hee.ro.park@samsung.com Principal Investigator: Hee Chul Park, M.D., Ph.D. 收起 <<
NCT02048371	Liposarcoma O... 展开 >>steogenic Sarcoma Ewing/Ewing-like Sarcoma Rhabdomyosarcoma 收起 <<	Phase 2	Recruiting	December 2020	United States, California ... 展开 >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Torie Fechner 626-256-4673 tfechner@coh.org Principal Investigator: Warren Chow, MD Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Magnolia Manzano 323-361-8156 mmanzano@chla.usc.edu Sarcoma Oncology Research Center Recruiting Santa Monica, California, United States, 90403 Contact: Victoria Chua 310-552-9999 vchua@sarcomaoncology.com Principal Investigator: Sant Chawla, MD Stanford University Recruiting Stanford, California, United States, 94305 Contact: Maria Ahern 650-725-6413 mahern@stanford.edu Principal Investigator: Kristen Ganjoo, MD United States, Florida Mayo Clinic - Florida Recruiting Jacksonville, Florida, United States, 32224 Contact: Steven Attia, DO 904-953-7292 Attia.Steven@mayo.edu Principal Investigator: Steven Attia, DO H. Lee Moffitt Terminated Tampa, Florida, United States, 33612 United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Rasima Cehic 312-695-2082 rasima.cehic@northwestern.edu Principal Investigator: Mark Agulnik, MD United States, Indiana Indiana University Recruiting Indianapolis, Indiana, United States, 46202 Contact: Michele Niland 317-278-0778 mniland@iupui.edu Principal Investigator: Daniel Rushing, MD United States, Massachusetts Dana Farber/Partners Cancer Care Terminated Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic - Minnesota Recruiting Rochester, Minnesota, United States, 55905 Contact: Elizabeth Smith 507-293-3817 Smith.Elizabeth6@mayo.edu Principal Investigator: Scott Okuno, MD United States, North Carolina Carolinas Healthcare System Recruiting Charlotte, North Carolina, United States, 28203 Contact: Michelle Treadwell 980-442-2332 Michelle.Treadwell@carolinashealthcare.org Principal Investigator: Michael Livingston, MD Duke University Recruiting Durham, North Carolina, United States, 27705 Contact: Colleen Piechocki 919-681-1883 colleen.piechocki@duke.edu Principal Investigator: Richard Riedel, MD United States, Ohio Ohio State University Recruiting Columbus, Ohio, United States, 43202 Contact: Comprehensive Cancer Center 800-293-5066 Jamesline@osumc.edu Principal Investigator: David Liebner, MD United States, Oregon Oregon Health and Science University Recruiting Portland, Oregon, United States, 97239 Contact: David Boody-Alter 503-418-9655 boodyalt@ohsu.edu Principal Investigator: Lara Davis, MD United States, Tennessee Vanderbilt University Recruiting Nashville, Tennessee, United States, 37232 Contact: Melissa Sindler 615-875-0060 melissa.m.sindler@vanderbilt.edu Principal Investigator: Vicky Keedy, MD United States, Utah Huntsman Cancer Institute Recruiting Salt Lake City, Utah, United States, 84112 Contact: Justin Parker 801-587-4702 justin.parker@hci.utah.edu Principal Investigator: Jennifer Wright, MD United States, Washington Seattle Cancer Care Alliance Recruiting Seattle, Washington, United States, 98109 Contact: Roxanne Moore 206-288-6425 romoore@seattlecca.org Principal Investigator: Elizabeth Loggers, MD, PhD 收起 <<
NCT03316872	Hepatocellular Carcinoma	Phase 2	Recruiting	April 2, 2022	Canada, Ontario ... 展开 >> Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Jennifer J. Knox, M.D. 416-946-2399 Principal Investigator: Jennifer J. Knox, M.D. 收起 <<
NCT02409524	Advanced Adult Hepatocellular ... 展开 >>Carcinoma 收起 <<	Phase 2	Unknown	August 2018	Thailand ... 展开 >> National Cancer Institute of Thailand Address: 268/1 Rama Rd. Ratchathewi Recruiting Bangkok, Thailand, 10400 Contact: Wirote Lausoontornsiri, MD 081-373-7690 wlausoon@gmail.com Contact: Nitiya Ritthidechratn 02-0260149 nitiya@immunovative.com Principal Investigator: Wirote Lausoontornsiri, MD Sub-Investigator: Somjin Chindavijak, MD Sub-Investigator: Jesada Suvikrom, MD 收起 <<
NCT00717756	-		Completed	-	-
NCT02910843	Rectal Cancer	Phase 1	Recruiting	December 2022	Switzerland ... 展开 >> St. Claraspital Basel Recruiting Basel, Switzerland, 4016 Contact: Dieter Köberle, MD +41 61 685 85 85 dieter.koeberle@claraspital.ch Principal Investigator: Dieter Köberle, MD Universitätsspital Basel Recruiting Basel, Switzerland, 4031 Contact: Viviane Hess, Prof +41 61 265 50 74 viviane.hess@usb.ch Principal Investigator: Viviane Hess, Prof Inselspital Bern Recruiting Bern, Switzerland, 3010 Contact: Martin D. Berger, MD +41 31 632 41 14 martin.berger@insel.ch Principal Investigator: Martin D. Berger, MD Kantonsspital Graubünden Recruiting Chur, Switzerland, 7000 Contact: Ioannis Metaxas, MD +41 81 256 66 46 ioannis.metaxas@ksgr.ch Principal Investigator: Ioannis Metaxas, MD Kantonsspital Luzern Recruiting Luzern, Switzerland, 6000 Contact: Ralph Winterhalder, MD +41 41 205 58 75 ralph.winterhalder@ksl.ch Principal Investigator: Ralph Winterhalder, MD Kantonsspital St. Gallen Recruiting St. Gallen, Switzerland, 9007 Contact: Markus Jörger, MD +41 71 494 29 22 markus.joerger@kssg.ch Principal Investigator: Markus Jörger, MD UniversitätsSpital Zürich Recruiting Zurich, Switzerland, 8091 Contact: Bernhard Pestalozzi, Prof +41 (0)44 255 34 40 bernhard.pestalozzi@usz.ch Principal Investigator: Bernhard Pestalozzi, Prof 收起 <<
NCT00314119	-		Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01649180	Renal Cell Carcinoma	Phase 2	Terminated(Closed due to prolo... 展开 >>nged enrollment timelines) 收起 <<	-	United States, Nebraska ... 展开 >> Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68106 United States, Ohio Cleveland Clinic, Taussig Cancer Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania, Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT01700699	-		Unknown	October 2013	Italy ... 展开 >> Department of Medicine and Surgery, Univeristy of Salerno Recruiting Baronissi, Salerno, Italy, 84081 Contact: Mario Vitale, MD +39 089672539 mavitale@unisa.it Principal Investigator: Mario Vitale, MD 收起 <<
NCT01649180	-		Terminated(Closed due to prolo... 展开 >>nged enrollment timelines) 收起 <<	-	-
NCT01871766	Rhabdomyosarcoma	Phase 2	Recruiting	June 2024	United States, Florida ... 展开 >> University of Florida Proton Therapy Institute Active, not recruiting Jacksonville, Florida, United States, 32206 Nemours Children's Clinic Active, not recruiting Jacksonville, Florida, United States, 32207 United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Matthew J. Krasin, MD 866-278-5833 referralInfo@stjude.org Principal Investigator: Matthew J. Krasin, MD United States, Texas Cook Children's Medical Center Recruiting Fort Worth, Texas, United States, 76104 Contact: Karen Albritton, MD 682-885-2103 karen.albritton@cookchildrens.org Principal Investigator: Karen Albritton, MD 收起 <<
NCT02071719	-		Terminated	October 2017	Netherlands ... 展开 >> VU Medical Center Amsterdam, Noord Holland, Netherlands, 1081 HV 收起 <<
NCT01946529	Desmoplastic Small Round Cell ... 展开 >>Tumor Ewing Sarcoma of Bone or Soft Tissue Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor 收起 <<	Phase 2	Active, not recruiting	July 2026	United States, Tennessee ... 展开 >> St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 收起 <<
NCT01946529	-		Active, not recruiting	-	-
NCT02779283	Acute Lymphoblastic Leukemia ... 展开 >> Acute Myeloid Leukemia 收起 <<	Phase 1	Recruiting	June 1, 2019	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Stephen E. Spurgeon 503-494-8950 spurgeos@ohsu.edu Principal Investigator: Stephen E. Spurgeon 收起 <<
NCT02423239	Hepatocellular Carcinoma ... 展开 >> Pancreatic Cancer 收起 <<	Phase 1	Unknown	December 2016	Germany ... 展开 >> University Hospital Bonn, Study Center Bonn (SZB) Clinical Study Core Unit Institute of Clinical Chemistry and Clinical Pharmacology University Hospital Bonn, Sigmund-Freud-Str. 25 Bonn, Germany, D-53127 Universitätsklinikum Hamburg-Eppendorf II. Medizinischen Klinik Martinistr. 52 Hamburg, Germany, 20246 Klinikum der Ruhr-Universitaet Bochum, Medizinische Klinik III - Hämatologie/Onkologie Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum Hölkeskampring 40 Herne, Germany, 44625 Klinikum der Universität München, Universitätsklinikum Großhadern Medizinische Klinik und Poliklinik III AG Onkologie Marchioninistr. 15 München, Germany, 81377 UNIFONTIS Praxis fur Integrative Onkologie, Hoppe-Seyler-Straße 6, Tübingen, Germany, 72076 Poland Osrodek Medyczny SAMARYTANIN, ul. Kazimierza Pużaka 11 Opole, Poland, 45-272 Wojewodzki Szpital Zespolony w Toruniu, ul. Św. Józefa 53-59 Toruń, Poland, 87-100 Spain Hospital Universitario Virgen de la Victoria, Servicio de Oncología Médica Campus de Teatinos, Málaga, Malaga, Spain, 29010 START MADRID-FJD, Hospital Fundación Jiménez Díaz, Av Reyes Católicos 2, Floor 1 28040 Madrid, Spain, 28040 Hospital Universitario Virgen del Rocio, Hospital Universitario Virgen del Rocío Oncología Médica Avda. Manuel Siurot, Sevilla, Spain, 41013 United Kingdom Beatson West of Scotland Cancer Centre, 1053 Great Western Rd, Glasgow, United Kingdom, G12 0YN St James's Hospital, Cancer Research UK Clinical Centre/Section of Oncology, Beckett St, Leeds, United Kingdom, LS9 7TF Freeman Hospital, Sir Bobby Robson Cancer Trials Research Centre, Freeman Road, High Heaton, Newcastle upon Tyne, United Kingdom, NE7 7DN 收起 <<
NCT02638428	Relapsed Pediatric Solid Tumor... 展开 >> Refractory Pediatric Solid Tumor Relapsed Pediatric AML Refractory Pediatric AML 收起 <<	Phase 2	Recruiting	December 2023	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Ki Woong Sung 82-2-3410-3529 kwsped@skku.edu Principal Investigator: Ki Woong Sung 收起 <<
NCT01911273	Carcinoma, Hepatocellular	Phase 2	Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<	-	United States, Pennsylvania ... 展开 >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Japan National Cancer Center Hospital East Kashiwa, Chiba, Japan, 277-8577 Kinki University Hospital, Department of Gastroenterology and Hepatology Osaka-Sayama, Osaka, Japan, 589-8511 National Cancer Center Hospital Chuo-ku, Tokyo, Japan, 104-0045 收起 <<
NCT01911273	-		Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<	-	-
NCT01446224	-		Completed	-	-
NCT02029001	Malignant Solid Neoplasms	Phase 2	Recruiting	October 2022	France ... 展开 >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Antoine ITALIANO +335 56 33 33 33 a.italiano@bordeaux.unicancer.fr Principal Investigator: Antoine ITALIANO Sub-Investigator: Delphine GARBAY Sub-Investigator: Maud TOULMONDE Sub-Investigator: Sophie COUSIN Sub-Investigator: Sylvestre LE MOULEC Sub-Investigator: Mathilde CABART Sub-Investigator: Guilhem ROUBAUD Centre Jean Perrin Not yet recruiting Clermont-Ferrand, France, 63011 Contact: Xavier DURANDO 04 73 27 81 31 xavier.durando@cjp.fr Principal Investigator: Xavier DURANDO Sub-Investigator: Pierre DALLOZ Sub-Investigator: Anne-Françoise DILLIES-LEGRAIN Sub-Investigator: Pascale DUBRAY-LONGERAS Sub-Investigator: Hakim MAHAMMEDI Sub-Investigator: Marie-Ange MOURET-REYNIER Sub-Investigator: Isabelle VAN PRAAGH DOREAU Institut Daniel Hollard Not yet recruiting Grenoble, France, 38028 Contact: Cécile LEYRONNAS 04 76 70 73 33 c.leyronnas@ghm-grenoble.fr Principal Investigator: Cécile LEYRONNAS, MD Sub-Investigator: Claire GARNIER-TIXIDRE, MD Sub-Investigator: Laurence LANCRY-LECOMTE, MD Sub-Investigator: Jérôme LONG, MD Sub-Investigator: Christine REBISCHUNG, MD Centre Leon Berard Recruiting Lyon, France, 69373 Contact: Jean-Yves BLAY +33478785126 jean-yves.blay@lyon.unicancer.fr Principal Investigator: Jean-Yves BLAY, MD Sub-Investigator: Virginie AVRILLON Sub-Investigator: Thomas BACHELOT Sub-Investigator: Christophe BERGERON Sub-Investigator: Pierre BIRON Sub-Investigator: Helen BOYLE Sub-Investigator: Philippe CASSIER Sub-Investigator: Patrick COMBEMALE Sub-Investigator: Maria CHELGHOUM Sub-Investigator: Françoise DESSEIGNE Sub-Investigator: Cécile FAURE-CONTER Sub-Investigator: Jérome FAYETTE Sub-Investigator: Aude FLECHON Sub-Investigator: Christelle DE LA FOUCHARDIERE Sub-Investigator: Didier FRAPPAZ Sub-Investigator: Pierre GUIBERT Sub-Investigator: Pierre-Etienne HEUDEL Sub-Investigator: Eve-Marie NEIDHARDT Sub-Investigator: Maurice PEROL Sub-Investigator: Isabelle RAY-COQUARD Sub-Investigator: Paul REBATTU Sub-Investigator: Pierre SAINTIGNY Sub-Investigator: Catherine TERRET Sub-Investigator: Olivier TREDAN Sub-Investigator: Olivia BALLY Sub-Investigator: Stéphane DEPIL Sub-Investigator: Olfa DERBEL Sub-Investigator: Nathalie MARQUES Sub-Investigator: Philippe TOUSSAINT Sub-Investigator: Mehdi BRAHMI Sub-Investigator: Matthieu SARABI Sub-Investigator: Alice BONNEVILLE-LEVARD Sub-Investigator: Nadège CORRADINI Sub-Investigator: Louis DOUBLET Sub-Investigator: Armelle DUFRESNE Sub-Investigator: Lauriane EBERST Sub-Investigator: Sylvie NEGRIER Sub-Investigator: Katell MICHAUX Sub-Investigator: Anne-Sophie MICHALLET Sub-Investigator: Guillaume MAURICEAU Sub-Investigator: Juliette REURE Sub-Investigator: Pauline ROCHEFORT Hopital Edouard Herriot Not yet recruiting Lyon, France, 69437 Contact: Julien FORESTIER, MD +33472119738 julien.forestier@chu-lyon.fr Principal Investigator: Julien FORESTIER Sub-Investigator: Catherine LOMBARD BOHAS Sub-Investigator: Thomas WALTER Sub-Investigator: Yann MOLIN Sub-Investigator: Noura BEN SLAMA Institut Paoli Calmettes Recruiting Marseille, France, 13273 Contact: François BERTUCCI +334 91 22 35 37 bertuccif@ipc.unicancer.fr Principal Investigator: François BERTUCCI Sub-Investigator: Jean-Marc EXTRA Sub-Investigator: Anthony GONCALVES Sub-Investigator: Gwenaêlle GRAVIS-MESCAM Sub-Investigator: Anne MADROSZYK-FLANDIN Sub-Investigator: Jean-Luc RAOUL Sub-Investigator: Delphine PERROT Sub-Investigator: Magali PROVENSAL Sub-Investigator: Carole TARPIN Sub-Investigator: Frédéric VIRET Sub-Investigator: Louis TASSY Sub-Investigator: Maria Antonietta CAPPIELLO Sub-Investigator: Slimane DERMECHE Sub-Investigator: Simon LAUNAY Sub-Investigator: Frederique ROUSSEAU Sub-Investigator: Nicolas MEYER Sub-Investigator: Loïc MOUREY Sub-Investigator: Elisabeth MOYAL Sub-Investigator: Roxana Maria RADUT Sub-Investigator: Henri ROCHE Sub-Investigator: Thibaud VALENTIN Sub-Investigator: Sarah ZAHI Institut Curie Recruiting Paris, France, 75248 Contact: Christophe LE TOURNEAU, MD +33144324672 Christophe.letourneau@curie.fr Principal Investigator: Christophe LE TOURNEAU, MD Sub-Investigator: Philippe BEUZEBOC Sub-Investigator: François-Clément BIDARD Sub-Investigator: Bruno BUECHER Sub-Investigator: Paul-Henri COTTU Sub-Investigator: Catherine DANIEL Sub-Investigator: Véronique DIERAS Sub-Investigator: Valérie LAURENCE Sub-Investigator: Alain LIVARTOWSKI Sub-Investigator: Jean-Yves PIERGA Sub-Investigator: Marie ALT Sub-Investigator: Delphine LOIRAT Sub-Investigator: Marie-Paule SABLIN Sub-Investigator: Mustapha ZOUBIR Sub-Investigator: Francesco RICCI Sub-Investigator: Emanuela ROMANO Sub-Investigator: Olivier COLLARD Centre Hospitalier Lyon Sud Recruiting Pierre-Bénite, France, 69495 Contact: Benoit YOU, MD +33478864319 benoit.you@chu-lyon.fr Principal Investigator: Benoit YOU, MD Sub-Investigator: Nathalie BONNIN Sub-Investigator: Gilles FREYER Sub-Investigator: Salima HAMIZI Sub-Investigator: Sophie TARTAS Sub-Investigator: Véronique TRILLET-LENOIR Sub-Investigator: Marion CHAUVENET Sub-Investigator: Denis MAILLET Sub-Investigator: Julien PERON Sub-Investigator: Claire FALANDRY Sub-Investigator: Olivia LE SAUX Institut de cancérologie LUCIEN NEUWIRTH Not yet recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Olivier COLLARD, MD 04 77 91 70 34 olivier.collard@icloire.fr Principal Investigator: Olivier COLLARD, MD Sub-Investigator: Claire BOSACKI, MD Sub-Investigator: Pierre FOURNEL, MD Sub-Investigator: Aline GUILLOT, MD Sub-Investigator: Jean-Philippe JACQUIN, MD Sub-Investigator: Thierry MURON, MD Sub-Investigator: Léa SABAN-ROCHE, MD Institut Claudius Regaud Recruiting Toulouse, France, 31059 Contact: Carlos-Alberto GOMEZ-ROCA 05 31 15 51 01 Gomez-roca.carlos@iuct-oncopole.fr Principal Investigator: Carlos-Alberto GOMEZ-ROCA Sub-Investigator: Christine CHEVREAU Sub-Investigator: Ewa-Anna COTTURA Sub-Investigator: Florence DALENC Sub-Investigator: Jean-Pierre DELORD Sub-Investigator: Marion DESLANDRES Sub-Investigator: Cécile GANDY Sub-Investigator: Laurence GLADIEFF Sub-Investigator: Eleonora MAIO D'ESPOSITO Sub-Investigator: Nicolas MEYER Sub-Investigator: Loïc MOUREY Sub-Investigator: Elisabeth MOYAL Sub-Investigator: Henri ROCHE Sub-Investigator: Thibaud VALENTIN Sub-Investigator: Sarah ZAHI Sub-Investigator: Roxana Maria RADUT 收起 <<
NCT02560012	Carcinoma, Renal Cell	Phase 2	Terminated(Loss of laboratory ... 展开 >>performing molecular analysis) 收起 <<	-	United States, Texas ... 展开 >> UTHealth Memorial Hermann Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02412475	Leukemia, Acute Myeloid	Phase 1	Active, not recruiting	February 2019	United States, Minnesota ... 展开 >> Children's Hospitals and Clinics of Minnesota Minneapolis, Minnesota, United States, 55404 United States, Wisconsin Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT01731158	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Unknown	May 2016	Germany ... 展开 >> Charité Berlin Berlin, Germany University Hospital Bonn Bonn, Germany University Hospital Dresden Dresden, Germany University Hospital Düsseldorf Düsseldorf, Germany Waldkrankenhaus St. Marien Erlangen, Germany University Hospital Essen Essen, Germany University Hospital Frankfurt Frankfurt, Germany University Hospital Freiburg Freiburg, Germany University Hospital Göttingen Göttingen, Germany Oncological Practice Hannover Hannover, Germany University Hospital Hannover Hannover, Germany University Hospital Magdeburg Magdeburg, Germany University Hospital Tübingen Tübingen, Germany 收起 <<
NCT01224730	Cancer	Phase 1	Completed	-	United States, Texas ... 展开 >> Dallas, Texas, United States, 75230 Houston, Texas, United States, 77030 收起 <<
NCT02560012	-		Terminated(Loss of laboratory ... 展开 >>performing molecular analysis) 收起 <<	-	-
NCT02559778	Neuroblastoma	Phase 2	Recruiting	September 2026	-
NCT01628640	Advanced Malignant Solid Neopl... 展开 >>asm Hepatocellular Carcinoma 收起 <<	Phase 1	Suspended(for evaluation of 3 ... 展开 >>patients enrolled on DL3A) 收起 <<	June 2025	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT01101906	Advanced Hepatocellular Carcin... 展开 >>oma (HCC) 收起 <<	Phase 2	Terminated(Company decided not... 展开 >> to pursue the development of this drug in this patient population at this time) 收起 <<	-	-
NCT01758575	-		Terminated	-	Netherlands ... 展开 >> VU University Medical Center Amsterdam, Netherlands, 1081HV 收起 <<
NCT02551718	Acute Leukemia of Ambiguous Li... 展开 >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia 收起 <<	Not Applicable	Recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker 206-616-1589 pbecker@u.washington.edu Principal Investigator: Pamela S. Becker 收起 <<
NCT01246817	Renal Cell Cancer	Phase 2	Unknown	-	Netherlands ... 展开 >> University Medical Centre Nijmegen Recruiting Nijmegen, Gelderland, Netherlands, 6500 HB Principal Investigator: C.M.L. van Herpen, Md PhD 收起 <<
NCT00610012	-		Active, not recruiting	August 2020	Germany ... 展开 >> iOMEDICO Freiburg, Germany 收起 <<
NCT01387503	Carcinoma, Hepatocellular ... 展开 >> Cirrhosis 收起 <<	Phase 2 Phase 3	Unknown	January 2014	Italy ... 展开 >> Ospedali Riuniti di Bergamo Recruiting Bergamo, Italy, 24125 Ospedale Maggiore di Milano Policlinico Recruiting Milano, Italy, 20122 Istituto Nazionale Tumori Recruiting Milano, Italy, 20133 Azienda Ospedaliera Ospedale Niguarda Ca' Granda Recruiting Milano, Italy, 20162 Azienda Ospedaliera Universitaria di Padova Recruiting Padova, Italy, 35128 Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT) Recruiting Palermo, Italy, 90133 Policlinico Tor Vergata Recruiting Roma, Italy, 00133 Ospedale "Lazzaro Spallanzani" Recruiting Roma, Italy, 00149 Ospedale Umberto Iº Policlinico di Roma Recruiting Roma, Italy, 00161 Ospedale Universitario Molinette S. Giovanni Battista di Torino Recruiting Torino, Italy, 10126 收起 <<
NCT03338166	-		Not yet recruiting	December 2018	-
NCT02776644	-		Completed	-	-
NCT00986661	Cancer Metastatic to the Liver... 展开 >> Hepatocellular Carcinoma 收起 <<	Phase 1	Recruiting	February 2020	United States, California ... 展开 >> Sharp Memorial Hospital Recruiting San Diego, California, United States, 92123 Contact: Amy King 858-939-5052 Amy.King@sharp.com Principal Investigator: Kristin Rice, M.D. United States, Florida Florida Hospital Tampa Recruiting Tampa, Florida, United States, 33613 Contact: Heather Bingaman, BS 813-615-7068 heather.bingaman@ahss.org Principal Investigator: Alexander Rosemurgy, M.D. United States, Pennsylvania St Luke's University Health Network Recruiting Bethlehem, Pennsylvania, United States, 18015 Contact: Alyse M LaLiberte, MPH 484-503-4151 Alyse.LaLiberte@sluhn.org Contact: Robyn Rex, RN, OCN, CCRP 484-503-4152 robyn.rex@sluhn.org Principal Investigator: Sanjiv Agarwala, MD United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Rhonda Combs, LPN 615-322-2260 rhonda.j.combs@vanderbilt.edu Contact: Melissa Ford, MSN, PhD, RN 615-875-7143 melissa.b.ford@vanderbilt.edu Principal Investigator: Daniel Brown, MD United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Gener Balmes, RN, CCRP 713-794-4153 gcbalmes@mdanderson.org Principal Investigator: Sapna Patel, MD 收起 <<
NCT01009801	Liver Cancer	Phase 1 Phase 2	Terminated(due to slow patient... 展开 >> recruitement.) 收起 <<	-	Switzerland ... 展开 >> Inselspital Bern Bern, Switzerland, CH-3010 Kantonsspital Graubuenden Chur, Switzerland, 7000 Hopital Cantonal Universitaire de Geneve Geneva, Switzerland, CH-1211 Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH-1011 Clinica Luganese di Moncucco Lugano, Switzerland, 6903 Institut Central des Hopitaux Valaisans / Hôpital de Sion Sion, Switzerland, CH-1951 Kantonsspital - St. Gallen St. Gallen, Switzerland, CH-9007 UniversitaetsSpital Zuerich Zurich, Switzerland, CH-8091 收起 <<
NCT03419572	-		Recruiting	January 5, 2021	-
NCT01827254	-		Completed	-	-
NCT02645149	Melanoma	Phase 4	Not yet recruiting	August 2021	Australia, New South Wales ... 展开 >> Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Maria Gonzalez 612 9911 7200 maria.gonzalez@melanoma.org.au Principal Investigator: John Thompson Westmead Hospital Westmead, New South Wales, Australia, 2145 Melanoma Institute Australia Not yet recruiting Wollstonecraft, New South Wales, Australia, 2065 Contact: Maria Gonzalez +612 9911 7200 maria.gonzalez@melanoma.org.au Contact: Alex Menzies +612 9911 7200 info@melanoma.org.au Sub-Investigator: Georgina Long Principal Investigator: Alex Menzies 收起 <<
NCT01827254	-		Completed	-	France ... 展开 >> CHU de la Timone Marseille, Cedex 5, France, 13335 Hopital albert Michalon Grenoble, Cedex 9, France, 38043 Centre Paul Papin Angers, France, 49100 Hôpital Saint-André Bordeaux Cedex, France, 33075 Centre Catalan Urologie Andrologie Cabestany, France, 66330 Centre Oscar Lambret - Cancérologie Urologie Digestive Lille Cedex, France, 59020 clinique de la Louvière Lille Cedex, France, 59042 Hopital Dupuytren - Oncologie Medicale Limoges Cedex, France, 87042 Centre Leon Berard, Service d'Oncologie Medicale Lyon Cedex 08, France, 69373 Institut Paoli-Calmettes / Hôpital de jour Marseille Cedex 9, France, 13273 Cedex 9 Hopital Timone Adultes Marseille Cedex, France, 13385 Hopital Europeen Georges Pompidou Paris Cedex 15, France, 75908 Centre Eugene Marquis Rennes, France, 35042 CHU Charles Nicolle ROUEN Cedex, France, 76031 Departement d'Oncologie Medicale-Institut de Cancerologie de la Loire Saint Priest en Jarez Cedex, France, 42271 Centre Rene Gauducheau - Service Oncologie Medicale St Herblain Cedex, France, 44805 Institut Claudius Regaud Toulouse, France, 31000 Centre Alexis Vautrin Vandoeuvre les Nancy, France, 54511 收起 <<
NCT02829840	Leukemia FLT3... 展开 >>-Mutated Acute Myeloid Leukemia FLT3-Mutated High-Risk Myelodysplastic Syndrome 收起 <<	Phase 1 Phase 2	Withdrawn	-	-
NCT01703910	Adenocarcinoma of Colon ... 展开 >> Adenocarcinoma of Rectum Metastatic Disease 收起 <<	Phase 2	Completed	-	Spain ... 展开 >> Hospital Universitario de Fuenlabrada Fuenlabrada, Madrid, Spain, 28950 Hospital Madrid Norte Sanchinarro Madrid, Spain, 28050 收起 <<
NCT00811993	Neoplasms	Phase 1	Terminated	-	United States, Arizona ... 展开 >> Tucson, Arizona, United States, 85724 United States, California San Francisco, California, United States, 94115 Santa Monica, California, United States, 90025 United States, District of Columbia Washington, District of Columbia, United States, 20007 United States, Illinois Chicago, Illinois, United States, 60637 United States, Minnesota Rochester, Minnesota, United States, 55905 United States, North Carolina Chapel Hill, North Carolina, United States, 27514 United States, Texas Houston, Texas, United States, 77030 收起 <<
NCT00601120	Renal Cell Carcinoma	Not Applicable	Withdrawn(This protocol was ne... 展开 >>ver officially opened and no patients were recruited.) 收起 <<	-	United States, Massachusetts ... 展开 >> Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 收起 <<
NCT02836847	Cholangiocarcinoma of the Extr... 展开 >>ahepatic Bile Duct Gallbladder Cancer 收起 <<	Phase 2	Recruiting	December 2020	China, Shanghai ... 展开 >> Xinhua Hospital Recruiting Shanghai, Shanghai, China, 200092 Contact: yingbin liu 13918803900 laoniulyb@163.com 收起 <<
NCT01636908	Cancer Advanc... 展开 >>ed Solid Tumors 收起 <<	Not Applicable	Active, not recruiting	-	Netherlands ... 展开 >> VUMedical Center Amsterdam, Netherlands, 1081 HV 收起 <<
NCT03520257	Hepatocellular Carcinoma	Phase 2	Not yet recruiting	June 30, 2019	-
NCT03680677	Leukemia, Acute ... 展开 >> MDS 收起 <<	Not Applicable	Not yet recruiting	November 2025	United States, Pennsylvania ... 展开 >> Abramson Cancer Center of the University of Pennsylvania Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 收起 <<

靶点	VEGFR2 VEGFR2, IC50:90 nM VEGFR2/Flk1, IC50:90 nM PDGFRβ mPDGFRβ, IC50:57 nM PDGFRβ, IC50:57 nM FGFR1 FGFR1, IC50:580 nM B-Raf B-Raf (V599E), IC50:38 nM B-Raf, IC50:22 nM
描述	The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. Sorafenib is a multitargeted inhibitor with IC50 values of 6nM, 22nM and 38nM for Raf-1, wt-BRAF and BRAF-V599E mutant, respectively, as well as less potent to mVEGFR2, mVEGFR3, mPDGFRβ, FLT3, c-Kit, VEGFR2 and FGFR1 with IC50 values of 15nM, 20nM, 57nM, 58nM, 68nM, 90nM and 580nM (measured by kinase assays), respectively. Sorafenib inhibited activation of the RAF/MEK/ERK pathway at concentration below 15μM, performing by suppressing p-Erk, in most of cell lines tested (like MDA-MB-231. Mia PaCa 2, HCT 116 and HT-29) independent of which mutation caused aberrant activation of the RAS/RAF pathway. Sorafenib targeted receptor tyrosine kinases and inhibited autophosphorylation of VEGFR-2 and PDGFR-β induced by VEGF165 (30ng/ml) in HUVECs/ NIH 3T3 cells and PDGF BB (10ng/ml) in HAoSMCs, respectively. Oral treatment with Sorafenib, at dose of 7.5-60mg/kg daily for 9 days, illustrated a spectrum of antitumor efficacy in a representative panel of tumor xenograft models in a dose-dependent manner, including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460 and A549. Sorafenib showed significant tumor angiogenesis activity, performing as daily oral administration of 30 or 60 mg/kg Sorafenib produced 50-80% inhibition of microvessel area and microvessel density compared with vehicle group in HT-29 tumors^[1].
作用机制	Sorafenib is a multitargeted ATP-competitive inhibitor.^[1]

CAS号	284461-73-0
分子式	C₂₁H₁₆ClF₃N₄O₃
分子量	464.83
SMILES Code	O=C(NC)C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C=C2)=C1
MDL No.	MFCD06411450

别名	Bay 43-9006
运输	蓝冰
InChI Key	MLDQJTXFUGDVEO-UHFFFAOYSA-N
Pubchem ID	216239

VEGFR2	VEGFR2, IC50:90 nM VEGFR2/Flk1, IC50:90 nM
PDGFRβ	mPDGFRβ, IC50:57 nM PDGFRβ, IC50:57 nM
FGFR1	FGFR1, IC50:580 nM
B-Raf	B-Raf (V599E), IC50:38 nM B-Raf, IC50:22 nM
Raf	Raf-1, IC50:6 nM
C-Raf/Raf-1	Raf-1, IC50:6 nM

697	Growth Inhibition Assay	IC50=7.05989 μM	SANGER
A101D	Growth Inhibition Assay	IC50=21.3752 μM	SANGER
A253	Growth Inhibition Assay	IC50=34.2296 μM	SANGER
A388	Growth Inhibition Assay	IC50=1.59165 μM	SANGER
A3-KAW	Growth Inhibition Assay	IC50=1.8842 μM	SANGER
A4-Fuk	Growth Inhibition Assay	IC50=9.7561 μM	SANGER
ACN	Growth Inhibition Assay	IC50=46.434 μM	SANGER
ALL-PO	Growth Inhibition Assay	IC50=0.03184 μM	SANGER
BB30-HNC	Growth Inhibition Assay	IC50=14.0609 μM	SANGER
BB65-RCC	Growth Inhibition Assay	IC50=0.47073 μM	SANGER
BC-1	Growth Inhibition Assay	IC50=3.7402 μM	SANGER
BC-3	Growth Inhibition Assay	IC50=4.23391 μM	SANGER
BE-13	Growth Inhibition Assay	IC50=2.69609 μM	SANGER
BV-173	Growth Inhibition Assay	IC50=5.95682 μM	SANGER
C2BBe1	Growth Inhibition Assay	IC50=24.3239 μM	SANGER
C8166	Growth Inhibition Assay	IC50=17.6833 μM	SANGER
Calu-6	Growth Inhibition Assay	IC50=13.6046 μM	SANGER
CESS	Growth Inhibition Assay	IC50=36.2848 μM	SANGER
CGTH-W-1	Growth Inhibition Assay	IC50=0.25022 μM	SANGER
CHP-126	Growth Inhibition Assay	IC50=11.9738 μM	SANGER
COLO-320-HSR	Growth Inhibition Assay	IC50=33.1603 μM	SANGER
COR-L279	Growth Inhibition Assay	IC50=18.1362 μM	SANGER
COR-L88	Growth Inhibition Assay	IC50=26.5796 μM	SANGER
CP66-MEL	Growth Inhibition Assay	IC50=39.0733 μM	SANGER
CTB-1	Growth Inhibition Assay	IC50=33.1101 μM	SANGER
CTV-1	Growth Inhibition Assay	IC50=42.8406 μM	SANGER
D-247MG	Growth Inhibition Assay	IC50=2.1448 μM	SANGER
D-392MG	Growth Inhibition Assay	IC50=7.62663 μM	SANGER
D-542MG	Growth Inhibition Assay	IC50=22.0256 μM	SANGER
Daudi	Growth Inhibition Assay	IC50=21.9304 μM	SANGER
DEL	Growth Inhibition Assay	IC50=12.0985 μM	SANGER
DG-75	Growth Inhibition Assay	IC50=43.7595 μM	SANGER
DJM-1	Growth Inhibition Assay	IC50=24.5221 μM	SANGER
DMS-114	Growth Inhibition Assay	IC50=10.5441 μM	SANGER
DMS-153	Growth Inhibition Assay	IC50=24.8614 μM	SANGER
DOHH-2	Growth Inhibition Assay	IC50=7.05676 μM	SANGER
DU-4475	Growth Inhibition Assay	IC50=23.8897 μM	SANGER
ECC12	Growth Inhibition Assay	IC50=24.2803 μM	SANGER
ECC4	Growth Inhibition Assay	IC50=15.0558 μM	SANGER
EC-GI-10	Growth Inhibition Assay	IC50=41.5805 μM	SANGER
EKVX	Growth Inhibition Assay	IC50=49.6628 μM	SANGER
EM-2	Growth Inhibition Assay	IC50=1.35578 μM	SANGER
ES1	Growth Inhibition Assay	IC50=14.1551 μM	SANGER
ES3	Growth Inhibition Assay	IC50=18.8041 μM	SANGER
ES6	Growth Inhibition Assay	IC50=22.7366 μM	SANGER
ES8	Growth Inhibition Assay	IC50=7.76503 μM	SANGER
EVSA-T	Growth Inhibition Assay	IC50=32.2585 μM	SANGER
EW-13	Growth Inhibition Assay	IC50=29.1746 μM	SANGER
EW-18	Growth Inhibition Assay	IC50=11.9044 μM	SANGER
EW-24	Growth Inhibition Assay	IC50=16.1661 μM	SANGER
EW-3	Growth Inhibition Assay	IC50=21.1889 μM	SANGER
GDM-1	Growth Inhibition Assay	IC50=0.90698 μM	SANGER
GOTO	Growth Inhibition Assay	IC50=17.8344 μM	SANGER
HCC2218	Growth Inhibition Assay	IC50=3.12003 μM	SANGER
HCC2998	Growth Inhibition Assay	IC50=0.88818 μM	SANGER
HDLM-2	Growth Inhibition Assay	IC50=16.0714 μM	SANGER
HD-MY-Z	Growth Inhibition Assay	IC50=8.63746 μM	SANGER
HH	Growth Inhibition Assay	IC50=11.3876 μM	SANGER
HL-60	Growth Inhibition Assay	IC50=3.06299 μM	SANGER
HOP-62	Growth Inhibition Assay	IC50=0.85088 μM	SANGER
HT-144	Growth Inhibition Assay	IC50=17.006 μM	SANGER
HUTU-80	Growth Inhibition Assay	IC50=21.3946 μM	SANGER
IST-MEL1	Growth Inhibition Assay	IC50=8.40002 μM	SANGER
IST-MES1	Growth Inhibition Assay	IC50=40.3096 μM	SANGER
IST-SL1	Growth Inhibition Assay	IC50=14.9616 μM	SANGER
IST-SL2	Growth Inhibition Assay	IC50=24.4362 μM	SANGER
JAR	Growth Inhibition Assay	IC50=5.50824 μM	SANGER
JiyoyeP-2003	Growth Inhibition Assay	IC50=10.4745 μM	SANGER
K052	Growth Inhibition Assay	IC50=2.74616 μM	SANGER
K5	Growth Inhibition Assay	IC50=38.43 μM	SANGER
K-562	Growth Inhibition Assay	IC50=18.7143 μM	SANGER
KG-1	Growth Inhibition Assay	IC50=1.47935 μM	SANGER
KM12	Growth Inhibition Assay	IC50=1.02098 μM	SANGER
KM-H2	Growth Inhibition Assay	IC50=20.3184 μM	SANGER
KMOE-2	Growth Inhibition Assay	IC50=2.8135 μM	SANGER
KNS-42	Growth Inhibition Assay	IC50=37.1237 μM	SANGER
KNS-81-FD	Growth Inhibition Assay	IC50=45.4058 μM	SANGER
KS-1	Growth Inhibition Assay	IC50=3.88198 μM	SANGER
L-540	Growth Inhibition Assay	IC50=2.75789 μM	SANGER
LAMA-84	Growth Inhibition Assay	IC50=1.37648 μM	SANGER
LB2241-RCC	Growth Inhibition Assay	IC50=33.3135 μM	SANGER
LB2518-MEL	Growth Inhibition Assay	IC50=1.20809 μM	SANGER
LB373-MEL-D	Growth Inhibition Assay	IC50=21.5615 μM	SANGER
LB831-BLC	Growth Inhibition Assay	IC50=36.0654 μM	SANGER
LC-1F	Growth Inhibition Assay	IC50=9.10834 μM	SANGER
LC-2-ad	Growth Inhibition Assay	IC50=27.6231 μM	SANGER
LC4-1	Growth Inhibition Assay	IC50=16.6119 μM	SANGER
LP-1	Growth Inhibition Assay	IC50=33.9956 μM	SANGER
LS-513	Growth Inhibition Assay	IC50=33.8638 μM	SANGER
LU-139	Growth Inhibition Assay	IC50=12.5413 μM	SANGER
LU-165	Growth Inhibition Assay	IC50=19.7008 μM	SANGER
LU-65	Growth Inhibition Assay	IC50=26.8535 μM	SANGER
LXF-289	Growth Inhibition Assay	IC50=31.4492 μM	SANGER
MC116	Growth Inhibition Assay	IC50=32.0826 μM	SANGER
MDA-MB-134-VI	Growth Inhibition Assay	IC50=15.4131 μM	SANGER
MEG-01	Growth Inhibition Assay	IC50=1.8098 μM	SANGER
MFH-ino	Growth Inhibition Assay	IC50=2.92185 μM	SANGER
MHH-CALL-2	Growth Inhibition Assay	IC50=37.1821 μM	SANGER
MHH-PREB-1	Growth Inhibition Assay	IC50=4.40484 μM	SANGER
ML-2	Growth Inhibition Assay	IC50=6.52849 μM	SANGER
MMAC-SF	Growth Inhibition Assay	IC50=35.8785 μM	SANGER
MOLT-16	Growth Inhibition Assay	IC50=6.25266 μM	SANGER
MONO-MAC-6	Growth Inhibition Assay	IC50=0.00418 μM	SANGER
MRK-nu-1	Growth Inhibition Assay	IC50=3.61468 μM	SANGER
MS-1	Growth Inhibition Assay	IC50=30.7278 μM	SANGER
MV-4-11	Growth Inhibition Assay	IC50=0.00000303 μM	SANGER
MZ1-PC	Growth Inhibition Assay	IC50=3.47509 μM	SANGER
MZ2-MEL	Growth Inhibition Assay	IC50=6.31839 μM	SANGER
MZ7-mel	Growth Inhibition Assay	IC50=3.66099 μM	SANGER
NB1	Growth Inhibition Assay	IC50=7.40407 μM	SANGER
NB13	Growth Inhibition Assay	IC50=25.0265 μM	SANGER
NB14	Growth Inhibition Assay	IC50=8.63133 μM	SANGER
NB6	Growth Inhibition Assay	IC50=9.76029 μM	SANGER
NB7	Growth Inhibition Assay	IC50=10.7526 μM	SANGER
NCI-H1299	Growth Inhibition Assay	IC50=13.2911 μM	SANGER
NCI-H1395	Growth Inhibition Assay	IC50=46.4756 μM	SANGER
NCI-H1436	Growth Inhibition Assay	IC50=1.21678 μM	SANGER
NCI-H1522	Growth Inhibition Assay	IC50=12.746 μM	SANGER
NCI-H1581	Growth Inhibition Assay	IC50=4.28798 μM	SANGER
NCI-H1694	Growth Inhibition Assay	IC50=14.4811 μM	SANGER
NCI-H1882	Growth Inhibition Assay	IC50=13.8555 μM	SANGER
NCI-H1963	Growth Inhibition Assay	IC50=35.3072 μM	SANGER
NCI-H209	Growth Inhibition Assay	IC50=47.1405 μM	SANGER
NCI-H2141	Growth Inhibition Assay	IC50=16.189 μM	SANGER
NCI-H2171	Growth Inhibition Assay	IC50=2.39764 μM	SANGER
NCI-H2196	Growth Inhibition Assay	IC50=33.2557 μM	SANGER
NCI-H2227	Growth Inhibition Assay	IC50=30.9806 μM	SANGER
NCI-H23	Growth Inhibition Assay	IC50=21.3992 μM	SANGER
NCI-H510A	Growth Inhibition Assay	IC50=5.41685 μM	SANGER
NCI-H747	Growth Inhibition Assay	IC50=11.1216 μM	SANGER
NCI-H748	Growth Inhibition Assay	IC50=49.4753 μM	SANGER
NCI-H82	Growth Inhibition Assay	IC50=45.5758 μM	SANGER
NCI-SNU-1	Growth Inhibition Assay	IC50=2.3162 μM	SANGER
NCI-SNU-16	Growth Inhibition Assay	IC50=9.21026 μM	SANGER
NEC8	Growth Inhibition Assay	IC50=36.5835 μM	SANGER
NKM-1	Growth Inhibition Assay	IC50=0.07416 μM	SANGER
no-10	Growth Inhibition Assay	IC50=1.61726 μM	SANGER
no-11	Growth Inhibition Assay	IC50=5.73568 μM	SANGER
NOMO-1	Growth Inhibition Assay	IC50=4.48905 μM	SANGER
NOS-1	Growth Inhibition Assay	IC50=0.5636 μM	SANGER
NTERA-S-cl-D1	Growth Inhibition Assay	IC50=12.0278 μM	SANGER
OCI-AML2	Growth Inhibition Assay	IC50=6.61062 μM	SANGER
ONS-76	Growth Inhibition Assay	IC50=27.332 μM	SANGER
OPM-2	Growth Inhibition Assay	IC50=39.8432 μM	SANGER
OS-RC-2	Growth Inhibition Assay	IC50=9.11243 μM	SANGER
OVCAR-4	Growth Inhibition Assay	IC50=2.21393 μM	SANGER
P30-OHK	Growth Inhibition Assay	IC50=12.5479 μM	SANGER
PF-382	Growth Inhibition Assay	IC50=21.4403 μM	SANGER
QIMR-WIL	Growth Inhibition Assay	IC50=5.07294 μM	SANGER
Ramos-2G6-4C10	Growth Inhibition Assay	IC50=16.1297 μM	SANGER
RL	Growth Inhibition Assay	IC50=20.9692 μM	SANGER
RPMI-8226	Growth Inhibition Assay	IC50=7.84511 μM	SANGER
RPMI-8866	Growth Inhibition Assay	IC50=46.1873 μM	SANGER
SCC-15	Growth Inhibition Assay	IC50=17.1638 μM	SANGER
SCH	Growth Inhibition Assay	IC50=15.4728 μM	SANGER
SF126	Growth Inhibition Assay	IC50=1.63812 μM	SANGER
SF539	Growth Inhibition Assay	IC50=5.13227 μM	SANGER
SH-4	Growth Inhibition Assay	IC50=0.65613 μM	SANGER
SHP-77	Growth Inhibition Assay	IC50=9.71662 μM	SANGER
SIG-M5	Growth Inhibition Assay	IC50=2.42242 μM	SANGER
SIMA	Growth Inhibition Assay	IC50=7.00101 μM	SANGER
SK-MEL-1	Growth Inhibition Assay	IC50=17.0072 μM	SANGER
SK-MM-2	Growth Inhibition Assay	IC50=34.9451 μM	SANGER
SK-N-DZ	Growth Inhibition Assay	IC50=26.3414 μM	SANGER
SK-NEP-1	Growth Inhibition Assay	IC50=4.16815 μM	SANGER
SK-N-FI	Growth Inhibition Assay	IC50=15.6534 μM	SANGER
SR	Growth Inhibition Assay	IC50=6.00678 μM	SANGER
ST486	Growth Inhibition Assay	IC50=3.83673 μM	SANGER
SW954	Growth Inhibition Assay	IC50=6.45866 μM	SANGER
TE-10	Growth Inhibition Assay	IC50=8.76353 μM	SANGER
TE-12	Growth Inhibition Assay	IC50=5.24929 μM	SANGER
TE-5	Growth Inhibition Assay	IC50=3.13162 μM	SANGER
TE-8	Growth Inhibition Assay	IC50=21.6394 μM	SANGER
TE-9	Growth Inhibition Assay	IC50=21.8513 μM	SANGER
TGBC1TKB	Growth Inhibition Assay	IC50=26.9828 μM	SANGER
TGW	Growth Inhibition Assay	IC50=49.0791 μM	SANGER
THP-1	Growth Inhibition Assay	IC50=27.2141 μM	SANGER
U-698-M	Growth Inhibition Assay	IC50=22.4603 μM	SANGER
UACC-257	Growth Inhibition Assay	IC50=13.5126 μM	SANGER
WSU-NHL	Growth Inhibition Assay	IC50=36.164 μM	SANGER

Sorafenib/索拉非尼 {[allProObj[0].p_purity_real_show]}

Sorafenib/索拉非尼纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Sorafenib/索拉非尼质控信息

Sorafenib/索拉非尼生物活性

Sorafenib/索拉非尼细胞实验

Sorafenib/索拉非尼动物实验

Sorafenib/索拉非尼动物研究

Sorafenib/索拉非尼临床研究

Sorafenib/索拉非尼参考文献

Sorafenib/索拉非尼实验方案

Sorafenib/索拉非尼技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Sorafenib/索拉非尼 {[allProObj[0].p_purity_real_show]}

Sorafenib/索拉非尼 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Sorafenib/索拉非尼 质控信息

Sorafenib/索拉非尼 生物活性

Sorafenib/索拉非尼 细胞实验

Sorafenib/索拉非尼 动物实验

Sorafenib/索拉非尼 动物研究

Sorafenib/索拉非尼 临床研究

Sorafenib/索拉非尼 参考文献

Sorafenib/索拉非尼 实验方案

Sorafenib/索拉非尼 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Sorafenib/索拉非尼纯度/质量文件产品仅供科研

Sorafenib/索拉非尼质控信息

Sorafenib/索拉非尼生物活性

Sorafenib/索拉非尼细胞实验

Sorafenib/索拉非尼动物实验

Sorafenib/索拉非尼动物研究

Sorafenib/索拉非尼临床研究

Sorafenib/索拉非尼参考文献

Sorafenib/索拉非尼实验方案

Sorafenib/索拉非尼技术信息